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Abstract of the Dissertation 
Regulation of Transcription and Stress Response by CarD in Mycobacteria 
by 
Ashley Louise Garner 
Doctor of Philosophy in Biology and Biomedical Sciences 
Program in Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2016 
Professor Christina Stallings, Chair 
Mycobacterium tuberculosis, the causative agent of Tuberculosis, infects over a third of 
the world’s population. To control this epidemic, we must develop new chemotherapeutic 
treatments, which requires further insight into the physiology of this bacterium. Previous studies 
have identified CarD as a transcriptional regulator essential during both acute and persistent 
infection. Depletion of CarD sensitizes strains to a diverse panel of stresses and deregulates 
several hundred genes and ribosomal RNA (rRNA). Chromatin immunoprecipitation sequencing 
experiments showed that CarD was localized to promoters throughout the genome, suggesting 
that CarD regulates transcription initiation.  
In collaboration with the Darst Lab, we published the first crystal structure of a CarD 
homolog. CarD’s N-terminal domain was homologous to a known RNA polymerase (RNAP) 
interacting domain and C-terminal domain with a novel fold. Modeling CarD onto initiation 
structures of RNAP position CarD’s C-terminal domain to interact with DNA. We identified 
three independent activities of CarD: binding RNAP, binding DNA, and the activity of a highly 
conserved tryptophan residue that we predict stabilizes the transcription bubble. Using a panel of 
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single mutations in carD that attenuate one of these three activities, I characterized the roles of 
each of CarD’s activities in vivo and in vitro. All three of CarD’s activities are necessary for 
optimal growth, antibiotic resistance, stabilizing RNAP-promoter complexes, and activating 
transcription from rRNA promoters. This work contributed to a model in which CarD slows the 
rate of transcription initiation DNA bubble collapse and accelerates DNA opening.  
In further studies of CarD, I discovered a correlation between the cellular concentration 
of CarD and growth rate and showed that this growth rate dependence is not due to an effect on 
the rRNA content of the cell. This separated CarD’s effect on growth rate from its effect on 
rRNA content for the first time, which indicates that this growth defect is a result of deregulation 
of non-rRNA promoters. Additionally, I elucidated a new mechanism of regulating CarD activity 
through turnover of free protein. 
Most recently, I discovered the extent of CarD regulation in mycobacteria through RNA 
sequencing experiments. These studies revealed that more than 80% of the transcripts in the 
genome are significantly affected by alterations in CarD activity. Furthermore, there are 
transcript-dependent effects of CarD that imply that CarD is responsive qualities of the 
promoters but showed that the promoter sequence only partial explains this specificity.  
My thesis work has dramatically advanced our understanding of the mechanism of 
transcriptional regulation by CarD.  CarD’s activity at transcription initiation complexes is an 
entirely novel mechanism of transcriptional regulation, creating a new paradigm of 
transcriptional regulation in prokaryotes. Furthermore, as CarD is conserved in many bacteria, its 
function has broad implications for bacterial transcription beyond mycobacteria. Finally, since 
CarD is essential in mycobacteria and absent from eukaryotes, my work will inform the 
development of new strategies to inhibit CarD activity as novel therapies to treat tuberculosis.  
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Tuberculosis: epidemiology and disease progressions 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, is an obligate 
pathogen that evolved in Africa with early humans and has caused disease throughout history (2, 
3). Today, about a third of the human population is infected Mtb and it causes more than a 
million deaths per year (4). The majority of infected individuals have latent tuberculosis, in 
which they are infected with live bacteria but have no symptoms and are not contagious. About 
10% of immunocompetent patients with latent tuberculosis will progress to active disease over 
their lifetime but this rate increases to a 5-15% reactivation rate per year among HIV positive 
individuals (5, 6). Active tuberculosis is most commonly a pulmonary disease where it causes a 
serious cough that can produce blood in the sputum, chest pain, fever, weakness, loss of appetite, 
night sweats, and weight loss. The bacterium can also disseminate from the lungs to infect other 
body sites, including the brain, bones, or diffuse bacteremia. This disease presentation is most 
common in children. The Bacillus Calmette–Guérin (BCG) vaccine against Mtb was created in 
the 1920s and has been in common use since 1948. The vaccine effectively prevents 
disseminated disease, including meningitis, but does not protect against development or 
reactivation of pulmonary disease and therefore has been unable to eradicate the disease. 
Treatment of active tuberculosis requires a two month intensive phase of treatment with 
ethambutol, isoniazid, pyrazinamide, and rifampicin, the four frontline antibiotics, followed by a 
four month continuous phase of treatment with isoniazid and rifampicin (7). The long treatment 
regimen, side effects of treatment, and limited access to healthcare in less developed countries all 
lead to poor patient compliance, which results in the development of antibiotic resistance. In 
2014, 480,000 patients developed multidrug-resistant tuberculosis, which is resistant to at least 
two frontline antibiotics. Treatment of multidrug resistant tuberculosis requires treatment with at 
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least 4 antibiotics the bacterium is susceptible to for 6 months followed by an at least an 18 
month long continuous treatment phase with multiple antibiotics (8). The limited antibiotics 
available to treat multidrug resistant tuberculosis infections and poor patient compliance results 
in a global cure rate of only 50%. Multidrug-resistant tuberculosis can evolve resistance to 
additional antibiotics resulting in about 10% of these infections being extensively drug-resistant 
and some strains gaining resistance to all currently antibiotics available to treat tuberculosis (4). 
Control of the global tuberculosis epidemic will require the development of novel antibiotics, 
development of which requires an enhanced understanding of mycobacterial physiology and 
virulence. 
Infection with Mtb occurs when the bacterium is inhaled into the lungs where it is 
engulfed by a phagocytic cell of the innate immune system. This interaction initiates a pro-
inflammatory response in which lymphocytes, monocytes, and fibroblasts are recruited to the site 
of infection and contain the infection by forming a granuloma (9). In most people, the immune 
system controls bacterial replication within the granuloma by exposing the bacterium to reactive 
oxygen and nitrogen species, attacking the mycobacterial cell surface with antimicrobial 
peptides, causing damage to the bacterium’s DNA, and limiting the bacterium’s access to 
oxygen, nutrients, and phosphate (10–21). While some patients who control infection likely 
eliminate the bacterium, others develop a latent infection in which bacterial loads are 
undetectable but remain present for the lifetime of the host (22). Other infected individuals, 
especially those who are immunocompromised, fail to control the infection and develop active 
disease. In these patients, the bacteria are not sealed within a granuloma and bacterial replication 
is not controlled. These individuals develop symptoms of infection, are contagious, and can die 
from the infection if it isn’t successfully treated. 
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The most common animal model used to study tuberculosis infection is the mouse. In 
murine infection, the bacteria replicate for the first 2-3 weeks of infection after which bacterial 
burden is prevented from increasing by the onset of adaptive immunity. Like humans, the 
mouse’s immune system imposes stresses on the bacteria and prevents replication, but differs 
from humans as mice do not form a true granuloma and the bacterial burden remains high for the 
lifetime of the mouse (23).  
Mtb’s transcriptional response to stress 
During infection, the ability of the bacterium to survive the onslaught of stresses imposed 
by the host is essential for survival and therefore targeting cellular factors involved in stress 
response may be a promising avenue for development of novel therapeutics. In order to survive 
these stresses, Mtb executes a complex, interconnected web of stress responses that rely on 
changes in gene expression. The responses to different stresses are integrated and coordinated, 
often resulting in overlapping regulons and stress responders. Not only do these highly effective 
stress response strategies protect Mtb from host immunity, but the resulting changes in 
physiology also contribute to antibiotic tolerance, which precludes eradication of the infection 
(24–29). Coordinating stress responses, virulence, and antibiotic tolerance requires rigorous 
regulation of transcription. Transcription in all bacteria is achieved by a single core RNAP 
enzyme, consisting of the essential subunits β, β’, and 2 α subunits along with the non-essential 
ω subunit (30, 31). To recognize and bind promoter sequences upstream from genes, the core 
RNAP associates with a σ subunit to form an RNAP holoenzyme. Most transcriptional regulation 
occurs at the level of initiation (32) and transcription factors can mediate this regulation by 
directly affecting the polymerase-promoter interaction, manipulating the equilibrium between 
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closed and open RNAP-promoter complexes (RPc and RPo respectively), or affecting rates of 
promoter escape (33, 34).  
While many of the transcriptional response pathways are similar in Mtb and 
Mycobacterium smegmatis, a model organism for Mtb, there are differences between the two 
organisms in the number of a transcriptional regulators encoded in the genomes, the regulon of 
conserved regulators, and the essentiality of the regulators.  M. smegmatis is a nonpathogenic, 
soil dwelling bacterium that replicates much faster than Mtb and must survive in a broader range 
of environments than the obligate pathogen Mtb. The more limited scope of environments Mtb is 
exposed to has allowed it to survive with a genome roughly two-thirds the size of M. smegmatis. 
The larger genome of M. smegmatis has allowed for an expansion is many transcription 
regulators as compared to Mtb. Despite these differences, many of the mechanisms by which the 
bacteria regulate transcription is similar in the two organism enabling many processes to be first 
studied in M. smegmatis. However, because there are differences between the bacteria, whenever 
possible researchers should verify that their findings are applicable to Mtb by directly testing 
hypotheses in Mtb. 
Sigma factors globally control gene expression. The first determinant of gene 
expression in response to different conditions is the activity of the σ factor repertoire. Each σ 
factor binds a specific promoter sequence, thus conferring what promoters are targeted by the 
RNAP holoenzyme for transcription. Changes in σ factor activity in response to different stresses 
and conditions are able to shift a bacterium’s expression profile. Compared to other obligate 
human pathogens, Mtb encodes the highest ratio of σ factors to genome size (35), which allow 
the bacterium to tailor its expression profile in response to a given environment. Even during 
exponential growth in culture, traditionally thought of as a relatively stress-free environment, 
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Mtb expresses its entire complement of σ factors (36–38), indicating that Mtb is poised to 
quickly respond to stress. Mtb’s σ factor network includes one essential housekeeping group 1 σ 
factor (σA), one stress-responsive group 2 σ factor (σB), and 11 group 3 and 4 alternative σ 
factors that also function as environmentally responsive regulators (σC-M) (35, 37, 39). This 
broad panel of σ factors allows Mtb to tune its transcriptional response for a large and diverse set 
of conditions. All of the σ factors in Mtb belong to the σ 70 family, whose members in E. coli 
recognize two sequences in the promoter DNA, the -10 element (recognized by sigma region 2.4) 
and the -35 element (recognized by sigma region 4.2) (40). Mtb promoters contain a conserved -
10 sequence that is essential and sometimes sufficient for transcription, while the -35 sequences 
are less conserved (40–42). The spacer region between -10 and -35 sequences in Mtb also varies 
dramatically compared to E. coli promoters (40, 43, 44). These differences in promoter elements 
may reflect the sigma diversity in Mtb (40, 44). 
Evidence that alternative σ factors are important in Mtb during infection has come from 
cell culture and animal infection models. sigE, sigF, sigG, sigH, and sigJ are upregulated during 
infection of macrophages (45, 46) and both sigE and sigG are necessary for survival within 
macrophages (47–49). Deletion of sigB, sigG, sigJ, or sigM has no effect in animal models (37, 
49–51). Deletion of sigD, sigE, sigH, or sigL results in delayed time to death without affecting 
bacterial burden (52–55), while deletion of sigC and sigF results in a delayed time to death and a 
decrease in bacterial burden during acute (sigC) or chronic (sigF) infection (56–58). The 
importance of individual σ factors during infection highlights both their central role in guiding 
Mtb’s stress response as well as the diverse adverse conditions encountered by Mtb during 
infection. 
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The stringent response controls energy expenditure during stress. In addition to 
sigma factors, the stringent response is another conserved global stress response in bacteria that 
regulates growth and metabolism based on cellular energy levels in harsh environments. In 
mycobacteria, the stringent response is best characterized during amino acid starvation when the 
RelMtb enzyme senses uncharged tRNAs in ribosomes and responds by transferring the 
pyrophosphate (PPi) group from ATP to GDP and GTP to synthesize hyperphosphorylated 
guanine nucleotides ppGpp and pppGpp (collectively called (p)ppGpp) (59). (p)ppGpp then 
coordinates downstream regulation of bacterial physiology and mediates changes in the 
transcriptional profile to support survival during stress. Deletion of relMtb led to 159 genes 
differentially expressed during starvation, including genes involved in coordinating metabolic 
rate reduction, production of mycobacterial cell wall and lipids, secreted proteins, and cell 
division machinery (60). RelMtb is required for survival in low nutrient conditions, long term 
culture, and during infection in animal models, all indicative of a strict requirement for RelMtb 
during exposure to stress (60–64). In E. coli, (p)ppGpp directly affects transcription initiation by 
binding the RNAP (65, 66). In contrast, in a number of Gram-positive bacteria, (p)ppGpp 
inhibits GTP biosynthesis by directly interacting with GTP synthesis enzymes, which impacts 
gene expression by altering initiating nucleotide levels (66–69). Although (p)ppGpp has not been 
demonstrated to directly bind Mtb RNAP or GTP synthesis enzymes, (p)ppGpp has been 
reported to influence mycobacterial RNAP activity in vitro, suggesting that the mechanism of 
(p)ppGpp action in Mtb transcriptional modulation requires further investigation (65, 67, 70). 
Two component systems control specific responses to stress. The transcriptional 
response to stress is further modified through regulation by two component systems and 
transcription factors that control expression of a limited set of genes in response to a specific 
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stress. By activating factors that regulate a smaller number of genes Mtb can tailor its 
transcriptional response to the specific environment it is encountering, which is particularly 
important for survival within the host. Mtb encodes 2 essential and 10 nonessential two-
component systems, which are classically recognized as bacterial systems to sense and respond 
to stress and changes in the environment (71). Each two component system consists of at least 
one sensor histidine kinase that responds to specific environmental conditions by 
autophosphorylation and phosphotransfer to its cognate response regulator, which then binds 
DNA and activates transcription of a specific regulon (71).  
In addition to its two component systems, transcription factors allow Mtb to respond to a 
stimulus through transcriptional expression or repression. Recently, researchers overexpressed 
200 predicted TFs in Mtb and performed chromatin immunoprecipitation sequencing 
experiments and microarray analyses to catalogue a genome-wide characterization of TF binding 
events and target gene expression (72–74). These reports describe 16,000 binding sites for 154 
TFs and identify regulatory routes for ~70% of the genome. The complex regulatory circuits that 
were uncovered highlight how much is still left to be investigated regarding how Mtb regulates 
transcription to integrate precise stress responses. While most transcription factors in Mtb are not 
essential, some iron binding transcription factors involved in regulating the cell’s redox state or 
iron metabolism are essential. The essentiality of these factors, including whiB1, whiB2, and 
ideR, indicates a particular need for Mtb to couple redox sensing and iron availability with basic 
cellular processes to maintain homeostasis.  
Additional determinants of stress response. The transcriptional regulators described 
above are in no way exhaustive in terms of all of the mechanisms of transcriptional regulation 
that Mtb employs to respond to stress. In particular, there is a growing area of research into the 
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roles of nucleoid associated proteins and small RNAs (75–78). Mtb also contains 11 
serine/threonine protein kinases that, like two component systems, are involved in signal 
transduction pathways that aid Mtb in adaptation to its environment (79). However, unlike two 
component systems that consist of sensor kinases that activate response regulators to directly 
modulate Mtb transcription, serine/threonine protein kinases are single proteins that 
phosphorylate numerous downstream targets (79). Although serine/threonine protein kinases do 
not directly affect Mtb transcription, they do influence gene expression by modifying the activity 
of other Mtb proteins with more direct roles in transcription, such as sigma factors, nucleoid-
associated proteins, anti-anti-sigma factors, and two component systems (80–84).These and other 
aspects of gene regulation further add to the complexity of stress responses in Mtb.  
RbpA and CarD: stress responsive transcriptional regulators in actinobacteria.  
Two important stress response regulators in mycobacteria that are not conserved across 
bacterial species are RbpA and CarD. Both of these proteins are RNAP-binding proteins that 
further modify gene expression from a given holoenzyme. While RbpA is limited to 
actinobacteria, CarD is present in numerous other bacterial phyla (85–87), including Bacillus 
and Thermus, but not in E. coli. rbpA is upregulated during oxidative stress, stationary phase, 
starvation, hypoxia, high temperatures, treatment with antibiotics, and during infection in 
macrophages (88–92). RbpA consists of a central RbpA core domain (RCD) flanked by an 
unstructured 26-aa N-terminal tail and a C-terminal σ interaction domain (SID) linked to the 
RCD by a 15-aa basic linker (BL) (93–95). RbpA forms a stable binary complex with the σ2-
domain of group 1 (σA in Mtb) and certain group 2 σ factors (σB in Mtb) through its SID (93–95), 
with additional contacts made between the N-terminus and the σ-factor (93). Based on structural 
modeling, the RbpA BL domain and adjacent residues interact with the DNA phosphate 
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backbone of the nontemplate strand upstream of the -10 promoter element in the RPo 
conformation (93). Additional contacts between RbpA and RNAP σ have been proposed based 
on crosslinking experiments (96–98), but the recent structural modeling of RbpA onto an RNAP-
promoter open complex would be incompatible with these interactions (94), suggesting that 
further analysis will be needed to resolve these inconsistencies. RbpA has been shown to 
increase the affinity of the σ -factor to the core RNAP, increase the affinity of RNAP 
holoenzyme to promoter DNA, and facilitate the formation of RPo (94, 99, 100), all of which 
could contribute to the ability of RbpA to promote RNAP-promoter complex formation and 
stability. The housekeeping σ factor, σ A, has been reported to have a similar affinity for Mtb 
RNAP core enzyme as the alternative σ factor σ F (98), in which case RbpA may be necessary to 
improve σ A affinity and competitiveness for RNAP in conditions that require the activity of σ A. 
In contrast, in E. coli σ 70 has a very high affinity to the RNAP core enzyme and thus can out-
compete other σ factors in conditions where it is required without accessary factors like RbpA.  
CarD was initially identified as being upregulated in response to various stresses, 
including oxidative stress, starvation, and a broad panel of antibiotics, but is essential in Mtb 
even during growth in nutrient rich cultures (85). In silico analysis suggested that CarD’s N-
terminus is homologous to the RNAP Interaction Domain (RID) of the Transcription Repair 
Coupling Factor (TRCF) that is known to interact with the RNAP β-subunit β1-lobe. To test if 
CarD also interacts with RNAP, immunoprecipitation experiments in M, smegmatis were 
designed (85). Using the known interaction of TRCF with RNAP, a model of CarD’s RID 
domain interacting with RNAP was constructed. This model predicted that an interaction 
between glutamate 138 (E138) of RNAP-β with arginines 25 and 47 (R25 and R47) of CarD was 
important for the strength of this complex (Fig 1A, (101)).  To test the accuracy of this modeled 
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interaction, both arginines in CarD were separately mutated to glutamates (R25E and R47E) in 
M. smegmatis and the effect on the strength of the interaction was tested by an 
immunoprecipitation. Both mutations were found to decreased the affinity of the interaction, 
although CarDR25E more dramatically attenuated the interaction than CarDR47E (Fig 1B). 
Interestingly, while strains singly expressing either mutant were viable in M. smegmatis, only the 
CarDR47E strain was viable in Mtb, suggesting that Mtb may have more stringent requirements for 
CarD than M. smegmatis. The less stringent requirements for CarD in M. smegmatis allow for a 
greater variety of genetic tools to be used in this organism than are viable in Mtb, thus 
representing a powerful model to study CarD’s function. Mutations that decreased CarD’s 
affinity for RNAP caused slower growth (Fig. 1C) and increased sensitivity to oxidative (Fig. 
1D) stress as well as antibiotics (Fig. 1E). In Mtb, strains expressing CarDR47E had lower 
bacterial burden in mice during persistent infections (Fig. 1FG). Together these data indicated 
that CarD’s interaction with RNAP was crucial for CarD to support growth and stress resistance 
in mycobacteria (101). 
Since CarD was shown to interact with RNAP, it was hypothesized that CarD may 
regulate transcription. To determine if CarD affects transcription, a microarray was performed 
comparing CarD-depleted cells to cells expressing CarD. Depletion of CarD resulted in 193 
transcripts being deregulated greater than 2-fold suggesting that CarD was a transcriptional 
regulator.  Genes involved in the translational machinery were over-represented among the 
deregulated transcripts and further analysis by quantitative reverse transcription PCR (qRT-PCR) 
found that depletion of CarD also significantly deregulated 16s ribosomal RNA (rRNA, (85)). 
These findings supported a role for CarD as a transcriptional regulator and specifically identified 
rRNA as a transcript dependent on CarD mediated regulation. 
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To determine which stage of transcription (initiation, elongation, termination) is regulated 
by CarD, chromatin immunoprecipitation sequencing (ChIP-seq) reactions were performed to 
determine the chromosomal localizations of a hemagglutinin (HA) tagged CarD, RNAP-β, and 
RNAP-σA (the housekeeping sigma factor) in M. smegmatis. RNAP-β was localized to DNA 
throughout the length of transcribed genes while RNAP-σA was specifically localized to 
promoter regions where transcripts were initiated. CarD was never localized to DNA in the 
absence of RNAP and its genomic localization was highly correlated to that of RNAP-σA (Fig 2). 
CarD was localized to promoter regions throughout the chromosome, including numerous 
promoter regions that were not deregulated by depletion of CarD (85, 87). The co-localization of 
CarD and RNAP-σA suggested that CarD was likely regulating transcription initiation and that it 
may be a more universal transcriptional regulator in mycobacteria than was suggested by the 
microarray of CarD depleted cells. 
A major advance in CarD research occurred in 2013 when the crystal structure of the 
Thermus thermophilus CarD was published (87). Since then numerous other crystal and NMR 
structures of CarD homologs have been solved (86, 102–104). These structures confirmed the 
expected structure of the N-terminal RID domain and revealed a largely α-helical C-terminus 
that was not homologous to any known protein structure (Fig. 3A). Based on the known 
interaction between TRCF and RNAP-β, CarD was modeled onto RNAP structures formed 
during transcription initiation of the Thermus aquaticus RNAP (Fig. 3B). CarD was specifically 
modeled onto RNAP initiation complexes RPc and RPo as the ChIP-seq experiments had shown 
that CarD was localized to promoter regions. These models positioned CarD’s C-terminal 
domain to interact with DNA just upstream of the promoter -10 motif via a conserved basic patch 
in CarD (Fig. 3C). Within this basic patch, there is a nearly universally conserved tryptophan 
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residue that sterically clashes with the DNA backbone of RPc but not RPo RNAP structures. 
CarD’s ability to bind DNA was tested via an electrophoretic mobility shift assay (EMSA), 
which demonstrated that addition of CarD retarded the migration of a DNA fragment encoding 
the promoter and leader sequences of a ribosomal RNA operon from M. smegmatis (Fig. 3D, 
(87)). As a result of these experiments, it was found that CarD binds DNA via its C-terminal 
domain in a sequence independent manner. CarD’s DNA binding ability and the structural 
studies suggested that CarD may regulate transcription by affecting RPo formation or stability by 
a mechanism that requires contact with both RNAP and promoter DNA and paved the way for 
mechanistic studies to determine the effect of CarD on transcription. 
Figure Legends 
Figure 1: CarD’s N-terminal interaction with RNAP is important for growth, stress resistance 
and virulence in Mtb 
A. Homology model (105) of Mtb CarD-RID with Mtb RNAP-β1 based on the crystal 
structure of the T. thermophilus TRCF-RID with T. aquaticus RNAP-β1 (106). 
Proteins are shown as backbone ribbons, with the CarD-RID in light pink and RNAP-
β1 in light cyan. Side chains of residues at the interaction interface discussed in the 
text are shown (CarD-RID, magenta; RNAP-β1, cyan).  
B. Immunoprecipitation experiments with a monoclonal antibody specific for HA in M. 
smegmatis ΔcarD attb::tetcarD expressing untagged CarDWT (lane 1, also expresses 
HA peptide), CarDWT-HA (lane 2), CarDR25E-HA (lane 3) or CarDR47E-HA (lane 4). 
Inputs (before immunoprecipitation) and eluates were analyzed by western blotting 
with antibodies specific for either the RNAP β subunit or HA. 
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C. Representative growth curve of Mtb ΔcarD attb::tetcarD expressing CarDWT or 
CarDR47E. 
D-E. Log phase Mtb ΔcarD attb::tetcarD expressing CarDWT or CarDR47E growing in 7H9 
broth were treated for 75 hours with (D) 25mM H2O2 or (E) 200 µg/ml rifampicin. 
After treatment, dilutions were plated on 7H10 and survival is graphically represented 
as the ratio of CFUs in treated as compared to untreated cultures.  
F-G. Bacterial titers in the lungs (F) and spleens (G) of C57Bl/6 infected with Mtb ΔcarD 
attb::tetcarD expressing CarDWT (open circles) or CarDR47E  (open triangles).  
Graphs in C-G show the mean ± SEM and each sample. Significance was determined 
by calculating the p value 724 from a student’s t test where * is significant with a p 
value < 0.05, ** is significant 725 with a p value < 0.01, and *** is significant with a 
p value <0.005. 
All panels in this figure were first published in (101). 
Figure 2: Normalized log2 of ChIP-seq reads from M. smegmatis DNA coimmunoprecipitated 
with RNAP β, σA, or CarD-HA. Aggregate profiles averaged over 62 highly active 
transcription units. Protein–DNA complexes containing CarD-HA, RNAP β, and 
RNAP σ were immunoprecipitated from M. smegmatis lysates. The coprecipitated 
DNA was sequenced, and the number of sequence reads per base pair was normalized 
to total reads per sample and expressed as a log2 value. Normalized reads per base 
pair from DNA precipitated from cells expressing only the HA epitope were used as 
background and subtracted from the other samples. The 62 transcription units were 
selected on the basis of high signal and isolation from sur- rounding transcription 
units. Data presented in this figure was published in (87). 
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Figure 3: Primary and 3D structural features of Mtb CarD. 
A. Crystal structure of T. thermophilus CarD (87), shown in ribbon format. The N-
terminal CarD-RID domain is shown in magenta and the C-terminal domain is in 
green. 
B. Structural model of the Thermus CarD/RPo complex. The model was generated as 
described in (87). The colors correspond to: CarD RID is in magenta, CarD C-term is 
in green, RNAP-β is in blue, RNAP-β’ is in pink, RNAP-σ is in orange, DNA is in 
green with the promoter element in yellow 
C. Crystal structure of T. thermophilus CarD, shown as a molecular surface and colored 
according to the electrostatic surface potential [red, −5 kT; white, neutral; blue, +5 
kT; where k is the Boltzmann constant, T is temperature (107). Three conserved 
residues in Mtb and their locations are indicated on the structure. 
D. Autoradiographs of EMSAs with 200 pmol CarD or no protein incubated with 20,000 
cpm (∼0.6 ng) of [γ32P]ATP-radiolabeled rrnAPL DNA. The reactions were 
separated on a nondenaturing polyacrylamide gel, which was then dried and exposed 
to film.  
Data presented in this figure was published in (87). 
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Abstract 
Although the basic mechanisms of prokaryotic transcription are conserved, it has become 
evident that some bacteria require additional factors to allow for efficient gene transcription. 
CarD is an RNA polymerase (RNAP) binding protein conserved in numerous bacterial species 
and essential in mycobacteria. Despite the importance of CarD, its function at transcription 
complexes remains unclear. We have generated a panel of mutations that individually target 
three independent functional modules of CarD: the RNAP interaction domain, the DNA binding 
domain, and a conserved tryptophan residue. Using these mutants and a combination of in vivo 
and in vitro approaches, we have discovered that CarD activates transcription by stabilizing an 
RNAP-promoter complex at ribosomal RNA promoters. We have dissected the roles of each 
functional module in CarD activity and built a model where each module contributes to 
stabilizing RNAP-promoter complexes. Our work highlights the requirement of all three modules 
of CarD in the obligate pathogen Mycobacterium tuberculosis (Mtb), but not in Mycobacterium 
smegmatis. We also report divergent use of the CarD functional modules in resisting oxidative 
stress and pigmentation. These studies provide new information regarding the functional 
domains involved in transcriptional regulation by CarD while also improving understanding of 
the physiology of Mtb. 
Introduction 
CarD is an essential transcriptional regulator in mycobacteria.  Its N-terminal domain is 
homologous to the RNAP interacting domain (RID) of the transcription repair coupling factor 
(TRCF, encoded by mfd). In vivo studies have characterized CarD mutants with decreased 
affinity for RNAP and shown that weakening this interaction decreases growth rate, increases 
stress sensitivity, and decreases virulence of Mtb, demonstrating this importance of this 
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interaction for CarD’s function (Chapter 1 Fig. 1, (101)). Evidence that CarD regulates 
transcription comes from a microarray study performed in Mycobacterium smegmatis that found 
deregulation of several hundred genes, including many genes associated with the translational 
machinery, upon depletion of the CarD protein (85). 
To further our understanding of CarD, the crystal structure of the Thermus thermophilus 
CarD was recently solved. This structure confirmed the predicted structure of the N-terminal 
domain and revealed the C-terminal domain to be largely alpha-helical and not homologous to 
any previously solved protein domain (Chapter 1 Fig. 3, (87)). In an effort to determine what 
stage of transcription may be regulated by CarD, chromatin immunoprecipitation sequencing 
experiments were performed.  These studies demonstrated that CarD is localized with RNA 
polymerase (RNAP) holoenzyme to DNA at promoter regions throughout the genome and has 
the same genomic distribution as the house keeping sigma factor, which supported a role for 
CarD in regulation of transcription initiation (Chapter 1 Fig. 2, (87)). Because CarD was 
proposed to regulate transcription initiation, CarD was modeled onto initiation complexes of the 
Thermus aquaticus RNAP. This model positions the C-terminal domain to interact with DNA 
just upstream of the -10 element of the promoter via a conserved basic patch within which is a 
highly conserved tryptophan residue. CarD’s ability to bind DNA was tested by an 
electrophoretic mobility shift assay that demonstrated that CarD binds DNA without sequence 
specificity (Chapter 1 Fig. 3, (87)).  
Numerous questions remain as to the mechanism by which CarD regulates transcription 
and the importance of CarD’s interaction with DNA. In this chapter we demonstrate for the first 
time both that CarD regulates transcription from promoters in vivo and that it stabilizes a RNAP-
promoter complex during transcription initiation.  Furthermore, we investigate many open 
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questions including what residues within CarD are necessary for its interaction with DNA, what 
the roles of this interaction are in CarD-mediated transcriptional regulation and pathogenesis, 
and how do the CarD/RNAP and CarD/DNA interactions affect one another. To address these 
questions, we isolated single point mutants in the CarD C-terminus and use these mutants to 
parse out the role of the CarD C-terminus in DNA binding, bacterial stress responses, 
pathogenesis, and regulation of transcription. In addition, we have begun to clarify the 
relationship between the RNAP binding and DNA binding activities of CarD. Our studies 
demonstrate that a conserved tryptophan residue in CarD that is physically located within the 
DNA binding domain does not phenotypically group with the mutants that abolish CarD’s 
interaction with DNA and performs a function that is important for CarD activity but is distinct 
from the DNA and RNAP binding activities. This is the first report to mechanistically investigate 
transcriptional regulation by CarD and to analyze the CarD C-terminal mutants in vivo. These 
studies reveal a functional distinction between the conserved tryptophan and the surrounding 
basic patch in the C-terminus of CarD. Together our studies dissect three functional regions of 
CarD and elucidate their interplay as it relates to CarD activity. These studies represent a step in 
understanding the mechanism of transcriptional regulation by CarD. 
Experimental Procedures 
Media and bacterial strains. (i) Mtb. All Mtb strains were derived from the Erdman 
strain and were grown at 37°C in 7H9 (broth) or 7H10 (agar) (Difco) media supplemented with 
60 µl L-1 oleic acid, 5 g L-1 bovine serum albumin (BSA), 2 g L-1 dextrose, 0.003 g L-1 catalase 
(OADC), 0.5% glycerol, and 0.05% Tween 80 (broth). Gene switching was used to construct 
strains of mycobacteria expressing different carD alleles and to test for their viability (110). 
Specifically, the Mtb ΔcarD attB::tet-carD strain (described previously in (85)) was transformed 
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with pMSG430smcarD, pMSG430smcarDW85A, pMSG430smcarDK90A, pMSG430smcarDK90E, 
pMSG430smcarDK125A, or pMSG430smcarDK125E (expresses M. smegmatis CarDWT, CarDW85A, 
CarDK90A, CarDK90E, CarDK125A, or CarDK125E, respectively, from a constitutive Pmyc1-tetO 
promoter, kanamycin resistant) to replace the pDB19-Rv3583c construct (expresses Mtb CarD 
from a constitutive Pmyc1-tetO promoter, zeocin resistant) at the attB site of Mtb ΔcarD 
attB::tet-carD. The transformants were selected on kanamycin. The carD gene from each 
transformant was sequenced to confirm the presence of the correct sequence. The Mtb carD 
attB::tet-carD strains transformed with pMSG430smcarD and pMSG430smcarDK125A were 
named csm41 and csm45, respectively. Previously described Mtb carD attB::tet-carD strains 
transformed with pDB19-Rv3583cWT and pDB19-Rv3583cR47E, named mgm3080 and mgm3081 
respectively, were also used in this paper (101). The Mtb and M. smegmatis CarDs have only 3 
conservative amino acid differences and complement each other both in vivo and in vitro.  
(ii) M. smegmatis. All M. smegmatis strains were derived from mc2155 and were grown 
at 37°C in LB supplemented with 0.5% dextrose, 0.5% glycerol, and 0.05% Tween 80 (broth). 
The M. smegmatis strains expressing either hemagglutinin (HA)-tagged or untagged CarDWT, 
CarDR25E, CarDR47E, CarDW85A, CarDK90A, CarDK90E, CarDK125A, or CarDK125E were engineered as 
described for the analogous Mtb strains using pMSG430 expression plasmids and the M. 
smegmatis carD attB::tet-carD strain (described previously in (85)). The M. smegmatis ΔcarD 
attB::tet-carD strains expressing Mtb CarDWT, Mtb CarDR25E, Mtb CarDR47E, M. smegmatis 
CarDW85A, M. smegmatis CarDK90A, M. smegmatis CarDK90E, M. smegmatis CarDK125A, or M. 
smegmatis CarDK125E from a constitutive Pmyc1-tetO promoter at the attB site of M. smegmatis 
ΔcarD attB::tet-carD were named mgm3043, mgm3044, mgm3045, csm34, csm32, csm33, 
csm35, and csm36, respectively. The strains expressing these same alleles but as C-terminal HA-
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tagged versions of CarD were named mgm3090, mgm3091, mgm3092, csm50, csm48, csm49, 
csm51, and csm52, respectively.  
All Mtb and M. smegmatis strains used in this chapter contain only one carD allele. 
Antibiotics and chemicals. In mycobacterial cultures, 20 µg ml-1 kanamycin, 12.5 µg 
ml-1 zeocin, 20 µg ml-1 streptomycin, 50 µg ml-1 hygromycin, and 50 ng ml-1 of 
anhydrotetracycline (ATc) were used. H2O2 (Fisher Scientific) was used at 25mM. 
Native Gel Electrophoresis Mobility Shift Assays (EMSAs). A DNA fragment 
containing the M. smegmatis rrnA promoter and leader sequences, called rrnAPL and 
corresponding to M. smegmatis mc2155 nucleotides 5,029,577–5,029,909, was used for EMSAs 
as previously described (Srivastava et al., 2013). The DNA (250 ng) was amplified with IRDye 
labelled primers. 1 pmol of labelled DNA, 1 μg of LightShift Poly(di/dc) competitor DNA 
(Thermo Scientific), 10 μg BSA, and 200 pmol of CarD proteins were mixed with binding buffer 
(20 mM Tris, pH 8, 150 mM NaCl) in a total volume of 20 μl and incubated for 20 min at room 
temperature. Samples were then electrophoresed on 4–20% non-denaturing TBE polyacrylamide 
gels (Invitrogen) and imaged using an Odyssey CLX imaging system (LI-COR). 
Western blotting and immunoprecipitation. For immunoprecipitation, 50 ml cultures 
were washed and lysed in 500 µl of NP-40 buffer (10 mM sodium phosphate, pH 8.0, 150 mM 
NaCl, 1% Nonidet® P-40, and Roche Complete protease inhibitor cocktail) by bead beating 
(FastPrep; MP Bio). Twenty-five microliters of lysate was used for the input sample and the rest 
was treated with DNase I (New England BioLabs), added to monoclonal anti-HA agarose 
(Sigma), and rotated overnight at 4°C. The matrix was washed 3 times with NP-40 buffer, and 
immunoprecipitated protein complexes were eluted with 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 
500 µg ml-1 HA peptide (Roche), and protease inhibitors. For the western blot analyses, CarD-
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HA and RNAP β were detected using mouse monoclonal antibodies specific for CarD (clone 
10F05; Memorial Sloan-Kettering Cancer Center Monoclonal Antibody Core Facility) and 
RNAP β (clone 8RB13; Neoclone, Madison, WI), respectively.  
Animal infections. Before infection, exponentially replicating Mtb csm41 (CarDWT) and 
csm45 (CarDK125A) strains were washed in PBS plus 0.05% Tween-80 and sonicated to disperse 
clumps. Eight- to nine-week-old female C57BL/6 mice (Jackson Laboratory) were exposed to 8 
× 107 CFU of the appropriate strain in an inhalation exposure system (Glas-Col) that delivers 
~100 bacteria per animal. The bacterial burden was determined by plating serial dilutions of lung 
and spleen homogenates onto 7H10 agar plates. The plates were incubated at 37°C in 5% CO2 
for 3 weeks prior to counting colonies. All procedures involving animals were conducted 
according to the National Institutes of Health (NIH) guidelines for the housing and care of 
laboratory animals, and they were performed in accordance with institutional regulations after 
protocol review and approval by the Institutional Animal Care and Use Committee of the 
Washington University in St. Louis School of Medicine (protocol 20130156, Analysis of 
Mycobacterial Pathogenesis). Washington University is registered as a research facility with the 
United States Department of Agriculture and is fully accredited by the American Association of 
Accreditation of Laboratory Animal Care. The Animal Welfare Assurance documentation is on 
file with the Office for Protection from Research Risks of the NIH. All animals used in these 
experiments were subjected to no or minimal discomfort. All mice were euthanized by CO2 
asphyxiation, which is approved by the American Veterinary Medical Association Panel on 
Euthanasia. 
Survival assays. Zone of inhibition assays: 500 µl of a log-phase M. smegmatis culture 
was plated on LB agar supplemented with 0.5% dextrose and 0.5% glycerol. A single 6-mm disk 
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(Sigma) was placed in the middle of the freshly plated bacterial lawn, and 5 µl of 1 mg ml-1 
ciprofloxacin, 100 mg ml-1 rifampicin, or 200 mg ml-1 streptomycin was spotted on the disk. The 
plates were then incubated for 2 days at 37 oC before the radius of the zone of inhibition was 
measured. For transient treatment in liquid culture assays, log-phase M. smegmatis cultures in 
LB broth supplemented with 0.5% dextrose, 0.5% glycerol, and 0.05% Tween 80 were treated 
with 10 μg ml-1 ciprofloxacin for 2 hrs or 25 mM H2O2 for 1 hr before plating dilutions made 
directly from the treated cultures. 
qRT-PCR. RNA was prepared from 5–10 mL of log-phase M. smegmatis mgm3043 
(CarDWT), mgm3044 (CarDR25E), mgm3045 (CarDR47E), csm32 (carDK90A), csm34 (CarDW85A), 
csm35 (CarDK125A), and csm36 (CarDK125E) or Mtb csm41 (CarDWT) and csm45 (CarDK125A) and 
16S rRNA levels were measured and normalized to sigA transcript levels as previously described 
(85). 
β-galactosidase Assays. M. smegmatis mgm3043, mgm3044, mgm3045, csm32, csm34, 
csm35, and csm36 were transformed with pHMG147-AP1-lacZ, pHMG147-AP2-lacZ, or 
pHMG147-AP3-lacZ (HygR episomal plasmid that expresses lacZ from the indicated promoters) 
to perform β-galactosidase assays in strains expressing CarD mutants. β-galactosidase activity 
was measured from log-phase cultures by pelleting the cells and washing them in Z buffer (60 
mM Na2HPO4, 60 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7) before resuspending them 
in 200 μL of Z buffer and bead beating four times (FastPrep; MP Bio) to lyse the cells. Total 
protein content in each lysate was measured by BCA assay (Pearce). A 50 mM final 
concentration of BME was added to the remaining lysate preparation and β-galactosidase activity 
was measured by adding a final concentration of 2 mg mL-1 ortho-nitrophenyl-β-galactoside 
(ONPG) solution in Z buffer. Change in ODλ420 absorbance was measured over time using the 
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Epoch Microplate Spectrophotometer (BioTek). β-galactosidase activity was calculated using the 
equation β-galactosidase activity = V max /(total protein concentration × volume of lysate) with 
V max being the rate of change in ODλ420 absorbance (measured as the slope).  
In Vitro Transcription Assays. The rrnAP123 (nucleotides 5,029,667-5,029,905 of the 
M. smegmatis mc2155 genome), rrnAP13 (nucleotides 1,469,982-1,470,234 of the Mtb Erdman 
strain), and rrnAP3 (nucleotides 1,470,113-1,470,157 of the Mtb Erdman strain) promoter 
fragments used in the in vitro transcription assays were cloned into the EcoRI and HindIII 
restriction enzyme recognition sites in the pRLG770 plasmid, which has been used previously 
for similar assays (111). The DNA segment from pRLG770 (112) containing the promoter, test 
transcript template, and terminator was then cloned into the NcoI and PstI sites in the pGem-T 
(Promega) plasmid. The plasmids were prepared from E. coli by midiprep (Qiagen) and 
phenol/chloroform extraction. CarD proteins used in in vitro transcription assays were diluted 
into 1 × dialysis buffer (20 mM Tris pH8.0, 150 mM NaCl, and 1 mM BME). Recombinant M. 
bovis core RNAP was purified from E. coli using a system kindly supplied by Dr. Robert 
Landick (113, 114). Recombinant M. bovis A was also purified from E. coli and added to the 
core RNAP to reconstitute the RNAP holoenzyme. For complex stability assays (87), 200 nM 
(for rrnAP3 or rrnAP13 assays) or 400 nM (rrnAP123 assays) M. smegmatis CarDWT, Mtb 
CarDR25E, M. smegmatis CarDW85A, M. smegmatis CarDK90A, or M. smegmatis CarDK125E was 
preincubated with 20 nM (for rrnAP3 or rrnAP13 assays) or 40 nM (rrnAP123 assays) 
Mycobacterium bovis core RNAP in 1x storage buffer (10 mM Tris·HCl, pH 8.0, 3 mM MgCl2, 
50 mM NaCl, 1 mM BME, and 50% (vol/vol) glycerol) for 10 min on ice, followed by the 
addition of 40 nM (for rrnAP3 or rrnAP13 assays) or 80 nM (rrnAP123 assays) M. bovis σA (in 
1x storage buffer). After 10 min, 50 ng of a supercoiled plasmid DNA containing a test promoter 
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was added and the reaction was brought to 12.5μL by dilution such that the final solutions 
contained 1 × transcription buffer (10 mM Tris-Cl, pH 8.0, 10 mM MgCl2, 50 μg mL-1 BSA, 40 
mM NaCl, and 1 mM DTT). 400 nM competitor DNA (double-stranded FullCon promoter DNA 
fragment (111)) was added and at the designated times after the addition of competitor, 
transcription was initiated by the addition of NTPs (100 μM GTP, CTP, and ATP; 10 μM UTP; 
and 0.1 μL [α -32P]UTP for rrnAP3 and rrnAP13 or 100 μM CTP and ATP, 500 μM GTP, 10 μM 
UTP, and 0.1 μL [α -32P]UTP for rrnAP123). A higher concentration of the initiating nucleotide 
GTP is required to achieve enough transcript from the M. smegmatis rrnAP3 promoter to be 
reliably detectable in these assays. After 15 min, the reactions were stopped with 2 × formamide 
buffer (98% (vol/vol) formamide, 5 mM EDTA) and run on a 6% urea PAGE gel.  
Results 
Single point mutations in the CarD C-terminal basic patch abolish the interaction 
between CarD and DNA in vitro. To determine the residues in the CarD C-terminus that were 
responsible for the interaction with DNA, we purified CarD proteins harboring a single mutation 
in the tryptophan or lysine residues (W85, K90, and K125 (Fig. 1A)) that are highly conserved 
among CarD homologs (87). EMSAs were performed to assay the effect of mutating W85, K90, 
and K125 on the ability of CarD to bind the DNA fragment rrnAPL, which contains the 
promoters and leader sequences of the M. smegmatis ribosomal RNA (rRNA) rrnA operon. This 
is the same DNA fragment that was used in the experiments that identified the C-terminus of 
CarD as a DNA binding domain (87) and was originally chosen due to CarD’s described role in 
regulating rRNA transcription (85). The CarDWT, CarDW85A, and CarDK125A proteins were all 
able to bind double stranded (dsDNA), as determined by a decrease in the unbound DNA band 
and the appearance of a slower migrating protein-bound DNA band in the EMSA (Fig. 1B). In 
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contrast, the CarDK90A, CarDK90E, and CarDK125E mutants lost the ability to bind DNA, as 
determined by the dramatic decrease in the slower migrating protein-bound DNA band and the 
retention of the unbound DNA band in the EMSA (Fig. 1B). Therefore, the conserved lysine 
residues in the basic patch are important for binding DNA and single point mutations in the basic 
patch compromise this activity.  
Disrupting the interaction between CarD and DNA does not affect the association of 
CarD with the RNAP but is detrimental for growth and viability. To investigate the role of 
the interaction between CarD and DNA in vivo, we attempted to replace the carD gene in M. 
smegmatis and Mtb with alleles encoding CarDK90A, CarDK90E, CarDK125A, or CarDK125E using a 
gene switching technique (101, 110). We successfully obtained all 4 mutants in M. smegmatis 
(Table 1). However, in Mtb we were only able to replace the carDWT gene with the carDK125A 
allele, which encodes the mutant that retains DNA binding activity in vitro during EMSA 
experiments (Fig. 1B and Table 1). In order to study the roles of the conserved tryptophan in 
CarD, we also attempted to replace the carD gene in M. smegmatis and Mtb with an allele 
encoding CarDW85A. We were able to engineer M. smegmatis strains expressing the CarDW85A 
mutant, but were unable to replace the Mtb carD allele with the carDW85A allele (Table 1). We 
had previously shown that Mtb was more sensitive to interfering with the RNAP binding activity 
of CarD than M. smegmatis (101). These studies demonstrate that Mtb is also more sensitive to 
interfering with CarD’s DNA binding activity and the conserved tryptophan, supporting the 
observation that Mtb has more stringent requirements for CarD’s activities than M. smegmatis. 
The possibility existed that changing the charge of the C-terminal basic patch would 
affect the stability or folding of CarD. In order to address this possibility, we constructed M. 
smegmatis strains expressing HA tagged CarDWT or CarD mutants and analyzed the amount of 
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each mutant protein present in the cell by western blot (Fig. 2A) as a readout for protein stability. 
Using these same strains, we also performed co-immunoprecipitation experiments to determine if 
the CarD C-terminal point mutants retain the ability to associate with the RNAP β subunit (Fig. 
2A) as a readout for proper folding. All of the C-terminal mutants were stably expressed in the 
bacteria and associated with RNAP  to the same degree as WT CarD except for CarDK90E, 
which was barely detectable in the cell lysate suggesting that stability of the protein is affected 
by this substitution (Fig. 2A). Therefore, we chose not to pursue this mutant further. Alanine 
substitution at the conserved tryptophan (CarDW85A) did not affect the amount of RNAP 
associated with CarD, demonstrating that not only does this residue not have a strong impact on 
binding dsDNA (Fig. 1B), it is also not involved in binding the RNAP (Fig. 2A) and indicates 
that this residue serves a unique function for CarD activity.  
To determine whether the CarD-DNA interaction and the conserved tryptophan in CarD 
are important for optimal growth, we measured the growth rate of the viable M. smegmatis (Fig. 
2B) and Mtb (Fig. 2C) CarD mutants. All strains used in this chapter contain only one carD 
allele. Based on at least 3 replicate experiments, M. smegmatis strains expressing the CarDW85A, 
CarDK90A, or CarDK125E mutant grew 1.23 (standard deviation, 0.084), 1.26 (standard deviation, 
0.069), or 1.31 (standard deviation, 0.404) times slower than control strains expressing CarDWT, 
respectively (Fig. 2B). This degree of decrease in growth rate is similar to what was observed 
previously with the CarDR25E mutant with weakened affinity to RNAP  (Fig. 2B and (101)). 
Therefore, even though these M. smegmatis strains are viable, efficient DNA binding and the 
conserved tryptophan are still required for optimal growth.  
The K125A substitution in CarD, which did not affect DNA binding in EMSA 
experiments, slowed the growth of both M. smegmatis (Fig. 2B) and Mtb (Fig. 2C). Specifically, 
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the M. smegmatis CarDK125A expressing strain grew 1.18 times slower than the control strain 
(standard deviation, 0.048) and the Mtb CarDK125A expressing strain grew 1.35 times (standard 
deviation, 0.026) slower than the control strain. This indicates that this mutation affects CarD’s 
function, despite maintaining WT levels of DNA binding in the EMSA assay.  
The growth defects were even more apparent on solid media where the colonies of the M. 
smegmatis CarDR25E, CarDW85A, CarDK90A, and CarDK125E mutant expressing strains were smaller 
than those of the WT strain, as illustrated in Fig. 2D at the 10-3 and 10-4 dilutions. In addition, we 
noticed that the colonies from the strains expressing the CarDR25E RID mutant and the CarDW85A 
mutant had defects in pigmentation, while this was not observed in the strains expressing CarD 
mutants that loss the ability to bind dsDNA. This illustrates an important distinction between the 
conserved tryptophan and the lysine residues involved in interacting with DNA in that mutating 
the tryptophan residue does not phenocopy the DNA binding mutants but rather appears more 
like a RID mutant without affecting the interaction with RNAP. Therefore, this supports that the 
tryptophan and lysine residues within the C-terminus of CarD confer different functions for 
CarD.  
Our discovery of CarD’s DNA binding activity also raised the question of whether the 
previously described mutations in the RID domain that weakened the interaction between CarD 
and the RNAP β subunit (101) also affected the interaction with DNA. To examine this 
possibility, we investigated the DNA binding activity of the CarDR25E and CarDR47E mutants in 
EMSAs (Fig. 2E). These experiments showed that the CarDR25E and CarDR47E mutants retained 
the ability to bind and shift the rrnAPL DNA fragment, as evidenced by both the accumulation of 
a slower migrating complex containing the labeled DNA and the disappearance of the band 
corresponding to the unbound DNA fraction in these samples. The altered migration of the 
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CarD-DNA complexes formed by these mutants as compared to CarDWT may be due to the 
altered net charge in the CarD mutants or changes in cooperativity of the sequence nonspecific 
binding of CarD. Regardless, the retained DNA binding by these mutants indicates that these 
substitutions in the CarD RID do not affect the ability of CarD to bind DNA in the absence of 
RNAP. Therefore, the RNAP and DNA binding activities of CarD are able to function 
independently of each other. 
The CarD-DNA interaction is dispensable for resistance to killing by oxidative 
stress. We have previously shown that both depletion of CarD and mutations that weaken the 
interaction between CarD and the RNAP dramatically compromise survival upon exposure to 
oxidative stress (Fig. 3, Chapter 1 Fig. 1, and (85, 101)), a stress encountered by Mtb during 
infection (115). To test whether the interaction between CarD and DNA is necessary for survival 
during oxidative stress, log-phase cultures of M. smegmatis strains expressing different carD 
alleles were treated with 25 mM H2O2 for 1 hour before dilutions were plated to count the 
surviving colony forming units (CFU) (Fig. 3). Strains expressing the CarDK90A or CarDK125E 
mutants, which lose the ability to bind DNA in EMSA experiments, were as resistant to 
oxidative stress as CarDWT expressing strains, indicating that the interaction between CarD and 
DNA is not required for the response to reactive oxygen species. These results further support 
that the CarD-RNAP and CarD-DNA interactions are independent, as mutations that weaken the 
interaction with RNAP but not with DNA cause sensitivity to reactive oxygen species. 
Interestingly, the W85A mutation in CarD sensitizes M. smegmatis to oxidative stress to a 
similar degree as mutations that weaken the interaction with RNAP (Fig. 3), but without 
affecting association with the RNAP (Fig. 2A). Therefore, the W85A substitution in CarD 
diverges from the CarD DNA binding mutants in the C-terminal basic patch in terms of the effect 
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on pigmentation and withstanding exposure to reactive oxygen species and we conclude that this 
conserved tryptophan is performing another function in CarD distinct from the RNAP and 
dsDNA binding activity of this protein. These data demonstrate that CarD encodes three 
activities that are distinct and operate independently of one another: 1) interaction with the 
RNAP, 2) interaction with dsDNA, and 3) an activity conferred by the conserve tryptophan at 
position 85. The role of CarD in combating oxidative stress requires a robust interaction with the 
RNAP β subunit and the conserved tryptophan residue, but not efficient binding to DNA.  
A mutation in the DNA binding domain of CarD affects the pathogenesis of Mtb in 
murine tissues. We have shown that CarD is required for acute and chronic Mtb infection in 
mice (85) and that weakening the interaction between CarD and the RNAP results in a decrease 
in bacterial burden in both the lungs and the spleen during chronic infection (Chapter 1 Fig. 1, 
(101)). To investigate the effect of mutations in the DNA binding domain of CarD on 
pathogenesis, we infected C57BL/6 mice with Mtb strains expressing either CarDWT or the 
CarDK125A mutant. Although the K125A substitution did not affect DNA binding in vitro, since it 
is our only viable Mtb CarD C-terminal mutant, we used it to study the effect of mutations in the 
basic patch in vivo. The CarDK125A mutant displayed WT kinetics and levels of virulence during 
early acute infection in the lungs, but peaked at a bacterial burden half a log lower than the 
CarDWT expressing strain (Fig. 4A). The lower bacterial burden in animals infected with the Mtb 
CarDK125A mutant continued into the chronic phase of infection. The virulence defect of the 
CarDK125A strain during the chronic phase of infection was also apparent in the spleen where the 
titers of the CarDK125A expressing strain were more than a half log lower than the CarDWT 
expressing strain by 5 weeks post infection (Fig. 4B). The K125A substitution itself did not 
affect CarD binding to the DNA template tested in vitro (Fig. 1B). However, the loss of DNA 
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binding by the CarDK125E mutant indicates that this lysine residue is involved in the association 
with DNA (Fig. 1B) and these data show that this lysine residue is also necessary for maintaining 
WT titers during chronic infection. Since both the CarD-RNAP and CarD-DNA interactions are 
required for maintaining high titers during chronic infection of mice (Fig. 4 and (101)), this 
excludes the source of attenuation being sensitivity to oxidative stress, since interfering with the 
ability of CarD to interact with DNA does not sensitize mycobacteria to reactive oxygen species 
(Fig. 3). Accordingly, we have previously shown that a CarD mutant with decreased affinity for 
the RNAP retains a virulence defect regardless of whether the mouse is able to mount a 
functional phagocytic oxidative burst (101). 
Each of CarD’s functional domains is important for resistance to clinically relevant 
antibiotics. We have previously shown that depleting CarD sensitizes M. smegmatis to killing by 
ciprofloxacin (85) and weakening the CarD-RNAP interaction increases the sensitivity of M. 
smegmatis to rifampicin and streptomycin (Chapter1 Fig. 1, (101)). To determine if the 
interaction between CarD and DNA is also necessary for antibiotic tolerance, we performed zone 
of inhibition assays and determined the sensitivity of M. smegmatis and Mtb strains expressing 
WT or mutant alleles of carD to clinically relevant antibiotics. We specifically tested sensitivity 
to ciprofloxacin (inhibition of DNA replication), rifampicin (inhibition of transcription), and 
streptomycin (inhibition of translation) since perturbations in CarD function have been 
associated with sensitivity to these drugs (85, 101). Each antibiotic targets a different essential 
cellular process, thereby testing the role of CarD’s DNA binding activity in response to 
antibiotics with effects on diverse cellular processes. We found that mutations in the basic patch 
important for interacting with DNA (K90A and K125E) caused increased sensitivity to 
ciprofloxacin, rifampicin, and streptomycin in M. smegmatis in zone of inhibition assays (Fig. 
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5A-C), indicating that the association of CarD with DNA is important in tolerating treatment 
with these antibiotics. Both the K90A and the K125E mutations abolish the interaction between 
CarD and the rrnAPL DNA fragment in EMSAs (Fig. 1B), but expression of CarDK125E causes 
strains to be more sensitive to rifampicin than expression of CarDK90A. This could be due to the 
more dramatic change in charge in the C-terminus of CarD in the K125E mutant. Expression of 
the CarDK125A mutant, which retains binding to the DNA template tested in vitro (Fig. 1B), also 
increases sensitivity of M. smegmatis to the antibiotics tested. The effect of the K125A mutation 
in CarD on antibiotic sensitivity, growth rate, and Mtb virulence indicates that this lysine residue 
is important for an activity that is affected by the alanine substitution. Using similar assays, we 
observed that the conserved tryptophan residue at position 85 in CarD is also important for 
tolerance to rifampicin, ciprofloxacin, and streptomycin in M. smegmatis and the W85A 
mutation results in sensitivity to these antibiotics that is comparable to mutations that either 
weaken the interaction with DNA (Fig. 5A-C).   
Previous experiments that examined the antibiotic sensitivity of M. smegmatis strains 
expressing CarD mutants with weakened affinity to the RNAP employed transient treatment 
assays in liquid cultures (85, 101). Since we were now using a zone of inhibition assay where the 
bacteria are continuously exposed to the antibiotics from a disk on solid agar, we also confirmed 
that the mutations that weaken the interaction between CarD and the RNAP (R25E and R47E) 
also increase the sensitivity of M. smegmatis to ciprofloxacin (Fig. 5A), rifampicin (Fig. 5B), and 
streptomycin (Fig. 5C) in these assays. These data demonstrate that the role of CarD during 
tolerance to these antibiotics requires all three of CarD’s proposed activities. This is distinct from 
the response to oxidative stress, where CarD’s ability to bind DNA is dispensable. 
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We had previously reported that depletion of CarD but not mutations in the RID domain 
increased sensitivity to ciprofloxacin in transient liquid kill assays in which exponential cultures 
of M. smegmatis were treated for 2 hours with antibiotic and then survival was monitored by 
plating the surviving CFUs (85, 101). Despite the increased sensitivity of all of the CarD mutants 
to ciprofloxacin in the zone of inhibition assays, we found no significant differences in 
sensitivity after 2 hours of antibiotic treatment in liquid culture (Fig. 5D), which is similar to 
previous reports. The difference between these results may lie in the experimental design where 
bacteria are only transiently exposed to the antibiotic in liquid cultures as opposed to continuous 
exposure in the zone of inhibition assays. These data suggest that, unlike cells depleted for CarD, 
strains encoding mutant alleles of carD are able to mount enough of a response to survive 
transient exposure to ciprofloxacin, but this response is less effective than in bacteria expressing 
CarDWT, thus resulting in sensitivity to prolonged exposure.   
Each of CarD’s functional domains is important for regulation of rRNA levels. We 
have shown that CarD is localized to promoters throughout the genome, indicating that it is 
likely a global transcriptional regulator (Chapter 1 Fig. 2, (87)). During initial characterization of 
CarD, a microarray was performed that compared the transcriptome of M. smegmatis expressing 
CarD to that of M. smegmatis depleted of CarD protein.  The most striking change in the 
transcriptome upon depletion of CarD was observed in transcripts related to the translational 
machinery, including rRNA itself (85).  We have chosen to first characterize CarD’s effect on 
regulation of rRNA promoters due to the exquisite sensitivity of the translation machinery to 
CarD depletion and the physiological importance of rRNA regulation. We predicted that the 
CarD mutants with weakened affinity to DNA or RNAP or with mutation of the conserved 
tryptophan display slower growth kinetics and increased sensitivity to antibiotics due to improper 
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transcriptional regulation by CarD, including transcriptional regulation of the translational 
machinery. To determine if the weakening CarD’s interactions with RNAP or DNA or mutation 
of the conserved tryptophan affect CarD’s regulation of rRNA, we performed quantitative real-
time PCR (qRT-PCR) to measure the levels of 16S rRNA in exponentially growing cultures of 
M. smegmatis and Mtb expressing WT or mutant alleles of carD. In M. smegmatis, mutations in 
CarD that affected the interaction with RNAP, the association with DNA, or the conserved 
tryptophan each led to decreased levels of rRNA in the bacteria, indicating that all of CarD’s 
activities are involved in regulating rRNA transcription (Fig. 6A). The strain expressing 
CarDK125E had a more severe defect in 16S rRNA transcript levels than the CarDK90A expressing 
strain, which mirrors the trend in survival defects during exposure to rifampicin (Fig. 5B). The 
importance of the lysine residue at position 125 was further confirmed when the CarDK125A 
mutant also had decreased levels of rRNA in M. smegmatis and Mtb as compared to CarDWT 
(Fig. 6A-B). Decreasing CarD’s affinity for RNAP also decreased 16S rRNA levels in Mtb (Fig. 
6B).  
CarD activates transcription initiation at rRNA promoters and requires each of its 
functional domains for this activity. CarD has been shown to localize to promoters throughout 
the genome (Chapter 1 Fig. 2, (87)) which supports a role for CarD in regulating transcription 
initiation, however this hypothesis has not been tested. To directly test the effect of CarD on 
rRNA promoter activity in vivo, we measured β-galactosidase (βgal) activity from lacZ fused to 
the rRNA promoters. In Mtb there is only one rRNA operon, rrnA, and transcription is driven by 
two promoters, P1 and P3 (116, 117). Transcription of the homologous rrnA operon in M. 
smegmatis is derived from similar P1 and P3 promoters as well as an additional P2 promoter 
(116, 117). Individual promoters from the M. smegmatis rrnA operon were cloned upstream of 
45  
the lacZ gene, transformed into M. smegmatis strains expressing WT or mutant alleles of carD, 
and β-galactosidase activity resulting from the expression of lacZ was measured to determine 
promoter activity in each M. smegmatis strain (Fig. 6C). Interfering with the ability of CarD to 
bind RNAP or DNA as well as mutation of the conserved tryptophan decreased transcription 
from M. smegmatis rrnA promoters P1 and P2 (Fig. 6C). This result indicates that CarDWT 
activates transcription from these promoters using a mechanism that is dependent on each of its 
functional domains. β-galactosidase activity measured from the rrnAP3 promoter was highly 
variable between replicates and any differences were not statistically significant, therefore we 
could not make conclusions regarding the role of CarD’s activities at this promoter in the lacZ 
fusion experiments. The mutations in the CarD DNA binding domain (K90A, K125A, and 
K125E) had more dramatic effects on transcription from the rrnAP2 promoter as compared to the 
rrnAP1 promoter, resulting in a greater decrease in β-galactosidase activity from that seen in 
CarDWT strains at the rrnAP2 promoters (Fig. 6C). This difference suggests that the strength of 
interaction between CarD and DNA is more important for initiation of transcription from the 
rrnAP2 promoter than from the rrnAP1 promoter. Conversely, the R25E and the W85A 
mutations in CarD lead to a similar fold decrease at both promoters (0.47 and 0.41 fold lower 
transcription in CarDR25E expressing strains and 0.31 and 0.35 fold lower in CarDW85A expressing 
strains for rrnAP1 and rrnAP2, respectively; Fig. 6C), indicating that the promoters require the 
same levels of the CarD-RNAP interaction and the activity conferred by the conserved 
tryptophan. The CarDK125E mutant also had a more dramatic defect in activating both the rrnAP1 
and rrnAP2 promoter as compared to the CarDK90A mutant, which agrees with the observation 
that the levels of 16S rRNA were lower in the CarDK125E expressing strain as compared to the 
CarDK90A expressing strain (Fig. 6A and C). These data demonstrate that each of CarD’s three 
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activities are critical for the activation of rRNA promoters by CarD. Unlike the other functions 
encoded by CarD, its interaction with DNA is the first activity ascribed to CarD that may exhibit 
some promoter specificity in terms of the importance of its activity. 
CarD requires its interactions with RNAP and DNA as well as the activity of the 
conserved tryptophan to stabilize RNAP-promoter complexes. The lower levels of rRNA and 
rrnA promoter activity (Fig. 6A-C) in mycobacterial strains expressing CarD mutants indicates 
both that CarD is regulating transcription initiation and that these activities are important for 
mechanism by which CarD regulates transcription. To investigate the mechanism of 
transcriptional regulation by CarD, we performed single round in vitro transcription assays. 
Specifically, mycobacterial RNAP A holoenzyme was incubated in the presence or absence of 
CarD with circular supercoiled DNA plasmids containing the Mtb rrnAP3 promoter driving 
transcription of a test transcript to allow for formation of transcription initiation complexes. 
dsDNA competitor was added to compete away free RNAP and prevent formation of new 
RNAP-promoter complexes. NTPs were added at successive time points after the addition of 
competitor and the amount of transcript produced was measured. As transcripts can only be 
initiated from transcription competent complexes formed prior to the addition of competitor, by 
monitoring the amount of transcription that occurs at different times following the addition of 
competitor, the half-life of the RNAP-promoter complexes can be calculated. Addition of 
CarDWT to single round in vitro transcription assays increased the half-life of the RNAP-
promoter complexes formed at the Mtb rrnAP3 promoter by 14.7 fold (Fig. 7A-C) indicating that 
CarDWT stabilizes a competitor resistant RNAP-promoter complex formed during transcription 
initiation.  
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In the above experiment, the Mtb rrnAP3 promoter was present in isolation of its natural 
genomic context. In the genome, the beginning of the -35 region of rrnAP3 is located 48 bp 
downstream from the end of the -10 region of rrnAP1. It is possible that the in vitro transcription 
assays with only one promoter neglect effects of the adjacent rrnAP1 promoter on the stability of 
initiation complexes formed at rrnAP3, which may alter how the initiation complexes respond to 
CarD activity. To study the stability of RNAP-promoter complexes formed at the Mtb rrnAP3 
promoter in its native context, we generated DNA templates containing nucleotides 1,469,982-
1,470,234 of the Mtb genome, which harbored both of the rrnA promoters and their intervening 
sequences. We designated this DNA fragment Mtb rrnAP13. rrnAP1 and rrnAP3 each produce a 
transcript of a unique length that can be quantified independently (Fig. 7A). However, the 
rrnAP1 promoter is relatively weak (116, 117) and transcription from the rrnAP1 promoter is not 
reliably detected in our assays. Single round in vitro transcription assays showed that in the 
absence of CarD, the RNAP-promoter complexes formed at Mtb rrnAP3 were 3 fold more stable 
when rrnAP1 was located upstream (Fig. 7C). Therefore, the upstream rrnAP1 promoter has a 
polar effect on transcription initiation complexes that form at rrnAP3. The addition of CarDWT to 
the reactions containing the rrnAP13 construct further stabilized the half-life of the RNAP-
promoter complexes formed at rrnAP3 (Fig. 7C). Interestingly, the addition of CarDWT resulted 
in a similar final RNAP-promoter complex half-life regardless of the context of rrnAP3. This 
data indicates that CarD has a maximum effect on the stability of the RNAP-promoter complexes 
at rrnAP3 that is independent of the stabilizing effect of the upstream rrnAP1 promoter (Fig. 7C).  
Using our point mutant collection, we investigated the contribution of each of CarD’s 
activities to its ability to stabilize RNAP-promoter complexes at the Mtb rrnAP3 promoter in the 
context of the rrnAP13 construct (Fig. 7D). Addition of CarDWT increased the half-life of the 
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RNAP-promoter complex at the Mtb rrnAP3 promoter 5.3 fold relative to the half-life of the 
complex in the absence of CarD (Fig. 7D). The residues involved in the interaction between 
CarD and the RNAP as well as the W85 residue in CarD were essential for the ability of CarD to 
stabilize RNAP-promoter complexes at Mtb rrnAP3 in the rrnAP13 construct, and mutations in 
these residues abolish this activity at this promoter (Fig. 7D). CarD mutants with decreased 
affinity for DNA, CarDK90A and CarDK125E, were also attenuated in their ability to stabilize the 
RNAP-promoters complexes at rrnAP3 (Fig. 7D). These data demonstrate that each of CarD’s 
functional domains are required for CarD’s ability to stabilize RNAP-rrnAP3 complexes, which 
could explain the lower levels of rRNA in strains expressing CarD mutants (Fig. 6A).  
Similar experiments were also performed to assay the effect of CarD on the stability 
RNAP-promoter complexes formed at M. smegmatis rrnAP3 in the context of the rrnAP123 
construct, which harbors nucleotides 5,029,667-5,029,905 of the M. smegmatis genome thus 
encoding all 3 rrnA promoters (Fig. 7A). Unlike CarDWT, the CarDR25E, CarDK90A, and CarDK125E 
mutants were unable to increase the half-life of RNAP-promoter complexes at M. smegmatis 
rrnAP3, demonstrating that the CarD-RNAP and CarD-DNA interactions are required for CarD’s 
activity at M. smegmatis rrnAP3 (Fig. 7E). The CarDW85A mutant had only a partial defect in the 
ability to stabilize complexes at this promoter as compared to CarDWT which may partially 
explain the essentiality of this mutation in Mtb but not M. smegmatis.  
Discussion 
In this chapter, we have dissected three independent activities encoded by CarD: binding 
the RNAP, binding dsDNA, and the yet to be elucidated function of the conserved tryptophan 
residue within the C-terminal basic patch. We have generated a panel of mutants that 
individually affect one of these activities and have used them to probe the functional importance 
49  
of each activity by both in vitro and in vivo assays. Biochemically, we have demonstrated that 
CarD stabilizes a competitor resistant RNAP-promoter complex formed during transcriptional 
initiation by a mechanism that is dependent upon all three of CarD’s activities (Fig. 7D-E). 
Mutating any single activity of CarD also compromises CarD’s ability to activate transcription of 
rRNA promoters in vivo, resulting in decreased transcription from rRNA promoters in 
transcriptional fusion assays (Fig. 6C) and lower rRNA levels (Fig. 6A-B). Furthermore, we 
have shown that all three of CarD’s activities are required for optimal growth rate and resistance 
to diverse stresses (Figs. 2 and 5).  
Much of the characterization of CarD’s role in mycobacteria has been focused on its 
importance in regulating rRNA transcription. The inability of CarD mutants to activate 
transcription of rRNA promoters in transcriptional fusion experiments (Fig. 6C) as well as the 
lower levels of 16S rRNA in CarD mutants (Fig. 6A-B) indicates that CarD functions as a 
transcriptional activator of these promoters. In all bacteria, the rates of ribosomal protein 
transcription, ribosome biogenesis, and cell growth correlate to the levels of rRNA production 
(118–120). One aspect of Mtb biology that contributes to its success as a pathogen is its ability to 
persist within the host by entering a state of dormancy (121, 122), which most likely requires 
stringent regulation of ribosome biogenesis and translation. However, the regulation of rRNA 
transcription in mycobacteria and its relationship to pathogenesis are under-investigated. 
Investigations into the mechanism by which CarD regulates rRNA transcription will shed light 
onto these important topics. 
An important advance in our understanding of the regulation of rRNA transcription by 
CarD was a kinetic analysis of CarD regulation of transcription at a rRNA promoter performed 
by our collaborators in the Galburt lab (109). In this study, a Cy3 fluorophore is placed at the +2 
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position relative to the transcription start site of the non-template strand of the Mtb rrnAP3 
promoter. The fluorophore’s fluorescence is enhanced 2-fold in RPo as compared to the free 
DNA or in RPc, allowing for monitoring of open complex formation and equilibrium in real time 
(109). This study and others have shown that, compared to the E. coli RNAP, the mycobacterial 
RNAP is deficient at formation of RPo and that CarD enhances this activity such that the M. 
bovis RNAP more closely resembles the E. coli RNAP (109, 123). The fluorescence assay was 
the first study to determine the kinetics of CarD’s effect on open complex formation. This kinetic 
analysis combined with the in vitro and in vivo dissection of CarD activity in this paper has led to 
the following model of CarD activity (Fig. 8A). With high affinity, CarD interacts with RPo 
where its interaction with RNAP and DNA as well as the activity of the conserved tryptophan 
stabilizes the complex by reducing the reverse rate of collapse back to closed complex. With 
lower affinity, CarD interacts with RPc and increases the forward rate of promoter opening. 
Analysis of CarD mutants with decreased affinity for RNAP or DNA or with mutation of the 
conserved tryptophan were all less able to stabilize the open complex in this assay. Importantly, I 
determined the cellular concentration of RNAP β, RNAP σ, and CarD in Mtb and found that the 
concentrations within the cell are similar to concentrations used in the fluorescence assay 
suggesting that CarD both inhibits promoter collapse and enhances opening in vivo (Fig. 8B, 
(109)).Our studies of single point mutants of CarD illustrate the importance of CarD-mediated 
regulation on establishing a gene expression profile that contributes to growth and stress 
resistance. 
While current data supports a role for CarD as an activator of rRNA transcription, 
investigations into CarD activity at non-ribosomal promoters has yet to be performed. As CarD 
is localized to promoters throughout the genome (87), it remains possible that CarD may not 
51  
always function as a transcriptional activator. For instance, if an RNAP holoenzyme has a high 
affinity for a promoter in the absence of CarD, further increasing the stability of this complex 
could repress transcription by inhibiting promoter escape by RNAP. The ability of a transcription 
factor to activate or repress transcription in this manner has been demonstrated for the phage ɸ29 
protein p4 which represses strong promoters but activates weak promoters by binding upstream 
of the promoter and interacting with the C-terminal domain of the RNAP α subunit (124). 
CarD homologs are essential in Mtb, M. smegmatis (85) and Myxococcus xanthus (125) 
and knockouts were not attainable in Borrelia burgdorferi (126). However, the reasons for CarD 
essentiality in these bacteria and how CarD confers antibiotic and stress tolerance in 
mycobacteria remain unknown. It is possible that CarD is essential due to its role in regulating 
rRNA transcription, however more studies are necessary to determine if this is the case. Since 
CarD is associated with all RNAP-A transcription initiation complexes within the M. smegmatis 
genome (87), it is likely that CarD is a general component of the transcription initiation 
machinery rather than regulation of specific transcripts. Organisms lacking CarD, such as E. coli, 
must have an alternative means to fulfill CarD’s role in transcription initiation. This may be 
accomplished if the bacteria lacking CarD encode a different accessory protein that renders CarD 
unnecessary or if there are inherent differences in the transcription complexes of these bacteria 
that allow them to function efficiently in the absence of CarD. Recent data on the inherent 
differences between the E. coli RNAP, which forms stable RPo’s, and the RNAPs of M. bovis, 
Thermus thermophilus, Thermus aquaticus, and Bacillus subtilis which all form unstable RPo’s 
suggest that there is more variation in bacterial RNAP than previously understood (109, 123, 
127–129). Interestingly, there are CarD homologs in both B. subtilis and Thermus spp. 
suggesting unstable RPo formation may be linked the maintaining a carD homolog (85–87).  
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However, carD is not essential in B. subtilis (personal communication with Dr. Jonathan 
Dworkin), suggesting the stability of RPo is not the only determinant of CarD essentiality (130). 
Our data has shown that all three functional modules of CarD are essential in Mtb but not in M. 
smegmatis. This implies that there is a more stringent requirement for CarD’s function in Mtb as 
compared to M. smegmatis. As an obligate pathogen, Mtb has evolved for its very specialized 
niche, whereas M. smegmatis and other environmental mycobacteria must be more versatile and 
generally contain larger genomes with greater redundancy in stress response pathways. 
Therefore, it is possible that M. smegmatis expresses other factors that allow for loss of the 
functions conferred by the conserved tryptophan and the DNA binding activity in CarD. Further 
comparison of the physiology of these two mycobacterial species could provide insight into the 
reasons behind the essentiality of CarD.  
Of the CarD mutants with amino acid substitutions in the C-terminus, we were only able 
to obtain a CarDK125A expressing strain in Mtb. The CarDK125A mutant retains WT levels of 
interaction with DNA in EMSA assays (Fig. 1B) and WT levels of association with the RNAP in 
co-immunoprecipitation assays (Fig. 2A) but results in decreased growth (Fig. 2B-C), decreased 
rRNA levels (Fig. 6A-B), and increased sensitivity to antibiotic treatment (Fig. 5A-C). 
Therefore, the K125A mutation does have functional consequences for CarD. These 
consequences could be the result of this mutation affecting the binding to sequences other than 
what was used in the EMSA or a defect in DNA binding that is undetectable by the EMSA. It 
also remains possible that the mutation affects an unknown function of CarD distinct from its 
interaction with either RNAP or DNA.  
One of the most surprising findings from our studies was that while the majority of CarD 
mutant phenotypes are similar regardless of which of CarD’s activities were targeted, increased 
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sensitivity to H2O2 and loss of pigmentation are specific for mutations at the conserved 
tryptophan or that weaken the interaction with RNAP (Fig. 3). This suggests that either dsDNA 
binding is dispensable for regulation of transcripts required for tolerating H2O2 treatment or 
CarD has a cellular function independent of its interaction with DNA but necessary to survive 
oxidative stress. Because the mutation of the conserved tryptophan results in sensitivity to 
reactive oxygen species without affecting the interaction with RNAP (Fig. 2A), it is unlikely that 
the CarD-mediated resistance is due to CarD physically shielding the RNAP from oxidative 
damage. The differential requirement for the association with the RNAP but not the DNA to 
withstand oxidative stress could be linked to the observation that the CarD/DNA interaction, but 
not the CarD/RNAP interaction, exhibits some promoter specificity in terms of the importance of 
its activity. However, the mechanism by which H2O2 is killing mycobacteria is currently 
unknown and the reason for increased sensitivity in some CarD mutants remains elusive.   
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Table 1: CarD mutants studied in this chapter
Mutation in CarD M. smegmatis M. tuberculosis Activity Affected by Mutation
R25E Viable Unattainable Interaction with RNAP
R47E Viable Viable Interaction with RNAP
W85A Viable Unattainable Unknown
K90A Viable Unattainable Interaction with dsDNA
K90E Viable Unattainable Interaction with dsDNA
K125A Viable Viable None Determined
K125E Viable Unattainable Interaction with dsDNA
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Figure Legends 
Figure 1. CarD’s C-terminal basic patch is responsible for its interaction with DNA.  
A.  Electrostatic surface diagram of Mtb CarD modified from (87) illustrating the 
location of W85, K90, and K125 within the basic patch.  
B.  Image of a nondenaturing polyacrylamide gel from an EMSA with no protein, M. 
smegmatis CarDWT, CarDW85A, CarDK90A, CarDK90E, CarDK125A, or CarDK125E 
incubated with IRDye labeled M. smegmatis rrnAPL DNA. The reactions were 
separated on a nondenaturing polyacrylamide gel, which was then imaged using the 
Odyssey CLX imaging system (LI-COR).  
 
Figure 2. Each of CarD’s functional domains is required for optimal growth in mycobacteria.  
A.  Immunoprecipitation experiments with a monoclonal antibody specific for HA in the 
M. smegmatis strains expressing CarDWT-HA (lane 1), CarDR25E-HA (lane 2), 
CarDK90A-HA (lane 3), CarDK90E-HA (lane 4), CarDW85A-HA (lane 5), CarDK125A-HA 
(lane 6), or CarDK125E-HA (lane 7). Inputs (before immunoprecipitation) and eluates 
were analyzed by western blotting with antibodies specific for either RNAP β (Panel 
A and D) or CarD (Panel B, C, and E). Panel C is a longer exposure of the film from 
panel B in order to show the CarDK90E band. 
B-C.  The doubling time of each CarD strain was expressed as a ratio to the doubling time 
of the CarDWT expressing strain for the M. smegmatis strains expressing CarDWT, 
CarDR25E, CarDK90A, CarDW85A, CarDK125A, or CarDK125E (B) and Mtb strains 
expressing CarDWT, CarDK125A, or CarDR47E (C). Each graph shows the mean ± SEM 
of data from at least three replicates. Significance of the differences between mutant 
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strains and WT were determined by calculating P values by Student’s t test. An 
asterisk indicates significance with a P value of <0.05, two asterisks indicate 
significance with a P value of <0.01, and three asterisks indicate significance with a P 
value of <0.005. 
D.  Plated dilutions of M. smegmatis strains expressing CarDWT, CarDR25E, CarDW85A, 
CarDK90A, CarDK125A, or CarDK125E on LB after 3 days of growth at 37°C. 
E.  Image of nondenaturing polyacrylamide gel from EMSAs with no protein, Mtb 
CarDWT, CarDR25E, or CarDR47E incubated with IRDye labeled M. smegmatis rrnAPL 
DNA. The reactions were separated on a nondenaturing polyacrylamide gel, which 
was then imaged using the Odyssey CLX imaging system (LI-COR). 
Figure 3. The CarD-DNA interaction is dispensable for resistance to killing by oxidative stress. 
Log-phase M. smegmatis strains expressing CarDWT, CarDR25E, CarDR47E, CarDW85A, 
CarDK90A, CarDK125A, or CarDK125E in LB were treated for 1 hr with 25 mM H2O2. 
After treatment, dilutions were plated on LB and the surviving CFUs were counted. 
Survival of each replicate is graphed as a ratio of CFU in treated cultures to that in 
untreated cultures along with the mean ± SEM of the ratios for each set of replicates. 
Each sample is represented by a black circle.  
Figure 4. A mutation in the DNA binding domain of CarD affects the pathogenesis of Mtb in 
murine tissues. C57BL/6 mice were infected by the aerosol route with the Mtb strains 
expressing either CarDWT (black circles) or CarDK125A (grey squares). Shown are 
bacterial titers in the lungs (A) and spleens (B) of the infected mice. Each time point 
is the mean ± SEM of data from 6 mice per strain, combined from two experiments. 
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The significance of the differences between the CarDK125A and the CarDWT strain in 
both panels were determined as described for Figure 2. 
Figure 5. Each of CarD’s functional domains is important for resistance to clinically relevant 
antibiotics.  
A-C. Survival of M. smegmatis strains during the disk zone of inhibition assays. Five 
hundred microliters of log-phase M. smegmatis strains expressing CarDWT, CarDR25E, 
CarDR47E, CarDW85A, CarDK90A, CarDK125A, or CarDK125E were plated on LB agar, and 
a disk spotted with 5µl of 1 mg ml-1 ciprofloxacin (A), 100 mg ml-1 rifampicin (B), or 
200 mg ml-1 streptomycin (C) was placed in the middle of the bacterial lawn. A 
representative experiment is shown above the x-axis. The radius of the zone of 
inhibition for each replicate and the mean ± SEM for each set of replicates is graphed, 
with each sample represented by a black circle. 
D.  Survival of M. smegmatis strains during transient ciprofloxacin treatment. Log-phase 
cultures of the M. smegmatis strains expressing CarDWT, CarDR25E, CarDR47E, 
CarDW85A, CarDK90A, CarDK125A, or CarDK125E growing in LB were treated for 2 hr 
with 10 μg ml-1 ciprofloxacin before the dilutions were plated to determine the 
surviving CFU. Graphed is the ratio of CFUs in treated cultures to that in untreated 
cultures for each replicate and the mean ± SEM for each set of replicates, with each 
sample represented by a black circle.  
For all panels, the significance of differences between mutant strains and WT were 
determined as described in Figure 2. 
Figure 6. Each of CarD’s functional domains are important for transcriptional regulation. 
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A-B. 16S rRNA levels in log phase cultures of M. smegmatis strains expressing CarDWT, 
CarDR25E, CarDR47E, CarDW85A, CarDK90A, CarDK125A, or CarDK125E grown in LB (A) 
and Mtb strains expressing CarDWT or CarDK125A grown in 7H9 (B) as determined by 
qRT-PCR and expressed as a ratio to the levels in CarDWT expressing strains. Each 
graph shows the mean ± SEM of data from at least 3 replicates and the significance of 
the differences between mutant strains and WT. 
C. M. smegmatis strains expressing CarDWT, CarDR25E, CarDR47E, CarDW85A, CarDK90A, 
CarDK125A, or CarDK125E were transformed with the promoter-lacZ fusion constructs 
diagramed above each graph. The ratio of β-galactosidase activity that resulted from 
lacZ expression from the M. smegmatis rrnAP1, rrnAP2, or rrnAP3 promoter in each 
fusion in the CarD mutant versus CarDWT expressing strains was calculated and 
graphed as the mean of at least 3 replicates ± SEM. Shown above each bar is the 
significance of the difference between the mutant strain and WT from the same 
promoter. The bracket designates the significance of the difference between the 
activation of the rrnAP1 and rrnAP2 promoters in the CarDK125E expressing strain.  
For all panels, the significance of differences were calculated as described in Figure 2. 
Figure 7. CarD’s interaction with DNA is important for stabilization of RNAP-promoter 
complexes.  
A.  Schematic of the Mtb and M. smegmatis rRNA promoter constructs used during in 
vitro transcription assays. The length of the rrnAP3-derived transcripts initiated at the 
promoter and ending at the terminator (T) are shown.  
B.  Autoradiographs of 32P-labeled transcripts on denaturing polyacrylamide gels from a 
representative complex stability assay using M. bovis RNAP-A holoenzyme and the 
59  
rrnAP3 construct. The amount of transcript formed at the indicated time-points 
following the addition of competitor is shown when no factor is added versus when 
CarDWT is added. The intensity of each band was quantified and the ratio to the 
intensity at time 0 was calculated and annotated under the gel.  
C.  The half-life (t1/2) of RNAP-promoter complexes formed at the rrnAP3 promoter in 
the Mtb rrnAP3 and the Mtb rrnAP13 constructs in the presence (hatched bars) and 
absence (solid grey bars) of CarDWT was calculated in GraphPad Prism based on the 
amount of transcripts formed during complex stability assays. The graph shows the 
mean of at least 3 replicates ± SEM and the significance of the differences in the 
comparisons designated by the brackets are shown. 
D-E.  Ratio of the t1/2 of RNAP-promoter complexes containing CarDWT, CarDR25E, 
CarDW85A, CarDK90A, or CarDK125E to the t1/2 of RNAP-promoter complexes in the 
absence of CarD as determined by single round complex stability in vitro 
transcription assays at the rrnAP3 promoter on the Mtb rrnAP13 construct (D) or the 
M. smegmatis rrnAP123 construct (E). The significance of differences as compared to 
the reactions containing no factor are shown. 
For all panels, the significance of differences were determined as described for Figure 2. 
Figure 8. Model of CarD activity at promoters. 
A. With high affinity, CarD interacts with the promoter DNA (1) and RNAP β (2) of 
RPo. These interactions stabilize RPo, which decreases the reverse rate of collapse to 
RPc (3). With lower affinity, CarD interacts with RPc and promotes formation of RPo (4). 
Together, these effects of CarD alter gene expression to improve viability and 
resistance to stress (5). 
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B. The cellular concentration of RNAP β, RNAP σA, and CarD in WT M. tuberculosis. 
Published in (109).  
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4. With lower affinity, CarD can also 
interact with RPc. This interaction 
promotes DNA opening 
3. Together these interactions 
stabilize the open complex 
5. Leads to a gene 
expression profile 
that improves 
viability and 
resistance to stress 
1. The basic patch in the C-
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Abstract 
CarD is an essential RNA polymerase (RNAP) interacting protein in Mycobacterium 
tuberculosis (Mtb) that stimulates formation of RNAP-promoter open complexes. CarD plays a 
complex role in Mtb growth and virulence that is not fully understood. Therefore, to gain further 
insight into the role of CarD in Mtb growth and virulence we determined the effect of increasing 
the affinity of CarD for RNAP. Using site-directed mutagenesis guided by crystal structures of 
CarD bound to RNAP, we identified amino acid substitutions that increase the affinity of CarD 
for RNAP. Using these substitutions, we show that increasing the affinity of CarD for RNAP 
increases the stability of the CarD protein in Mtb. In addition, we show that increasing the 
affinity of CarD for RNAP increases growth rate in Mtb without affecting ribosomal RNA 
(rRNA) transcription. We further show that increasing the affinity of CarD for RNAP reduces 
Mtb virulence in a mouse model of infection despite the improved growth rate in vitro. Our 
findings suggest that the CarD-RNAP interaction protects CarD from proteolytic degradation in 
Mtb, establish that growth rate and rRNA transcription can be uncoupled in Mtb, and 
demonstrate that the strength of the CarD-RNAP interaction has been finely tuned to optimize 
virulence. 
Introduction 
Mycobacterium tuberculosis (Mtb) remains a major global health problem, resulting in 
9.6 million new cases of tuberculosis (TB) in 2014 and 1.5 million TB-related deaths that year 
(4). Control of the Mtb epidemic is hampered by the increasing prevalence of multidrug resistant 
strains, which resulted in 480,000 patients developing multidrug-resistant TB in 2014. In order to 
develop new strategies to battle this pathogen, we must gain a better understanding of the 
molecular processes involved in its survival and pathogenesis. Recent studies have identified 
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numerous aspects of mycobacterial physiology that differ from what has been identified in model 
organisms and highlight the importance of research directly in mycobacteria to understand their 
lineage specific physiology. We have identified CarD as an essential transcriptional regulator in 
mycobacteria that is not conserved in the model organism Escherichia coli, which has 
traditionally been used to study mechanisms of transcription (85). carD is conserved in all 
mycobacteria and numerous other bacteria (85–87, 125), but is not found in eukaryotes. 
Therefore, studying CarD will broaden our understanding of prokaryotic transcription while also 
characterizing a promising potential target for desperately needed new therapeutic strategies for 
TB. 
Chromatin immunoprecipitation-sequencing (ChIP-seq) experiments in mycobacteria 
demonstrated that CarD is localized with RNA polymerase (RNAP) holoenzyme at promoters 
throughout the genome, indicating that CarD is a global regulator of transcription initiation 
(Chapter 1 Fig. 2, (87)). CarD interacts directly with the β1-lobe of the RNAP-β subunit through 
its N-terminal RNAP interaction domain (RID) (Chapter 2 Fig. 1 (85, 101, 125)) and with DNA 
just upstream of the -10 element of the promoter through a conserved basic patch in its C-
terminal domain (Chapter 2 Fig. 3, (86, 87, 108)). Within the basic patch, studies have identified 
a highly conserved tryptophan residue that is proposed to wedge into the minor groove at the 
upstream edge of the transcription bubble (86, 87). Thus far, CarD’s activity has primarily been 
studied on ribosomal RNA (rRNA) promoters. Using in vitro transcription assays, we have 
shown that CarD stabilizes RNAP-promoter open complexes at rRNA promoters during 
transcription initiation and that CarD requires interactions with both RNAP and DNA as well as 
the activity of the conserved tryptophan to do so (Chapter 2 Fig. 7, (87, 101, 108, 109)). 
Recently, a bulk fluorescence assay was used to measure the effect of CarD on the kinetics of 
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transcription initiation at the Mtb rRNA promoter rrnAP3. These studies revealed that, compared 
to the E. coli RNAP, the Mycobacterium bovis (Mbo) RNAP forms a significantly less stable 
open complex at rrnAP3 in the absence of CarD. Addition of CarD stabilizes Mbo RNAP-
rrnAP3 open complexes by binding to the RNAP-promoter open complex with high affinity and 
preventing collapse to closed complex. With lower affinity, CarD also binds the RNAP-promoter 
closed complex and promotes melting of the DNA to form open complex. Importantly, the 
cellular concentration of CarD in wild-type (WT) Mtb is sufficient for both of these activities to 
be physiologically relevant (Chapter 3 Fig. 8, (109)). Mycobacterial strains expressing mutants 
of CarD with weakened affinity for the RNAP-β subunit, weakened affinity for DNA, or that are 
mutated at the conserved tryptophan all express lower levels of rRNA, exhibit lower rRNA 
promoter activation in promoter-lacZ fusion experiments, grow slower, and are more sensitive to 
multiple stresses and antibiotics as compared to strains expressing WT CarD (Chapter 3, (87, 
101, 108)).  
In this study, we use CarD mutants with increased affinity for RNAP to dissect the role of 
CarD binding to RNAP in vitro and in vivo. We detail the distinct effects of increasing the 
affinity of CarD to RNAP on open complex stability, transcriptional regulation, CarD protein 
stability, and the effects of these changes on growth and virulence. These studies expand our 
understanding of the global transcription regulator CarD and the impact of CarD activity on the 
physiology of Mtb, while also providing insight into how CarD activity is regulated. 
Experimental Procedures 
Bacterial two-hybrid assays. The bacterial two hybrid assay used in this study is based 
upon the demonstration that contact between a protein domain fused to the  subunit of RNA 
polymerase and a partner protein fused to the bacteriophage CI protein activates transcription of 
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a lacZ reporter gene under the control of a test promoter bearing an upstream  operator (131). 
Assays were performed as described using FW102 F′ OL2-62 reporter strain cells, which contain 
the test promoter placOL2-62 driving the expression of a linked lacZ gene on an F′ episome 
(131). Plasmids used in these assays included pBR-Mt CarD (1 to 66), which encodes residues 
1 to 248 of the E. coli RNAP  subunit fused to residues 1-66 of Mtb CarD (101), plasmid 
pBR, which encodes the WT α subunit, and plasmid pACCI-Mt 1, which encodes residues 1 
to 236 of the bacteriophage CI protein fused to residues 52 to 178 of the  subunit of Mtb 
RNAP fused to residues 379 to 440 of the  subunit of Mtb RNAP via two glycine residues 
(101). Plasmids carrying amino acid substitutions at residue I27 of Mtb CarD were introduced 
into pBR-CarD (1 to 66) by PCR.  
FW102 F′ OL2-62 were cotransformed with either the indicated pBR-Mt CarD (1 to 66) 
derivative and pACCI-Mt 1 or pBR and pACCI-Mt 1. Individual transformants were 
selected and grown in LB supplemented with carbenicillin (100 g/ml), chloramphenicol (25 
g/ml), and kanamycin (50 g/ml). No IPTG was present in the growth media. -galactosidase 
assays were performed as described in (101). Graphs in Figures 1E and 1F depict the -
galactosidase activity in cells containing the indicated pBR-Mt CarD (1 to 66) derivative and 
pACCI-Mt 1. The bar labeled “No CarD” in Figure 1E depicts the -galactosidase activity 
observed in cells containing pBR and pACCI-Mt 1. 
Bacterial strains and growth conditions. (i) Mtb. All Mtb strains were derived from the 
Erdman strain and were grown at 37°C in Sauton’s broth media (0.5 g L-1 KH2PO4, 0.5 g L-1 
MgSO4, 4 g L-1 L-asparagine, 60 ml glycerol, 0.05 g L-1 ferric ammonium citrate, 2.0 g L-1 citric 
acid, 0.1 ml L-1 1% ZnSO4, 0.05% Tween 80, pH 7.0) or 7H10 agar media (Difco) supplemented 
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with 60 µl L-1 oleic acid, 5 g L-1 bovine serum albumin (BSA), 2 g L-1 dextrose, 0.003 g L-1 
catalase (OADC), and 0.5% glycerol. Gene switching was used to construct strains of 
mycobacteria expressing different carD alleles and to test for their viability (101, 110). 
Specifically, the Mtb ΔcarD attB::tet-carD strain (described previously in (85)) was transformed 
with pMSG430Rv3583cI27F, pMSG430Rv3583cI27W, or pMSG430Rv3583cR47E (expresses Mtb 
CarDWT, CarDI27F, CarDI27W, or CarDR47E, respectively, from a constitutive Pmyc1-tetO 
promoter, kanamycin resistant) or pDB19Rv3583c (expresses CarDWT from a constitutive 
Pmyc1-tetO promoter, zeocin resistant). The transformants were selected on 20 µg ml-1 
kanamycin or 1.25 µg ml-1 zeocin. The carD gene from each transformant was sequenced to 
confirm the presence of the correct sequence. The Mtb ΔcarD attB::tet-carD strains transformed 
with pDB19Rv3583cWT, pMSG430Rv3583cI27F, pMSG430Rv3583cI27W, or 
pMSG430Rv3583cR47E were named mgm3080, csm230, csm231 and csm195, respectively. (ii) 
M. smegmatis. All M. smegmatis strains were derived from mc2155 and were grown at 37°C in 
LB supplemented with 0.5% dextrose, 0.5% glycerol, and 0.05% Tween 80 (broth). The M. 
smegmatis strains expressing hemagglutinin (HA)-tagged CarDWT, CarDR25E, CarDI27F, or 
CarDI27W were engineered as described for the analogous Mtb strains using pMSG430 expression 
plasmids and the M. smegmatis ΔcarD attB::tet-carD strain (described previously in (85)). The 
M. smegmatis ΔcarD attB::tet-carD strains expressing C-terminal HA-tagged versions of Mtb 
CarDWT, Mtb CarDR25E, Mtb CarDI27F, or Mtb CarDI27W from a constitutive Pmyc1-tetO promoter 
at the attB site of M. smegmatis ΔcarD attB::tet-carD were named mgm3090, mgm3091, 
csm228, and csm229, respectively.  
Cell lysate. 20ml of exponential cultures of Mtb were lysed in 500 μl NP-40 buffer (10 
mM sodium 182 phosphate [pH 8.0], 150 mM NaCl, and 0.25% NP-40) by bead beating three 
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times. 
Immunoprecipitation. Lysate from M. smegmatis strains expressing HA-tagged alleles 
of CarD was bound to monoclonal anti-HA agarose (Sigma) and complexes were eluted as 
previously described (101, 108).  
Western blot analysis. Protein samples were mixed with an SDS-PAGE loading buffer 
and ran on a 4-12% Bis-Tris protein gel (Invitrogen). HA-tagged CarD in the 
immunoprecipitation experiment was detected using a mouse monoclonal antibody (clone 
10F05; Memorial Sloan-Kettering Cancer Center Monoclonal Antibody Core Facility). To 
determine protein concentrations in cell lysate, CarD was detected with a rabbit polyclonal 
antibody (85).  RNAP-β was detected with a mouse monoclonal antibody in both experiments 
(clone 8RB13; Neoclone, Madison, WI). Horseradish peroxidase conjugated secondary 
antibodies against mouse or rabbit (Perkin Elmer) were used for detection.  
Native gel electrophoretic mobility shift assays (EMSAs) by radiolabeling. A DNA 
fragment containing the rrnA promoter and leader sequences, called rrnAPL and corresponding 
to M. smegmatis mc2155 nucleotides 5,029,577–5,029,909, was prepared and radiolabeled as 
previously described (87). 1 pmol of labelled DNA was incubated with 200 pmol of M. 
smegmatis CarDWT, M. smegmatis CarDK125E, Mtb CarDI27F, or Mtb CarDI27W proteins for 20 min 
at room temperature and analyzed via electrophoresis as previously described (87).  
RNA was prepared from 20-30 ml of log-phase Mtb Erdman (WT Mtb), mgm3080 
(CarDWT), csm195 (CarDR47E), csm230 (CarDI27F), and csm231 (CarDI27W). 16S rRNA and carD 
levels were measured and normalized to sigA transcript levels as previously described (85). 
Mouse infections. Infection of mice with exponentially replicating Mtb Erdman strain 
(WT Mtb), csm3080 (CarDWT), csm230 (CarDI27F) and csm231 (CarDI27W) strains and 
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determination of bacterial loads was performed as previously described (101, 108). All 
procedures involving animals were conducted according to the National Institutes of Health 
(NIH) guidelines for the housing and care of laboratory animals, and they were performed in 
accordance with institutional regulations after protocol review and approval by the Institutional 
Animal Care and Use Committee of the Washington University in St. Louis School of Medicine 
(protocol 20130156, Analysis of Mycobacterial Pathogenesis). Washington University is 
registered as a research facility with the United States Department of Agriculture and is fully 
accredited by the American Association of Accreditation of Laboratory Animal Care. The 
Animal Welfare Assurance documentation is on file with the Office for Protection from 
Research Risks of the NIH. All animals used in these experiments were subjected to no or 
minimal discomfort. All mice were euthanized by CO2 asphyxiation, which is approved by the 
American Veterinary Medical Association Panel on Euthanasia. 
Protein preparation for biochemical assays. Recombinant Mycobacterium bovis (Mbo) 
core RNAP was purified from E. coli using a system kindly supplied by Dr. Robert Landick 
(113, 114) as previously described (108). Recombinant Mbo σA, which is identical to Mtb σA, 
was purified from E. coli and added to the core RNAP to reconstitute the RNAP holoenzyme.  
Preparation of fluorescent promoter DNA fragments. The DNA template contains 
nucleotides 1,470,151 to 1,470,300 of the Mtb Erdman genomic DNA, which includes the 
rrnAP3 promoter. Cy3-labeled promoter DNA was prepared as previously described (109). 
Stopped-flow fluorescence assay. Stopped-flow fluorescence experiments were 
performed as previously described (109). All experiments were performed using a final Mbo 
RNAP-A holoenzyme concentration of 225 nM and a final promoter DNA concentration of 10 
nM. Experiments were performed at 25° C in the following final solution conditions: 14 mM 
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Tris pH 8.0, 120 mM NaCl, 10 mM MgCl2, 1 mM DTT, 0.1 mg/ml BSA, and 10% glycerol by 
volume. Equal volume mixing of protein with promoter DNA was performed in a stopped-flow 
apparatus (Applied Photophysics SX-20, total shot volume 150 µl, dead time < 2 ms), so the 
initial protein and DNA solutions were each diluted by half in order to reach their final reaction 
concentrations. Due to slight hardware variations in different stopped-flow instruments, 
excitation light was provided by either a 510 nm fixed-wavelength LED light source or a 515 nm 
light source from an arc lamp passed through a monochromator. The difference in excitation 
light had no effect on the data. In all cases emission was collected at 570+ nm using a long-pass 
filter. Fluorescence was monitored for 20 min. 
At least 2 traces were collected and averaged per condition. Traces were plotted as fold-
change over DNA according to (F-F0)/F0, where F0 is the buffer-subtracted signal for DNA 
alone and F is the buffer-subtracted signal for DNA mixed with protein. The final point of each 
trace was used as a measure of equilibrium fluorescence. The fold-change traces were fit to a 
triple exponential from 0.1-1200 s using the ProData Viewer software from Applied 
Photophysics. The slowest observed rate dominated the fractional amplitude of the fits and was 
used as a measurement of kobs3. Conditions that were repeated multiple times on different days 
were used to estimate standard error of the mean (SEM). An average SEM was used to estimate 
uncertainty for specific conditions that were only repeated multiple times on the same day. 
In vitro transcription assays. CarD proteins used in in vitro transcription assays were 
diluted into 1× dialysis buffer (20 mM Tris pH 8.0, 150 mM NaCl, and 1 mM BME). For the 
aborted 3nt transcript assay (123), a linear fragment of dsDNA Mtb Erdman strain genomic DNA 
containing nucleotides 1,470,151 to 1,470,300 which includes the Mtb rrnAP3 promoter was 
prepared by annealing and extending primers overlapping 85bp primers (Integrated DNA 
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Technologies Coralville, USA). Reaction conditions were as follows: 200 nM Mbo core RNAP, 
2 μM Mbo σA, 2 μM CarD or equivalent volume of buffer, 10 nM linear DNA template, 210 µM 
GpU dinucleotide, 21 µM UTP, 0.1 μl [α - 32 P]-UTP, 13.25 mM Tris pH 8.0, 59 mM NaCl, 
10.12 mM MgCl2, 5% (vol/vol) glycerol, 1mM DTT, and 0.1 mg/ml BSA (NEB) in a total 
volume of 20 μl. Mbo core and σA were incubated for 10 min at 37°C followed by the addition of 
CarD and 10 more minutes of incubation at 37°C. The DNA template was added and the 
reactions were diluted to 17.5 μl and incubated at 37°C for 10 minutes. Reactions were initiated 
with addition of a 2.5 μl mixture containing GpU, UTP, and the radiolabeled UTP and incubated 
at 37°C. After 20 min, the reactions were stopped with 2 × formamide buffer [98% (vol/vol) 
formamide, 5 mM EDTA] and run on a 22% urea PAGE gel. Transcripts were quantified using 
phosphorimagery and analyzed using Image Gauge software. 
Results 
Identification of amino acid substitutions in the N-terminus of CarD that increase 
the affinity of CarD for RNAP-β. To identify substitutions that strengthen the Mtb 
CarD/RNAP- 1-lobe interaction, we employed site directed mutagenesis guided by a 
comparison between our X-ray structure of Thermus thermophilus (Tth) CarD in complex with 
the 1-lobe of Tth RNAP, solved to 2.4 Å resolution (4XAX (86); Fig. 1A), and the structure of 
Mtb CarD in complex with the RNAP- 1 and 2 lobes of Mtb RNAP (4KBM; (132)) solved to 
2.11 Å. The 1-lobes from each structure were aligned over 919 atoms in PyMOL (version 1.8 
Schrödinger, LLC) to give an RMS of 1.095 Å and interactions between the 1-lobe and the 
CarD-RID domains were compared. Many of the interactions were conserved between the Tth 
and Mtb structures (Fig. 1, B and D), but a significant difference was noted in a region that 
included a loop at the tip of the RID (residues 26-29 in Mtb) that was not modeled in the Mtb 
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structure, presumably due to a lack of density. Cartoon rendering by B-factors (PyMOL) of both 
structures revealed that this loop was highly disordered in Mtb, but well-ordered in Tth, 
presumably due to its interaction with the 1-lobe (Fig. 1C). In particular, the Tth structure 
revealed a non-polar interaction between loop residue V28 from CarD (I27 in Mtb) and I101 and 
I108 from the 1-lobe (I140 and I147 in Mtb) that was not visible in the Mtb structure due to 
disorder (Fig. 1B). Based on the Tth structure of the 1-lobe in complex with CarD, we predicted 
that the isoleucine side chain at position 27 of Mtb CarD likely contributes to an interaction 
between the Mtb CarD-RID and the Mtb 1-lobe that may not have been observed in the crystal 
structure due to crystal packing constraints. Furthermore, structural modeling predicts that 
removal of the isoleucine side chain at position 27 of the Mtb CarD-RID would weaken the 
interaction between the Mtb CarD-RID and the Mtb 1-lobe whereas substitutions of position 27 
with residues containing side chains that are more hydrophobic than isoleucine might strengthen 
the interaction between the Mtb CarD-RID and the Mtb 1-lobe.  
To test these predictions, we employed a bacterial two-hybrid assay that detects the 
interaction between the Mtb CarD-RID and the Mtb 1-lobe (101). In this assay, the interaction 
between WT Mtb CarD-RID and the Mtb 1-lobe results in a 3-fold increase in -galactosidase 
(-gal) activity from the two-hybrid test promoter (Fig. 1E). Substitution of I27 of the CarD-RID 
with alanine or glycine reduced the -gal activity to near background levels while substitution of 
I27 of the CarD-RID with the bulkier hydrophobic residues phenylalanine and tryptophan 
resulted in a 7-fold and 9-fold increase, respectively, in -gal activity relative to that observed 
with the WT Mtb CarD-RID (Fig. 1, E and F). The results of the two hybrid assays indicate that 
I27A and I27G substitutions weaken the interaction between the Mtb CarD-RID and the Mtb 1-
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lobe while I27F and I27W substitutions strengthen the interaction between the Mtb CarD-RID 
and the Mtb 1-lobe, consistent with the predictions from the structural modeling. 
To determine if the CarD I27F and I27W mutations increase the affinity of the interaction 
between CarD and RNAP-β subunit in vivo, we constructed Mycobacterium smegmatis strains 
expressing HA-tagged CarDWT, CarDR25E, CarDI27F, or CarDI27W. Co-immunoprecipitation 
experiments in M. smegmatis demonstrated that CarDI27W and CarDI27F mutants co-precipitated 
more RNAP-β than CarDWT (Fig. 1G). As previously reported, the CarDR25E mutant, which has 
lower affinity for RNAP-β than CarDWT, co-precipitated less RNAP-β than CarDWT (101). The 
CarDI27W mutant associated with more RNAP-β than CarDI27F, indicating a higher affinity 
interaction. To determine if mutations at I27 specifically affect only the interaction with RNAP 
and not DNA, we performed an electrophoretic mobility shift (EMSA) assay previously used to 
demonstrate CarD’s DNA binding activity (87, 108). This assay uses the rrnAPL DNA fragment, 
which contains the promoters and leader sequences of the M. smegmatis rRNA rrnA operon, and 
was chosen due to CarD’s described role in regulating rRNA transcription. In contrast to a 
mutation in the DNA binding domain of CarD (K125E) that abolished the ability of CarD to bind 
and shift DNA (108), neither CarDI27F nor CarDI27W affected CarD’s ability to bind and shift 
DNA, indicating that their effects are limited to CarD’s interaction with RNAP (Fig. 1H).  
CarDI27F and CarDI27W mutants stabilize open complexes at lower concentrations 
than CarDWT. CarD regulates transcription initiation by binding to and stabilizing RNAP-
promoter open complexes (Chapter 3, (86, 87, 108, 109, 123)). We have previously developed a 
fluorescence assay for CarD activity that reports on open complex formation in real-time. In this 
assay, a Cy3 label, which exhibits a 2-fold fluorescence enhancement in open complex, is 
incorporated at the +2 position on the non-template strand of the Mtb rrnAP3 promoter within a 
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linear fragment of Mtb genomic DNA containing nucleotides 1,470,151 to 1,470,300 (109). Mbo 
RNAP-σA holoenzyme with or without Mtb CarD is then mixed with the labeled DNA fragment 
via stopped-flow spectrophotometry and fluorescence is monitored for 20 minutes. The Cy3 
label increases fluorescence in the open complex conformation and thus the rate of open complex 
formation can be monitored as a change in fluorescence. The amplitude of the fluorescence 
intensity curve correlates to the equilibrium amount of open complex in a given condition (109). 
To monitor the effect of increasing the affinity of CarD for RNAP on the formation and stability 
of open complexes, we performed this assay with concentrations of CarDI27F and CarDI27W 
ranging for 0 to 1800 nM and fixed concentrations of RNAP (225 nM) and promoter DNA (10 
nM) (Fig. 2A). We found that the CarD concentration necessary to reach half of the maximum 
level of open complex at saturation (half-maximal concentration) was lower for CarDI27F (17 ± 2 
nM) and CarDI27W (23 ± 3 nM) than for CarDWT (59 ± 10 nM), consistent with a higher affinity 
of the CarD I27 mutants for RNAP in initiation complexes compared to CarDWT (Fig. 2A). 
  CarDI27F and CarDI27W mutants accelerate promoter opening at lower 
concentrations than CarDWT. We have previously reported modeling based on the trends of the 
slowest observed rate in the real-time fluorescent traces (kobs3) that suggests that CarD stabilizes 
open complex through a two-tiered concentration-dependent mechanism where CarD associates 
with both open and closed complexes with different affinities (109). More specifically, the model 
predicts that at low concentrations (i.e. < 100 nM), CarDWT binds to open complex and prevents 
bubble collapse, resulting in more open complex and a slower observed rate. The model further 
predicts that at higher concentrations, CarDWT binds to the closed complex and accelerates the 
rate of opening, resulting in still more open complex and an acceleration in the observed rate. 
Analysis of kobs3 as a function of CarD concentration was performed for the CarD I27 mutants as 
82  
previously described (109) (Fig. 2B). We found that the I27 mutants begin to accelerate kobs3 at 
lower concentrations (< 50 nM) than WT CarD (100 nM). In fact, for CarDI27W we did not 
observe a deceleration in kobs3 even at the lowest concentration tested (16 nM). The two-tiered 
kinetic model predicts that acceleration in kobs3 arises from CarD binding to closed complex, 
which increases the rate of promoter opening. Thus, our working model predicts that, even at 16 
nM, CarDI27W is associating with closed complex and accelerating opening. The acceleration of 
the observed rate at lower concentrations coupled with the lower half-maximal concentration for 
open complex stabilization is consistent with a model where the CarD I27 mutants have higher 
affinities to both closed and open RNAP-promoter complexes as compared to CarDWT. 
Increasing the affinity of CarD to RNAP increases formation of initial RNA 
products. To investigate whether increasing the affinity of CarD for RNAP affects RNA 
synthesis, we monitored initial product formation in a multi-round in vitro transcription assay 
(123). Mbo RNAP-σA holoenzyme was incubated with the promoter template used in the 
fluorescence assays, but without the Cy3 label, in the presence or absence of WT or mutant Mtb 
CarD. GpU dinucleotide was used as the initiating nucleotide and radiolabeled uridine 
triphosphate (UTP) was added as the extending nucleotide. Reactions were incubated for 20 
minutes, after which the amount of initial trinucleotide RNA products (GpUpU) were quantified. 
Addition of CarDWT protein increases the amount of initial RNA product formation ~6 fold as 
compared to the amount of product produced in the absence of CarD (Fig. 2C), whereas 
CarDR25E, which has decreased affinity for RNAP, only increases the amount of product formed 
~2 fold. In contrast, CarDI27F and CarDI27W increase the amount of product formed ~9 fold. 
These data demonstrate that increasing the affinity of CarD to the RNAP results in an increase in 
initial RNA product formation. We infer that the effect of strengthening the interaction between 
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CarD and RNAP on initial RNA product formation is a consequence of an increase in the 
formation of RNAP-promoter complexes (Fig 2). 
Increasing the affinity of CarD for RNAP stabilizes the CarD protein in Mtb. In 
previous work, we constructed a strain of Mtb in which a copy of carD is expressed from a 
constitutive promoter at the attB site, a non-endogenous chromosomal locus, and the endogenous 
copy of carD is deleted (85). We have previously shown that a strain of Mtb that expresses 
carDR47E, which encodes a protein with weakened affinity to the RNAP, from the attB site results 
in slower growth than a strain expressing carDWT from the attB site (Chapter 1, Fig. 1, (101)). To 
determine the effects of increasing the affinity of CarD for RNAP in the bacteria, we constructed 
Mtb strains expressing carDI27F or carDI27W from the attB site. We first determined the 
expression levels of the carD alleles in each strain by measuring carD transcript and protein 
levels. We found the CarDWT, CarDI27F, CarDI27W, and CarDR47E all produce equal levels of carD 
transcript, as expected given that the strains express the carD gene from the same promoter (Fig. 
3A). However, when we examined protein content in these strains we found that the CarDI27F and 
CarDI27W strains reproducibly had more CarD protein than the CarDWT strain (Fig. 3B). 
Additionally, this effect is proportional to the magnitude of the change in affinity, as the 
CarDI27W strain reproducibly has more CarD protein than the CarDI27F strain and the CarDWT 
strain had more CarD protein than CarDR47E. Given the equal amount of transcript being 
produced, the different levels of protein indicate post-translational differences in the stability of 
CarD protein in these strains. CarD has previously been identified as a Clp protease substrate in 
Mtb (133). Taken together, our data can be explained in the context of a model where CarD is 
protected from proteolysis when associated with RNAP.  
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Increasing CarD’s affinity for RNAP increases growth rate in Mtb. We have 
previously reported that decreasing CarD’s affinity for RNAP decreases growth rate in Mtb 
strain (Chapter 1 Fig 1, (101)). To determine the effect of increasing CarD’s affinity for RNAP 
on growth rate, we monitored growth in liquid Sauton’s media and found that the CarDI27F and 
CarDI27W strains had a faster doubling time than the CarDWT strain (26.31, 25.75, and 30.74 
hours doubling time, respectively) (Fig. 3, C and D). These results, as well as the growth defect 
previously reported in a strain expressing a CarD mutant with lower affinity for RNAP (101), 
demonstrate that the affinity of CarD to the RNAP can impact growth rate in Mtb.  
Increasing the affinity of CarD to RNAP does not result in differences in rRNA 
transcript levels in Mtb, despite the effects on growth rate. We have previously shown that 
decreasing the affinity of CarD for RNAP results in decreased rRNA levels and slower growth 
(Chapter 1 Fig. 1(101)). Because rRNA levels are often correlated to growth rate (119, 134, 135), 
the decreased rRNA levels in the CarD mutants with lower affinity for RNAP could contribute to 
the growth defect associated with these mutations. To determine the effect of increasing the 
affinity of the interaction between CarD and RNAP on regulation of rRNA transcription in the 
bacterium, we isolated RNA from exponential cultures of CarDWT, CarDI27F, and CarDI27W 
strains in Sauton’s media and performed quantitative real-time PCR (qRT-PCR) analysis for the 
levels of 16S rRNA (Fig. 3E). The CarD I27 mutants that have higher affinity for RNAP express 
the same amount of rRNA as the CarDWT strain, indicating that the faster growth in these strains 
is not a result of increasing rRNA expression. Therefore, rRNA levels and growth rate are 
uncoupled in strains expressing CarD proteins with varying affinities to RNAP. Thus, the effects 
of altering CarD’s affinity to RNAP on growth rate can occur independently of effects on rRNA 
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transcription. To the best of our knowledge, this is also the first report of rRNA transcription and 
growth rate being uncoupled in Mtb.  
Increasing the affinity of CarD for RNAP attenuates survival of Mtb during 
infection of mice. We have previously shown that weakening the interaction of CarD with 
RNAP results in decreased bacterial survival by 35 days post infection (dpi) in mice (Chapter 1, 
Fig. 1, (101)). To determine the effect of increasing the affinity of CarD for RNAP on virulence, 
we infected C57BL/6J mice with the Mtb CarDWT, CarDI27F, or CarDI27W strains and measured 
bacterial burden in the lungs at 21 and 35 dpi (Fig. 4). Both the CarDI27F and CarDI27W mutants 
were attenuated for survival in the mice and displayed significantly lower bacterial burden in the 
lungs (Fig. 4). Specifically, the CarDI27W strain displayed significantly lower bacterial burden 
than the CarDWT strain at 21 and 35 dpi while the CarDI27F strain had lower bacterial burdens 
than CarDWT at 35 dpi. The severity of the virulence defect in the CarD mutants mirrors the 
effect of these mutations on the affinity of CarD for RNAP, with CarDI27W exhibiting both a 
higher affinity and a more pronounced virulence defect than CarDI27F. These data show that 
although increasing the affinity of CarD to RNAP increases the rate of formation of transcription 
competent RNAP-promoter complexes and increases growth rates in culture, it results in a loss 
of virulence. The degree of attenuation at 35 dpi for the CarD I27 mutants is similar to that 
previously reported for Mtb strains expressing a mutant CarD protein with lower affinity to the 
RNAP (101). Thus, either decreasing or increasing the affinity of CarD for RNAP has a 
detrimental effect on virulence of Mtb. We, therefore, propose that this indicates that the affinity 
of CarD for RNAP is finely tuned to the physiology of this obligate pathogen to optimize 
virulence. 
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Discussion 
In this manuscript, we have investigated both the biochemical and physiological effects 
of increasing the affinity of CarD for RNAP. Our findings reveal new aspects of CarD regulation 
and the effect of increasing the affinity of CarD for RNAP-β on growth rate and virulence.  
Using a real-time fluorescence assay we found that increasing the affinity of CarD to 
RNAP leads to a decrease in the concentration of CarD required for half-maximal open complex 
formation and stability (Fig 2A). Our data further show that the higher affinity CarD mutants 
result in increased stability of an RNAP-promoter complex and an increase in the formation of 
initial RNA products (Fig. 2C). However, despite these positive effects of the CarD I27 mutants 
on the formation of transcription competent RNAP-promoter complexes at rrnAP3 in vitro, Mtb 
strains expressing CarDI27F or CarDI27W did not contain higher levels of rRNA than the CarDWT 
strain (Fig. 3E). Therefore, there must be other factors at play in vivo that impact whether rRNA 
transcription responds to changes in the affinity of CarD to the RNAP.  
We found that increasing to affinity of CarD for RNAP results in an increase in growth 
rate without changing the levels of rRNA (Fig. 3C and D). Furthermore, we found that increasing 
the affinity of CarD to RNAP in Mtb results in attenuated virulence in mice (Fig. 4). Together 
these findings demonstrate that the differences in growth rate and virulence of the CarD I27 
mutant strains are not a result of altered rRNA content but are instead another consequence of 
varied levels or activity of CarD proteins, thus uncoupling the role of CarD in regulating rRNA 
content from its effect on growth rate. Therefore, the essential function of CarD is unlikely to be 
limited to regulation of rRNA expression. In fact, CarD is localized to promoter-bound RNAP 
holoenzymes throughout the genome (87). We have shown that in the absence of CarD, the 
mycobacterial RNAP is only weakly able to form open complexes at rrnAP3 (86, 109, 123). 
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These studies suggest that CarD may in fact be a general component of the transcription 
initiation machinery in mycobacteria and that its essential role is enabling the mycobacterial 
RNAP to efficiently form open complexes at all promoters in the genome. In particular, changes 
in the affinity of CarD to the RNAP could result in a global dysregulation of gene expression. 
Alternatively, phenotypes of CarD mutants may result from deregulation of a specific subset of 
genes differentially regulated by CarD. It should also be noted that, despite the presence at all 
promoters, at this point CarD activity has only been evaluated at mycobacterial rRNA promoters 
and consensus promoters from E. coli. Therefore, a priority of future work will be to clarify the 
role of CarD in global transcription regulation. 
 Using multiple CarD mutants, we have also revealed a role for the CarD-RNAP 
interaction in regulating CarD protein levels. Increasing the affinity of CarD for RNAP increases 
the cellular concentration of CarD without affecting carD transcript levels (Fig. 3, A and B). The 
effect on CarD protein concentration is proportional to the affinity for RNAP and, of the strains 
expressing carD from the attB site, CarDI27W has the highest affinity for RNAP and the highest 
concentration of CarD protein while CarDR47E has the lowest affinity for CarD and the lowest 
CarD protein levels (Fig. 3, A and B). These data suggest that CarD is protected from proteolytic 
degradation while associated with RNAP. Since CarD is a known target of the Clp protease in 
mycobacteria (133), one possibility is that Clp-mediated degradation of CarD is more efficient 
when CarD is not associated with RNAP. Thus, our findings provide a mechanistic explanation 
for our previous observation that mycobacteria contain a similar concentration of CarD and the 
housekeeping sigma factor (109) and suggest that there may be a detrimental effect of excess, 
free cellular CarD.  
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Figure Legends 
Figure 1. Single point mutations in CarD specifically increase CarD’s affinity to RNAP-β.  
A. Crystal structure of Tth CarD in complex with the 1-lobe of Tth RNAP reveals 
molecular interactions between the two proteins at high resolution (2.4 Å) detail.  
B. Structural alignment of the 1-lobes of Tth CarD:1-lobe and Mtb CarD:1-lobe 
structures to compare the interactions between CarD-RID and RNAP-in each 
organism.  
C. Atom displacement was rendered visually using PyMOL B-factor rendering. The 
spectrum scale above illustrates a range of low B-factors (highly ordered, blue 
indicates under 30%) to high B-factors (disordered, red indicates 90% or higher).  
D. Alignment of Tth (top) and Mtb (bottom) CarD-RID comparing interactions with their 
cognate RNAP 1-lobe. Black shading indicates residues that are identical and yellow 
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shading indicates residues that are homologous. The following groups are considered 
homologous: (R, K), (E, D), (V, I, L, M, A), (S, T), and (Q, N). Bullets are defined in 
the figure by interactions unique to each organism or shared by both.  
E-F. Results of -galactosidase assays (101, 131) examining the effects of amino acid 
substitutions at position 27 of the Mtb CarD-RID on the interaction between the Mtb 
CarD-RID and the Mtb 1-lobe. The bar graphs show β-galactosidase activity in 
Miller units observed in assays done using cells containing the indicated Mtb CarD-
RID derivative and the Mtb β1 lobe as well as assays done using cells containing only 
the Mtb β1 lobe. Each graph shows the mean ± SEM of data from five replicates. 
Statistical significance was analyzed by ANOVA and Tukey’s multiple comparison 
test. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; or ****, p ≤ 0.0001.   
G. Immunoprecipitation experiments with a monoclonal antibody specific for HA in the 
M. smegmatis ΔcarD attB::tet-carD strain expressing CarDWT-HA (lane 1), CarDR25E-
HA (lane 2), CarDI27F-HA (lane 3), or CarDI27W-HA (lane 4). Immunoprecipitated 
eluates were analyzed by western blotting with monoclonal antibodies specific for 
either RNAP-β or CarD. (H) Autoradiograph of EMSA with Mtb CarDI27F, Mtb 
CarDI27W, no protein, M. smegmatis CarDK125E, or M. smegmatis CarDWT incubated 
with 20,000 cpm (approximately 0.6 ng) of [γ32P]ATP-radiolabeled M. smegmatis 
rrnAPL DNA. The reactions were separated on a non-denaturing polyacrylamide gel, 
which was then dried and exposed to film.  
Figure 2. Effects of increasing the affinity of CarD for RNAP on open complex stability.  
A. Equilibrium fluorescence fold-change normalized to the fold-change at high CarD 
concentrations (saturation) for each mutant of CarD with 225 nM Mbo RNAP-σA and 
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10 nM Cy3-labeled Mtb rrnAP3 promoter. Both Mtb CarDI27F (red triangles) and 
CarDI27W (blue squares) mutants achieve a half-maximal effect (dashed line) at lower 
concentrations (17 ± 2 nM for CarDI27F, and 23 ± 3 nM for CarDI27W) than Mtb 
CarDWT (black circles, 59 ± 10 nM).  
B. kobs3, calculated using ProData Viewer software from Applied Photophysics, of open 
complex formation as a function of CarD concentration for Mtb CarDWT (black 
circles), CarDI27F (red triangles), and CarDI27W (blue squares). The legend for B is 
shared with A.  
C. In vitro transcription assay showing a representative gel and a graph of the ratio of the 
amount of 3nt initial transcript formed by 200 nM Mbo RNAP-σA from 10 nM of a 
linear DNA fragment in the presence of 2 µM CarD versus in the absence of CarD for 
reactions containing no CarD, Mtb CarDWT, CarDR25E, CarDI27F, or CarDI27W. The 
graph shows the mean ± SEM of data from at least four replicates. Statistical 
significance was analyzed by ANOVA and Tukey’s multiple comparison test. *, p ≤ 
0.05; **, p ≤ 0.01; ***, p ≤ 0.001; or ****, p ≤ 0.0001. 
Figure 3. Increasing CarD’s affinity for RNAP results in more stable CarD protein and faster 
growth without a change in rRNA expression.  
A. The ratio of carD transcript levels in exponential cultures of the ΔcarD attB::tet-carD 
strain expressing CarDI27F, CarDI27W, or CarDR47E to levels in the CarDWT strain when 
grown in Sauton’s media. Transcript levels were determined using qRT-PCR and 
normalized to sigA.  
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B. Western blot analysis of two biological replicates of lysates from the same cultures as 
used in (A). Membranes were blotted with a monoclonal antibody against RNAP-β 
(top) or a polyclonal antibody against CarD (bottom).  
C. Representative growth curves of the ΔcarD attB::tet-carD strain expressing CarDWT 
(circles), CarDI27F (squares), or CarDI27W (triangles) in Sauton’s media.  
D. Doubling times of the ΔcarD attB::tet-carD strain expressing CarDWT, CarDI27F, or 
CarDI27W in Sauton’s media.  
E. Ratio of 16S rRNA levels in exponential cultures of the ΔcarD attB::tet-carD strain 
expressing CarDI27F or CarDI27W to levels in the CarDWT strain when grown in 
Sauton’s media. Transcript levels were determined using qRT-PCR and normalized to 
sigA.  
Each graph shows the mean ± SEM of data from at least three replicates. Statistical 
significance was analyzed by ANOVA and Tukey’s multiple comparison test. n.s. = 
not significant, *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; or ****, p ≤ 0.0001. 
Figure 4. Increasing CarD’s affinity for RNAP attenuates Mtb in a mouse model of infection.  
Dot plot of colony forming units (CFU) in the lungs of C57BL/6J mice infected with the 
ΔcarD attB::tet-carD strain expressing either CarDWT (circles), CarDI27F (squares), or 
CarDI27W (triangles). Each time point is the mean ± SEM of data from at least 6 mice 
per strain. Statistical significance was analyzed by ANOVA and Tukey’s multiple 
comparison test. *, p ≤ 0.05; **, p ≤ 0.01; ***, or p ≤ 0.001. All comparisons were 
tested and only significantly different comparisons are shown. 
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Abstract 
CarD is an RNA polymerase (RNAP) binding protein conserved in numerous bacterial 
species and essential in mycobacteria. Chromatin immunoprecipitation sequencing reactions 
have shown that CarD is globally localized to promoters throughout the genome. However, thus 
far its function has only been studied in detail at ribosomal RNA (rRNA) promoters and 
consensus Escherichia coli promoters. In this study we utilize a panel of Mycobacterium 
tuberculosis and Mycobacterium smegmatis strains that express different concentrations of 
CarDWT or CarD mutants to define the in vivo CarD regulon in these species. The CarD 
mutations we examine individually target either CarD’s interaction with RNAP or DNA. These 
studies are the first to investigate the regulatory activity of CarD at non-rRNA promoters and 
provide the first evidence that CarD is important for regulation of the majority of promoters in 
M. tuberculosis. We show that CarD activity is influenced by promoter sequence by identifying a 
correlation between promoter motifs and regulation by CarD. In M. smegmatis, we provide 
evidence of an effect of the nucleoid associated protein EspR on gene expression in CarD 
mutants. These studies provide new information regarding the global regulatory activity of CarD 
in mycobacteria and provide the first insights into determinants of CarD-mediated regulation. 
Introduction 
Ribosomal RNA (rRNA) operons include the most well characterized mycobacterial 
promoters, regulation of which is essential for growth and viability. Early studies of CarD found 
that depletion of CarD regulates rRNA and we therefore chose to focus our initial efforts to 
characterize CarD’s activity as a transcriptional regulator on these operons. In vivo, CarD has 
been shown to activate transcription from rRNA promoters, and to be required for wild-type 
(WT) levels of rRNA in the cell (Chapter 2 Fig. 6, (87, 108)). Biochemically, we have shown 
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that CarD stabilizes the RNA polymerase (RNAP)-promoter open complex (RPo) formed during 
transcription initiation (Chapter 2, Fig. 7, (87, 108, 109, 123)). These studies have contributed to 
a model in which CarD’s N-terminal domain interacts with the RNAP β-subunit (Chapter 1 Fig. 
1, (85, 101)). At transcription initiation complexes, this interaction with RNAP positions CarD’s 
C-terminus to interact with DNA just upstream of the -10 promoter motif (Chapter 1 Fig. 3, (86, 
87)). The interaction between CarD and DNA is electrostatic, mediated by a basic patch on 
CarD, and is sequence independent (Chapter 1 Fig. 3, (87, 108)). CarD interacts with the RPo 
with high affinity and stabilizes RPo by reducing the rate of collapse back to RNAP-promoter 
closed complex (RPc). CarD interacts with RPc with lower affinity, but at physiologically 
relevant concentrations (Chapter 2 Fig. 8, (109)). This interaction with RPc promotes melting of 
the promoter and transition to RPo (109). In addition to CarD’s interactions with RNAP and with 
promoter DNA, CarD has a conserved tryptophan residue (W85) that has been proposed to 
wedge into the splayed minor groove at the upstream edge of the transcription bubble to stabilize 
RPo (86, 87, 108). To date, this model of CarD activity has only been tested on rRNA promoters 
and consensus Escherichia coli promoters (86, 108, 109, 123). 
A prominent open question in CarD research concerns its effect at non-rRNA promoters. 
Chromatin immunoprecipitation sequencing (ChIP-seq) experiments have shown that CarD is 
globally localized to promoters throughout the Mycobacterium smegmatis chromosome, 
suggesting it may be a general member of the transcription initiation machinery in mycobacteria 
(Chapter 1 Fig. 2, (87)). Additionally, several groups have shown that, compared to the E. coli 
RNAP, the mycobacterial RNAP is inherently deficient in formation of stable RPo and may 
require CarD to form stable, initiation-competent complexes (109, 123). If CarD’s activity at 
rRNA promoters is representative of its activity at all promoters, then we would expect a global 
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decrease in transcription in the absence of CarD. However, initial microarray experiments in M. 
smegmatis that compared CarD-depleted cells to cells expressing CarD found only a small 
portion of the genome to be deregulated greater than 2-fold. Importantly, interpretation of these 
results is confounded by the cell death caused by CarD-depletion, which also affects transcript 
abundance (85). It is therefore difficult to determine the extent of the CarD regulon from this 
experiment.  
During our studies, we have constructed numerous strains of mycobacteria in which 
CarD’s ability to regulate transcription is affected without causing cell death. Decreasing the 
affinity of CarD’s interaction with either RNAP or DNA causes in vivo phenotypes including 
decreased ability of CarD to activate transcription of rRNA promoters, decreased growth rate, 
and increased stress sensitivity (Chapter 1 Fig. 1, Chapter 2 Fig. 2, 3, 5, and 6, (87, 101, 108). 
Biochemically, we have shown that mutations that weaken these interactions attenuate CarD’s 
ability to stabilize the open complex, which is crucial for CarD-mediated transcriptional 
regulation (Chapter 2 Fig 7, (87, 108, 109, 123)). Together these results show that CarD’s 
interactions with both RNAP and DNA are crucial for its transcriptional regulatory activity (101, 
108, 109). We have also developed mutants (CarDI27F and CarDI27W) with increased affinity for 
RNAP (Chapter 3). These mutations stimulate of production of a 3nt aborted transcript and 
increase the half-life of RNAP-promoter complexes as compared to CarDWT (Chapter 3 Fig. 2, 
(136)). In vivo, these strains have similar expression of rRNA as CarDWT encoding strains but 
grow faster than the CarDWT strain (Chapter 3 Fig. 3, (136)). Additionally, CarD’s regulatory 
activity is concentration-dependent: in vitro assays have shown that both the amount of open 
complex at equilibrium and the kinetics of RPo formation are influenced by CarD concentration 
(109). In vivo, mycobacteria upregulate carD in response to numerous stresses, which suggests 
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that varying the concentration of CarD might affect gene expression (85). These viable strains 
with altered CarD activity represent a powerful tool with which we can assay CarD’s regulatory 
role at non-rRNA promoters.  
To determine the role of CarD in regulation of non-rRNA promoters and identify factors 
that may modify CarD’s activity, we performed RNA sequencing (RNA-seq) analysis of the 
transcriptomes of Mtb strains that express either mutants with individually attenuated CarD 
activities (e.g. DNA binding, RNAP binding) or that express different concentrations of the CarD 
protein. We show that CarD is important for regulation of the majority of transcripts in Mtb, but 
observe variable effects on regulation of specific transcripts, which suggests CarD’s activity may 
be affected by promoter characteristics or other factors such as genomic architecture or nucleoid 
associated proteins. By analyzing DNA sequences upstream of transcription start sites of 
regulated transcriptions, we found a correlation of -10 promoter motifs with transcripts 
deregulated upon alterations in CarD. We find that transcripts lacking a recognizable -10 
promoter motif are more sensitive to alterations in CarD than promoters with recognizable 
motifs. These studies represent a major advance in our understanding of CarD activity at non-
ribosomal promoters and its role in promoting efficient gene expression in the cell.  
Experimental Procedures 
Bacterial strains and growth conditions. All Mtb strains were derived from the Erdman 
strain and were grown at 37°C in Sauton’s broth media (0.5 g L-1 KH2PO4, 0.5 g L-1 MgSO4, 4 g 
L-1 L-asparagine, 60 ml glycerol, 0.05 g L-1 ferric ammonium citrate, 2.0 g L-1 citric acid, 0.1 ml 
L-1 1% ZnSO4, 0.05% Tween 80, pH 7.0). Gene switching was used to construct the mgm3080, 
csm230, csm231, csm195, and csm196 strains of M. tuberculosis (expressing CarDWT, CarDI27F, 
CarDI27W, CarDR47E, and CarDK125A, respectively) used in this study. Construction of these strains 
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has been detailed in previous studies (85, 101, 108, 136).  
All strains used in this manuscript encode only one carD allele. 
RNA Preparation. RNA was prepared from 30 ml of log-phase M. tuberculosis 
Mgm3080 (CarDWT), csm230 (CarDI27F), csm231 (CarDI27W), csm195 (CarDR47E), and csm195 
(CarDK125A) in triplicate, as previously described (85). 1-5 µg of DNA-free RNA from each 
replicate was submitted to the Genome Technology Access Center (GTAC) at Washington 
University. Ribozero was used to deplete rRNA and Illumina sequencing was used to determine 
the transcriptome of each strain. 
Construction of Venn Diagrams. Venn diagrams were constructed through the use of 
either https://www.stefanjol.nl/venny or Venny website (137). Some final images in this paper 
were further modified. 
Alignment of Sequencing Reads. The short reads from the next-generation sequencing 
machine are aligned to the genome of interest using Tophat software. Tophat allows splitting the 
reads to align to the genome to address alternate splicing. Since our genomes of interest do not 
contain introns, the choice of aligners is not an issue. After the reads were aligned to the genome, 
we found the average coverage per gene using HTSEQ package (138). HTseq allows counting 
the reads per gene, per exon or any other genomic feature as indicated in the general feature 
format (GFF) file. The average coverage per gene depends on the two factors: the biology and 
the total number of reads sequenced per sample. In order to eliminate the bias introduced by 
different read counts in different samples, we employed “upper quantile” normalization. The 
genes that are differentially expressed between different experimental conditions are found using 
DEseq package (139). We applied a false discovery rate of 0.01 to select genes that are 
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differentially expressed between multiple experimental conditions. All the plots were generated 
using custom scripts in R. 
Results 
Decreasing CarD’s affinity for RNAP or DNA causes non-uniform deregulation of 
expression of the majority of the genes in Mtb with a high degree of similarity between the 
two sets of deregulated genes. In previous work, we constructed strains of Mtb in which a copy 
of carD is expressed from a constitutive promoter at the attB site, a non-endogenous 
chromosomal locus, and the endogenous copy of carD is deleted (85). We have previously 
shown that the decreasing CarD’s affinity for RNAP (CarDR47E) or DNA (CarDK125A) causes 
decreased growth rate, deregulated rRNA expression, and increased stress sensitivity (Chapter 1 
Fig. 1, Chapter 2 Fig. 2, 3, 5, and 6, (87, 101, 108)). While the CarDK125A mutation does not 
affect CarD’s ability to bind DNA in an EMSA assay, the mutation is within the DNA binding 
basic patch and has phenotypes consistent with an effect on DNA binding in vivo (Chapter 2, 
(108)). We have shown biochemically that weakening the interaction with RNAP or DNA 
decreases CarD’s ability to stabilize open complex at rRNA promoters (Chapter 2 Fig. 7, (108, 
109)). To determine the effect of these mutations on transcriptional regulation of non-rRNA 
promoters, we compared the transcriptomes of the strains expressing CarDR47E or CarDK125A to a 
strain expressing CarDWT from the same chromosomal locus (Table 1), (mgm3080, designated as 
CarDWT). Importantly, while the carD transcript is expressed similarly, we have previously 
shown that the CarDR47E strain has a lower cellular concentration of CarD than the CarDWT strain 
(Chapter 3, Fig. 3). Decreasing CarD’s affinity for RNAP had global effects on the Mtb 
transcriptome, significantly deregulating 2,454 transcripts, or 61% of the transcriptome when a 
false discovery rate (FDR) of less than 0.01 is used to determine significance and no fold-change 
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cut off is imposed (Fig. 1A). The fold change of deregulated transcripts varies from 1.23-8.36 
fold-upregulated and 1.24-3.93 fold-downregulated with an average of 1.57-fold upregulated or 
1.52 fold downregulated. If we use this average deregulation as a fold change cut off and only 
look at transcripts deregulated greater than 1.5-fold, CarDR47E upregulated 611 transcripts and 
downregulates 483. The CarDK125A mutation also had dramatic effects on the transcriptome, 
significantly deregulating 2,247 transcripts, of which 743 were deregulated greater than 1.5-fold 
(Fig. 1B). In this strain, transcripts were significantly upregulated between 1.12 and 43.11 
(average of 1.53) while transcripts were downregulated between 1.12 and 6.10 (average of 1.42). 
Both the CarDR47E and CarDK125A mutants decrease growth rate, decrease rRNA levels, increase 
antibiotic sensitivity, decrease virulence, and attenuate CarD’s ability to stabilize RPo. The 
phenotypic similarity of these two mutants is reflected in their effect on the transcriptome of 
Mtb, as 86.1% of transcripts significantly down regulated by CarDK125A and 80.4% of transcripts 
upregulated by CarDK125A without a fold change cut off, are similarly down or upregulated by 
CarDR47E (Fig 1C). Only 0.3% of transcripts downregulated by CarDK125A and 1.2% of transcripts 
upregulated by CarDK125A are inversely regulated in the CarDR47E strain. This indicates that 
CarD’s interactions with RNAP and/ or DNA are broadly required for CarD mediated gene 
regulation and supports phenotypic analysis that suggested that the requirement for these 
activities are linked such that transcripts are more likely to require both than either 
independently.  
The one phenotype that is not shared between mutants with decreased affinity for RNAP 
or DNA is sensitivity to oxidative stress, which is observed only in mutants with decreased 
affinity for RNAP or mutation of the conserved W85 residue (Chapter 1 Fig. 1, Chapter 2 Fig. 3, 
(101, 108)). Based on this difference in sensitivity to oxidative stress, it was suggested that there 
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are transcripts deregulated by decreasing CarD’s affinity for RNAP that are not deregulated by 
decreasing CarD’s affinity for DNA (Chapter 2, (108)). While the CarDR47E strain does 
upregulate 301 transcripts and downregulate 264 transcripts that are not shared with CarDK125A 
and CarDK125A upregulates 232 and downregulates 135 transcripts that are not shared with 
CarDR47E, we found no differences in regulation of examined genes known to respond to, or 
regulate the response to, oxidative stress. Importantly, this study is examining the transcriptome 
of exponential cultures not being subjected to oxidative stress. It remains likely that these two 
mutants have distinct transcriptional responses to oxidative stress that simply isn’t apparent in 
the absence of the stress. 
Analysis of the transcriptome of loss-of-function CarD mutants suggests that 
CarDWT can act as a transcriptional repressor. At rRNA promoters, decreasing CarD’s 
affinity for RNAP or DNA has been shown to decrease CarD’s effect on stabilization of RPo in 
vitro, which decreases transcription from these promoters in vivo (Chapter 2 Fig. 6 and 7, (87, 
108, 109)). If CarD similarly activates transcription from all promoters it regulates, then 
decreasing CarD’s affinity for either RNAP or DNA would uniformly result in downregulation 
of directly regulated transcripts. This is not supported by the RNA-seq data as transcripts 
deregulated in either CarDR47E or CarDK125A are slightly more likely to be upregulated in these 
mutants than downregulated (53.8% and 56.2% of transcripts deregulated in CarDR47E and 
CarDK125A, respectively, are upregulated, Fig. 1AB). While upregulation of some transcripts may 
result from indirect effects through deregulation of other transcription regulators, the prevalence 
of upregulated transcripts in these strains supports a direct role for CarD in the repression of 
transcripts. Assuming that CarD stabilizes RPo at all regulated promoters, CarD likely represses 
transcription by hyperstabilizing RPo and inhibiting promoter escape or transition to the 
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elongation complex. The ability of a transcription factor that regulates transcription by 
stabilizing an RNAP-promoter complex to activate or repress transcription in a promoter-specific 
manner has previously been described for the phage ϕ29 protein p4 (124). While the ability of 
CarD to repress transcription must still be demonstrated biochemically, these data are the first to 
suggest that this may be a physiologically relevant activity of CarD. 
Increasing CarD’s affinity for RNAP deregulates the transcriptome differently than 
mutations than loss of function mutants. We have previously characterized two mutants of 
isoleucine 27 in CarD’s N-terminal domain (CarDI27F and CarDI27W) that both increase CarD’s 
affinity for RNAP (Chapter 3, (136)). In vivo, increasing CarD’s affinity for RNAP causes less 
severe phenotypes than decreasing CarD’s affinity for RNAP or DNA: CarDI27F and CarDI27W 
are not sensitized to any stress that has been tested (treatment with streptomycin, rifampicin, 
ciprofloxacin, ethambutol, or hydrogen peroxide), nor do these mutations cause deregulation of 
rRNA (Chapter 3 Fig. 3). Increasing CarD’s affinity for RNAP results in faster growth than the 
CarDWT strain in liquid Mtb cultures, however it does not increase the fitness of Mtb as these 
mutations cause a virulence defect in mice (Chapter 3 Fig. 3 and 4, (136)). In keeping with these 
mild in vivo phenotypes, when we compare the transcriptomes of the high affinity mutants to the 
CarDWT strain we find that increasing CarD’s affinity for RNAP has a smaller effect on the 
transcriptome than was observed in the loss-of-function mutants. In the CarDI27F and CarDI27W 
strains, a total of 912 and 1,333 transcripts are deregulated, respectively, compared to the 
CarDWT strain when a FDR of less than 0.01 is used to determine significance and no fold 
change cut off is imposed on the data (Fig. 2A). The fold change of up and downregulated 
transcripts, respectively, in the CarDI27F strain varies from 1.23-8.36-fold change with an average 
of 1.56 and 1.24-3.93 fold change with an average of 1.53. Similarly, the fold change of 
106  
transcripts in the CarDI27W strain varies from 1.22-13.96-fold change with an average of 1.57 for 
upregulated transcripts and 1.21-4.20 with an average of 1.53 for downregulated transcripts. 
When the data are constrained by a 1.5-fold change cut off, 390 (250 upregulated, 140 
downregulated) and 590 (365 upregulated, 224 downregulated) transcripts are deregulated in 
CarDI27F or CarDI27W, respectively. The I27F and I27W mutations both strengthen the affinity of 
CarD for RNAP, but this effect is more pronounced in the I27W mutant (Chapter 3 Fig. 1, 
(136)). Similarly, the transcripts deregulated in the CarDI27F and CarDI27W strains overlap 
heavily, but a larger number of transcripts are deregulated in the CarDI27W strain (Fig. 2C). There 
are no transcripts upregulated in one high-affinity mutant and downregulated in the other, which 
underlines the similarity in the effects of these two mutations.  
CarD has a stronger affinity for RNAP and is more highly expressed in the CarDI27F and 
CarD127W strains than the CarDWT strains; conversely, CarD has a weakened affinity for RNAP 
and is less highly expressed in the CarDR47E strain than the CarDWT strain. We would therefore 
predict that these two classes of CarD mutants should have opposite effects on the transcriptome. 
We find that 69.8% and 68.3% of transcripts deregulated in CarDI27F and CarDI27W, respectively, 
are also deregulated in CarDR47E (Fig. 3AB). Importantly, 30% of transcripts deregulated in these 
mutants were not deregulated in the CarDR47E strain, which indicates that transcripts deregulated 
in individual mutants do not completely define the CarD regulon and highlights the importance 
of testing the effect of numerous alterations in CarD on transcript regulation. CarDI27F and 
CarDI27W, respectively, have the opposite effect as CarDR47E on regulation of 72.4% and 68.9% 
of the transcripts that are deregulated in both CarDR47E and the indicated I27 mutants, which 
supports our prediction based on our understanding of these CarD mutants. We predict that the 
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transcripts that are similarly deregulated in the I27 mutants and the CarDR47E mutant are likely 
the result of indirect regulation through deregulation of other transcription factors.  
Increased concentrations of CarDWT are correlated with increased growth rate in 
Mtb. We have previously demonstrated different concentrations of CarD in strains of Mtb 
expressing CarD mutants with altered affinity for RNAP (Chapter 3, Fig.3). To directly assay the 
effect of CarD concentration on gene expression we wanted to compare two strains expressing 
the same allele of CarD but at different cellular concentrations. When we compare expression of 
the carD allele from the endogenous locus to expression of carD from the non-endogenous locus 
used in our engineered CarD strains we find that carD is expressed 3.4 fold higher in the WT 
Mtb strain than the CarDWT strain (Fig. 4A). This difference in gene expression is reflected in 
protein concentration as the WT Mtb strain also expressed higher concentration of the CarD 
protein (Fig. 4B). This higher cellular concentration of CarD has phenotypic effects on the 
bacterium including increased growth rate (Fig. 4C) in the WT Mtb strain.  Interestingly, the 
growth rate in WT Mtb is comparable to the growth rate previously reported in the CarD mutants 
with higher affinity (24.2, 26.3, and 25.8 hours doubling time for WT Mtb, CarDI27F, and 
CarDI27W respectively) despite the WT Mtb strain having higher cellular concentrations of CarD 
than the high affinity mutants (Fig. 4B). Therefore, increasing the affinity of CarD to the RNAP 
can compensate for the negative effect of lower levels of carD expression on growth rate. These 
results, as well as the growth defect previously reported in a strain expressing a CarD mutant 
with lower affinity for RNAP (101), suggest that a minimum amount of CarD must associate 
with RNAP at initiation complexes for WT-like growth. Importantly, we have previously shown 
similar expression of rRNA in the high affinity mutants and the CarDWT strain, suggesting that 
CarD’s effect on growth can be independent from its effect on rRNA regulation (Chapter 3, Fig. 
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3). To determine in the higher concentration of CarD in the WT Mtb strain was rescuing growth 
through higher expression of rRNA we performed qRT-PCR on exponential cultures of WT Mtb 
and the CarDWT strain.  Similar to results from the high affinity mutants, we found similar 
expression of rRNA in these strains (Fig. 4D).  
Increasing the concentration of CarD for RNAP attenuates survival of Mtb during 
infection of mice. To determine if the concentration of CarD affects virulence, we compared the 
virulence of WT Mtb and CarDWT in C57BL/6J mice in the lungs at 21 and 35 dpi (Fig. 4E). We 
found that at 35 dpi WT Mtb had significantly lower bacterial burdens in the lungs than the 
CarDWT strain (Fig. 4E), which expresses lower levels of carD transcript and has lower cellular 
concentrations of CarD protein (Fig. 4AB). Therefore, the CarD concentration-dependent growth 
defect of the CarDWT strain does not cause a virulence defect in mice and in fact correlates with 
higher bacterial burden in early chronic infection. These data highlight the impact of differences 
in CarD protein concentration on the fitness of Mtb and may support the importance of 
regulating CarD protein levels. 
Changes in CarD concentration cause significant, non-uniform deregulation of the 
majority of the transcriptome. The differences in both growth rate and virulence of the CarDWT 
and the WT Mtb strains indicate that the cellular concentration of CarD in vivo can affect gene 
expression. This corresponds to in vitro data in which, when experiments are performed with a 
constant concentration of RNAP, the amount of RPo formed at equilibrium is dependent on the 
concentration of CarD in the reaction (109). To determine how altering CarD’s cellular 
concentration affects CarD’s regulon, we performed RNA-seq on exponential cultures to 
compare the WT Mtb, which expresses carD from the endogenous locus, and the CarDWT strain, 
in which carD is expressed at a lower level from the attB locus. To be consistent with other 
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comparisons in this study, we designated the CarDWT strain as the control. When we use a FDR 
cut off of less than 0.01 to determine significance and do not impose a fold change cut off, 52% 
of the transcriptome is significantly deregulated in the WT Mtb strain when compared to the 
CarDWT strain (Fig. 5A). Within these deregulated transcripts, we find a similar number of 
transcripts up- and downregulated, with large variations in the fold change in expression. 
Downregulated transcripts vary from 1.11 to 60.24 fold lower in WT Mtb, with an average fold 
change of 1.39. Upregulated transcripts vary from 1.15 to 8.25 fold higher in the WT Mtb strain, 
with an average fold change of 1.50. This variability in response to altered CarD concentration 
suggests that CarD’s activity may be influenced by promoter specificity or other intrinsic 
properties of these transcripts, such as genomic location, in a manner that is affect by 
concentration of CarD as well as alterations in its activities. If we impose a fold-change cut-off 
on the data and only look at deregulated transcripts with greater than 1.5-fold changes, then 315 
transcripts are downregulated in WT Mtb and 283 transcripts are upregulated, for a total of 598 
transcripts or 15% of the transcriptome. The dramatic decrease in the number of genes affected 
by alteration in CarD concentration upon implementation of a fold-change cut off indicates that 
changes in CarD concentration has a subtle but significant effect on the majority of transcripts 
that are sensitive to CarD concentration. Importantly, there is a sizeable portion of the 
transcriptome that is more substantially affected by CarD concentration and it is likely 
deregulation of these transcripts that causes the growth defect in the CarDWT strain (Chapter 3 
Fig. 3, (136)).  
Both concentration and affinity are important drivers of transcript regulation in 
CarD mutants with increased affinity for RNAP. In addition to their direct effects on RNAP 
affinity, mutations of CarD’s RNAP interacting domain (RID) also affect the cellular 
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concentration of CarD. Specifically, we have shown that the cellular concentration of CarD 
protein in strains that express carD from the attB site is proportional to CarD’s affinity for 
RNAP with CarDR47E having the lowest affinity and concentration, followed by CarDWT, 
CarDI27F, and CarDI27W, which has both the highest affinity and the highest cellular 
concentration. The WT Mtb strain, which has higher transcriptional expression of carD, has the 
highest cellular concentration of CarD protein (Chapter 3 Fig. 3, (136)). Our RNA-seq analysis 
of the WT Mtb strain demonstrated that gene expression can be affected by CarD protein 
concentration. Both the similarity of the CarDR47E and CarDK125A transcriptomes and our in vitro 
analysis of CarD mutants indicate that affecting CarD’s affinity for RNAP directly affect gene 
expression in a concentration-independent manner. To gain insight into the roles for alterations 
in concentration and affinity in the deregulation of transcripts in the CarD RID mutants we 
analyzed the expression of individual transcripts within each mutant in comparison to either WT 
Mtb or CarDWT as well as in comparison of the two CarDWT encoding strains to each other.  
We initially examined the roles for affinity and concentration in deregulation of 
transcripts in the high affinity CarD mutants. Because we know both the relative CarD 
concentrations and affinities of CarD for RNAP in these four strains (CarDWT, WT Mtb, 
CarDI27F, and CarDI27W), one can predict gene expression patterns for various regulatory 
possibilities (Table 2). Since both CarDI27F and CarDI27W have higher affinity for RNAP than 
either strain that encodes a WT allele of CarD and a cellular concentration of CarD that falls 
between the two WT encoding strains we would predict similar gene expression profiles in 
response to different regulatory possibilities and will therefore refer to the two mutants 
collectively during this discussion.  
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In the simplest regulatory schemes, regulation of a gene may be exclusively affected by 
either alteration of affinity (scheme A) or concentration (scheme B). If regulation of a gene is 
exclusively affected by alterations of affinity (scheme A), we would expect the gene to be either 
up or down regulated in the I27 mutant compared to both strains encoding a WT allele of CarD. 
Since the two strains encoding a WT allele of CarD have the same affinity for RNAP, we would 
expect the gene not be deregulated when they are compared to each other. If we examine the 
genes significantly deregulated in CarDI27F without a fold-change cut off, we find that 135 fit this 
expression profile with 44 downregulated in CarDI27F compared to either of the WT encoding 
strains and 91 upregulated. In the CarDI27W strain, 89 downregulated and 136 upregulated 
transcripts fit this expression profile. Transcripts that fit this expression profile are the only ones 
deregulated in the I27 mutants that solely respond to differences in affinity but this regulatory 
scheme only account for 10% of genes deregulated in CarDI27F and 12% of genes deregulated in 
CarDI27W, which indicates that differences in concentration are an important driver of 
deregulation in these strains.  
Alternatively, if deregulation of a transcript is exclusively caused by alterations in 
concentration of CarD (scheme B), we would predict that a transcript would be up or down 
regulated in the comparison of CarDWT to the WT Mtb strain, dependent on whether more CarD 
increases or decreases transcription of that transcript. Because the I27 mutants have an 
intermediate concentration, we would expect they would have the same effect on gene 
expression as the WT Mtb strain when compared to the CarDWT strain but the opposite effect 
when compared to the WT Mtb strain (e.g. if a transcript is upregulated in WT Mtb compared to 
CarDWT, we would expect it would be upregulated in an I27 mutant compared to CarDWT but 
downregulated in the I27 mutant compared to WT Mtb). Importantly, we would predict to see 
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this same expression profile if changes in concentration are the primary driver of deregulated but 
affinity had a minor effect (scheme D1), so we cannot totally rule out an effect of affinity in 
regulation of these transcripts. In the CarDI27F mutant, we find 43 transcripts with this expression 
profile, of which 29 transcripts have lower expression in WT Mtb compared to CarDWT and 14 
have higher expression in the WT Mtb strain. In the CarDI27W mutant, 35 transcripts fit this 
expression profile and have lower expression in the WT Mtb strain and 17 fit this expression 
profile and have higher expression in the WT Mtb strain when it is compared to the CarDWT 
strain. As only 3% of the transcripts deregulated in either mutant fit this expression profile, we 
can conclude that the majority of the transcripts deregulated in the I27 mutants are likely due to a 
combination of affinity and concentration.  
If a gene is affected by both concentration and affinity (scheme C), then it could be 
regulated in numerous ways. The first regulation scheme we considered is if were equally 
affected both concentration and affinity and if both factors affected regulation in a similar 
manner such that both higher affinity and higher concentration led to either more or less 
expression of the transcript (Scheme C1). In the case that both concentration and affinity 
increase expression of the transcript, then we would expect the transcript to be upregulated in the 
I27 mutant compared to CarDWT because the mutant has higher affinity. When the I27 mutant is 
compared to WT Mtb, the mutant would have higher affinity but WT Mtb would have higher 
concentration. In this scheme, we predict these two effects would balance each other and we 
would see no change in expression. WT Mtb has higher CarD concentration than CarDWT, so we 
would expect the transcript to also be upregulated in WT Mtb relative to CarDWT. 373 transcripts 
deregulated in CarDI27F and 459 transcripts deregulated in CarDI27W have this expression trend. If 
increasing both concentration and expression led to less transcript expression, we would expect 
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the gene to be down in the I27 mutants and WT Mtb relative to CarDWT and equal in the I27 
mutants relative to WT Mtb. We see this expression pattern to 220 transcripts deregulated in 
CarDI27F and 323 transcripts in CarDI27W. We also considered the regulatory scheme in which 
concentration and affinity are equally important but have opposite effects on transcript 
expression (scheme C2). If increasing concentration and decreasing CarD’s affinity for RNAP 
increases transcript expression, then we would expect the transcript to be similarly expressed in 
the CarDWT strain and the I27 mutant since the mutant has both higher expression and higher 
affinity. The transcript would be down regulated in the I27 mutant relative to WT Mtb as WT 
Mtb has higher expression and lower affinity of CarD for RNAP than the I27 mutants. The 
transcript would be upregulated in WT Mtb compared to the CarDWT strain due to the higher 
CarD concentration in the WT Mtb strain. This matches the expression data for 196 transcripts 
deregulated in CarDI27F and 212 transcripts deregulated in CarDI27W. If decreasing concentration 
and increasing affinity increases transcript expression, then we would expect no difference in the 
I27 mutants relative to CarDWT but upregulation relative to the WT Mtb strain. The transcript 
would be downregulated in WT Mtb relative to CarDWT. This expression scheme matches the 
expression profile of 201 transcripts deregulated in CarDI27F and 180 transcripts deregulated in 
CarDI27W. Of all the gene expression schemes we considered, these two schemes in which 
concentration and affinity are equally important explain the regulatory pattern of the largest 
number of genes, together accounting for regulation of 71% of transcripts deregulated in 
CarDI27F and 64% of transcripts deregulated in CarDI27W. The large numbers of transcripts 
explained by regulatory schemes in which concentration and affinity are equally important 
indicate that both are key drivers of regulation of CarD activity. 
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We next considered regulatory schemes in which contribution of concentration and 
affinity are not equal. If we considered concentration to be primary driver of deregulation 
(scheme D1) we predicted the same expression profiles as when concentration was the only 
cause of deregulation (scheme B). However, if affinity is dominant to concentration and both 
have the same effect on regulation, such that increasing concentration and affinity increases gene 
expression, we predict a gene expression profile that is unique to this analysis (scheme D2). The 
transcript would be upregulated in the I27 mutants relative to either strain encoding a WT allele 
of CarD because of the higher affinity of the mutants for RNAP. The transcript would also be 
upregulated in the WT Mtb strain relative to the CarDWT strain because of the higher 
concentration of CarD in the WT Mtb strain. 24 transcripts in CarDI27F and 73 transcripts in 
CarDI27W have this expression profile. Concentration and affinity may also be negatively 
correlated with expression such that increasing either decreases transcript expression. Here we 
would expect down regulation the in the I27 mutants relative to either strain expressing a WT 
allele of CarD and down regulation of the transcript in WT Mtb relative to CarDWT. We observe 
this expression profile for 17 transcripts deregulated in CarDI27F and 42 transcripts deregulated in 
CarDI27W. We also considered a scheme in which affinity is the dominant driver of affinity but 
regulation is also affected by concentration but it has the opposite effect (scheme D3). If higher 
affinity and lower concentration increase expression, then a transcript would be upregulated in 
the mutant relative to either strain expressing a WT allele of CarD because of affinity but the 
same transcript would be downregulated in WT Mtb relative to the CarDWT strain because of the 
increased concentration of CarD in WT Mtb. We find 25 transcripts deregulated in CarDI27F and 
32 transcripts deregulated in CarDI27W with this expression pattern. If higher affinity and lower 
concentration decrease expression, then the transcript should be downregulated in the I27 
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mutants and upregulated in WT Mtb when compared to the CarDWT strain. This expression 
pattern is observed for 10 transcripts deregulated in CarDI27F and 14 transcripts deregulated in 
CarDI27W. While a substantially smaller number of deregulated transcripts follow this scheme 
than when we considered concentration and affinity to have equal effects, we find that affinity if 
more than 5 times as likely to be the dominant driver of deregulation than concentration in both 
mutants (the number of transcripts in schemes A, D2, and D3 versus the number of transcripts in 
schemes B/D1) underscoring the role for increasing CarD’s affinity for RNAP in directly 
affecting transcript expression. 
In total, we have been able to dissect the roles of affinity and concentration in the 
regulation of 89.3% of transcripts deregulated in CarDI27F and 87.9% of transcripts deregulated 
in CarDI27W. The transcripts deregulated in CarDI27F and CarDI27W are highly similar which 
would predict that many of the transcripts deregulated in CarDI27F should also be deregulated in 
CarDI27W and that they should be in the same regulatory scheme in each mutant. The data 
supports this with 81.6% of transcripts deregulated in CarDI27F with identified regulatory 
schemes are also deregulated with the same regulatory scheme in CarDI27W.  
It is more difficult to separate the effect of decreased CarD concentration from the effect 
of decreased RNAP affinity in the CarDR47E strain, as the concentration of CarD in the CarDR47E 
strain is lower than the concentration of CarD in either the CarDWT strain or WT Mtb (136). This 
results in many of the regulatory schemes discussed above yielding the same gene expression 
profile. Because this limits our ability to interpret the data we did not do this type of analysis for 
CarDR47E. 
Transcripts lacking a recognizable -10 promoter motif are more sensitive to 
alterations in CarD. Transcriptional expression of transcripts is usually regulated, at least in 
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part, by the promoter that drives its expression. Structural studies have mapped CarD’s 
interaction with DNA to the bases from -10 to -14 relative to the TSS (86), which partially 
overlaps with the -10 promoter motif, which suggests that CarD’s regulatory activity may be 
affected by promoter sequence. It has been very difficult to identify promoters in mycobacteria 
in part because of the GC richness of their genome, which has made it difficult to correlate 
promoter sequences to RNA-seq data. Identification of promoters in Mtb was recently facilitated 
by identification of the primary transcription start sites (TSS) of 1,778 transcripts. The sequences 
upstream of the TSSs were mined for promoter motifs (140). There are 4,037 identified 
transcripts in Mtb which includes genes, sRNA, and tRNAs. As many mycobacterial genes are in 
operons, these 1,778 primary TSSs likely account for the majority of TSSs in the genome. A 
consensus mycobacterial -10 motif of TANNNT was detectable in the first 20 bp upstream of the 
TSS for 72.3% of these transcripts. Of the transcripts that lack a TANNNT motif, a 
GNNANNNT motif was detected for just over half of the remaining TSSs, accounting for 15.6% 
of all the transcripts with a mapped TSS. For the remaining 12.1% of mapped TSSs, there was no 
detectable -10 motif. No -35 motif was detected in first 50 bp upstream for any of the mapped 
TSSs (140). 
To determine if the -10 motif is predictive of deregulation upon mutation or alteration in 
concentrations of CarD, we compiled a list of transcripts with mapped TSSs that were up and/or 
downregulated greater than 1.5-fold in at least one of the WT Mtb, CarDI27F, CarDI27W, CarDR47E, 
or CarDK125A strains when compared to the CarDWT strain. Transcripts that were deregulated in 
multiple mutants are only counted once in this analysis, for a total of 750 promoter sequences. 
As we have throughout this study, we used the CarDWT strain as a reference strain. If we 
calculate the frequency of different -10 motifs of the deregulated transcripts we find that the 
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frequency of a TANNNT motif has decreased from 72.3% to 70.0% and the frequency of the 
transcripts without a detectable -10 motif has increased from 12.1% to 14.9%, compared to the 
frequencies of these motifs in TSSs throughout the genome (Fig 6A). The frequency of the 
GNNANNNT motif did not change (15.1% vs. 15.6% in all genomic TSSs). This trend of an 
increased frequency of promoters that lack a -10 motif in transcripts deregulated by alterations in 
CarD is more pronounced as the stringency of the fold-change cut off is increased from 1.5 to 3-
fold change. When TSSs for deregulated transcripts in the CarDWT strain are examined with 
either a 2- or 3-fold cut off, the distribution of TANNNT, GNNANNNT, and unrecognizable 
promoter motifs in this sample is statistically significantly different than the distribution of 
promoter motifs in the genome as a whole (Fig. 6A). While only 57 transcripts deregulated 
greater than 3-fold in at least one mutant have a mapped TSS, the correlation between lacking a 
recognizable promoter motif and deregulation is most apparent at this cut off, accounting for 
28.1% of all promoters, which is more than twice the rate of this promoter type in the genome as 
a whole. This indicates that the promoters lacking a recognizable motif are both more likely to be 
deregulated by alterations in CarD and the promoters are more likely to be deregulated by a 
larger fold change than transcripts driven by promoters with different -10 motifs.  
To determine if promoters lacking a recognizable motif were particularly correlated with 
a given alteration in CarD, we separated the 750 transcripts with a mapped TSS that were 
deregulated greater than 1.5-fold in a least one mutant by strain and direction of deregulation in 
comparison to the CarDWT strain. In this analysis, any promoter that is deregulated in more than 
strain is included in each analysis to which it is relevant; therefore, many promoter motifs are 
considered in multiple comparisons. In every strain analyzed (WT Mtb, CarDR47E, CarDK125A, 
CarDI27F, and CarDI27W), the distribution of promoter motifs associated with upregulated 
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transcripts is significantly different than the genome average. Upregulated transcripts are more 
likely to be associated with promoters lacking a motif and less often associated with TANNNT 
motif promoters than transcripts that were not upregulated by alterations in CarD (Fig. 6B). In 
addition to being less likely to be deregulated greater than 1.5 fold by alterations of CarD in any 
strain, promoters that contain a TANNNT motif are also likely to be deregulated in a smaller 
number of strains. Specifically, within the promoters deregulated greater than 1.5-fold, 
TANNNT motif promoters are deregulated in an average of 1.9 strains while promoters without 
a recognizable motif are deregulated in an average of 2.4 strains (Fig. 6C). The relatively high 
prevalence of promoters without a recognizable -10 motif driving expression of deregulated 
transcripts suggests that these promoters are particularly sensitive to alterations in CarD. Both 
CarD and -10 promoter motifs are known to contribute to formation of RPo, which may explain 
the sensitivity of promoters lacking a recognizable -10 motif to alterations in CarD. 
Alternatively, the promoter without a recognizable -10 motif may be promoters recognized by 
alternative sigma factors. Nothing is known about CarD mediated regulation of holo-RNAP 
associated with alternative sigma factors, however several ways that these transcripts may be 
affected by alterations in CarD could be proposed. Firstly, CarD may directly regulate 
transcription from promoters recognized by alternative sigma factors in such a way that makes 
them sensitive to alterations in CarD. Secondly, alternative sigma factors may not associate with 
CarD and the apparent upregulation of these transcripts may reflect global changes in 
housekeeping sigma factor driven transcripts resulting in an apparent upregulation of alternative 
sigma factor transcripts. Thirdly, alterations in CarD may deregulate transcription in a way that 
decreases the bacterium’s fitness and activates stress response pathways that are regulated by 
alternative sigma factors, resulting in an increase in the abundance of these transcripts as an 
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indirect effect of alterations in CarD. Importantly, all 3 promoter motifs are found associated 
with both CarD-sensitive and insensitive transcripts, which suggests that -10 promoter motifs do 
not completely explain CarD-mediated regulation (Fig. 6AB). 
Effect of decreasing CarD’s affinity for RNAP or DNA in M. smegmatis. 
M. smegmatis is commonly used as a model organism to study Mtb, including studies of CarD. 
To test if CarD had the same effects on global gene expression in M. smegmatis as we observed 
in Mtb, we performed an RNA-seq experiment on strains of M. smegmatis expressing CarDWT, a 
strain with decreased affinity for RNAP (CarDR25E), and a strain with decreased affinity for DNA 
(CarDK90A) from the attB site. M. smegmatis is less sensitive to alterations in CarD than Mtb, 
which allows for viability of more severely attenuated CarD mutants. To see the largest possible 
effect of alterations in CarD we used the CarDR25E mutant that has a more dramatic decrease in 
affinity for RNAP than CarDR47E (101) and the CarDK90A mutant that doesn’t bind DNA in the 
EMSA assay (108) (Table 3). Importantly, in M. smegmatis, decreasing CarD’s affinity for 
RNAP does not decrease the cellular concentration of CarD so all 3 strains have similar 
concentrations of CarD (Fig. 7A). 
When the transcriptome of the M. smegmatis CarDR25E strain is compared to the CarDWT 
strain and a FDR of less than 0.01 is used to determine significance only 95 transcripts or 1% of 
the transcriptome is significantly deregulated. Of these transcripts 76 are downregulated and 19 
are upregulated (Fig. 7B). With a FDR cut off of less than 0.01, the smallest fold change to be 
considered significant is 2.16-fold change from CarDWT, likely because the CarDWT replicates in 
this experiment were somewhat variable than in the Mtb data set. Results of this comparison are 
very different than when the CarDR47E mutant is compared to the CarDWT strain in Mtb. One of 
the most apparent differences is that a much smaller percent of the genome is deregulated in the 
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M. smegmatis comparison. If the Mtb CarDR47E data set is analyzed with a 2.16-fold cut off, 227 
transcripts or 6% of the Mtb transcriptome are still deregulated, suggesting the higher variability 
of the M. smegmatis does not completely explain the differences in the transcriptome. Of the 227 
transcripts deregulated greater than 2.16-fold in the Mtb CarDR47E, 34% are downregulated, 
which is substantially different than the M. smegmatis CarDR25E strain where 80% of transcripts 
are downregulated. The smaller percent of the genome deregulated by decreasing CarD’s affinity 
for RNAP in M. smegmatis that Mtb may indicate differences in the regulatory role of CarD in 
the two organisms or that the larger percentage of the genome deregulated in Mtb is a result of 
the decreased concentration of CarD in the CarDR47E strain compared to the CarDWT strain in 
Mtb.  
When the transcriptome of the M. smegmatis CarDK90A strain is compared to the CarDWT 
strain and a FDR of less than 0.01 is used to determine significance, 229 transcripts or 3% of the 
genome is deregulated (Fig. 7C). The smallest fold change that is significant in this data set is 
1.92-fold different than WT. If this same fold change cut off is applied the to the comparison 
between CarDK125A and CarDWT in Mtb, then 6% of the genome is deregulated, indicating that a 
smaller percentage of the genome is deregulated in M. smegmatis for this mutant as well. Only 
30% of deregulated transcripts are upregulated in the CarDK90A strain, which is a larger 
percentage than was upregulated in the CarDR25E strain but still less than the 72% of transcripts 
deregulated greater than 1.9-fold that were upregulated in the CarDK125A comparison in Mtb. The 
sparsity of upregulated transcripts in the CarDR25E and CarDK90A strains may indicate that 
CarDWT is less likely to repress transcription in M. smegmatis than Mtb. Both CarDK125A and 
CarDK90A are not expected to alter the concentration of CarD in M. smegmatis or Mtb, so this 
smaller effect is reflective of differences in regulation by CarD in the two organisms. In Mtb, 
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there was substantial correlation between the genes deregulated in CarDK125A and CarDR47E. This 
is not reflected in the M. smegmatis data set, where only 38 transcripts or 17% of the genes 
deregulated in the CarDK90A strain are also deregulated in the CarDR25E strain (Fig. 7D).  
Genomic context correlates with CarD regulation in M. smegmatis. Transcription start 
sites have not been mapped in M. smegmatis so we were unable to identify promoters. We 
therefore looked for other possible determinants of CarD gene expression. Genomic localization 
can affect gene expression through differences in DNA packing and promoter accessibility. To 
identify a possible role for genomic context in CarD mediated regulation, we normalized reads in 
each of the CarD mutant strains to the CarDWT strain and plotted these by genomic location to 
determine if there is a correlation between the genomic localization of a transcript and its 
regulation by CarD (Fig. 8A). We found genomic islands that are enriched for downregulated 
transcripts compared to the genome as a whole in both CarDR25E and CarDK90A and genomic 
islands enriched for upregulated transcripts compared to the genome as a whole in CarDK90A. 
These findings suggest a potential role for genomic context in CarD regulation. Interestingly, 
while we there are very few significantly downregulated transcripts shared between both 
mutants, we find that the down regulated genomic islands are shared between the two mutants, 
suggesting that this effect of genomic context may affect both mutants. 
To further investigate the possibility that genomic context can cause down regulation of 
transcripts in both CarDR25E and CarDK90A, we examined the 33 M. smegmatis transcripts 
downregulated in both the CarDR25E and CarDK90A strains (Fig. 7D). In line with a possible role 
for genomic context in deregulation of these shard transcripts, we found that 25 of these 
transcripts are encoded between msmeg_3926 and msmeg_3955. Downregulation of genes in this 
region in both CarDR25E and CarDK90A was confirmed by quantitative real-time PCR (qRT-PCR) 
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(Fig. 8B). There are multiple operons encoded in this region and the predicted function of genes 
encoded here do not suggest a common function suggesting that this region may be 
downregulated due to genomic context rather than the transcripts encoded. In fact, every single 
gene in this region trends toward downregulation in both mutants but some transcripts did not 
meet the significance cut off in our RNA-seq analysis. Additionally, this region of the genome 
encodes 3 of the 5 most down downregulated transcripts in either mutant strain. 
 We have previously performed a screen for transposon mutants in M. smegmatis 
that restore CarDWT-like expression of lacZ in the CarDR25E mutant when expression was driven 
by rRNA operon promoters. Of the 551 hits found in this screen, 459 hits were mutants of espR, 
a nucleoid associated protein (unpublished data, (141)). This class of proteins bind DNA and can 
influence transcription via occlusion of promoters, bridging DNA, wrapping DNA, or bending 
DNA (142). They can also constrain supercoiling and compaction of DNA. To test is EspR was 
influencing regulation of msmeg_3926-msmeg_3955, we compared regulation of these genes in 
the CarDWT and CarDR25E strains in both a espR encoding and a ΔespR background by qRT-PCR 
(Fig 8C). Preliminary analysis suggests that deletion of espR may restore expression of these 
transcripts in the CarDR25E background, although ΔespR also increases expression of these genes 
in the CarDWT background. To determine if ΔespR increases expression of transcripts in the 
CarDR25E background at all promoter, we performed qRT-PCR on a selection of genes 
deregulated in the CarDR25E strain at other locations in the genome (Fig. 8D). At promoters from 
other regions of the genome ΔespR does not restore expression to CarDWT levels. This supports a 
hypothesis in which is it a specific local effect of EspR on genes between msmeg_3926-
msmeg_3955 that is causing downregulation of these genes in the CarD mutants and indicating 
that CarD’s activity can be affected by the presence of nucleoid associated proteins.  
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Genomic context correlates with CarD-mediated regulation in Mtb. Because genomic 
context may be a determinant of CarD regulation in M. smegmatis, we wanted to determine if we 
see a similar effect in Mtb. As in M. smegmatis, we normalized reads in each of the CarD mutant 
strains to the CarDWT strain and plotted these by genomic location (Fig. 9). This analysis clearly 
shows genomic islands where transcripts are more likely to be upregulated in the CarDR47E, 
CarDI27F, and CarDI27W strains suggesting these mutations may be influenced by the genomic 
context of the transcripts. Unlike in M. smegmatis, the genomic islands of deregulated genes in 
Mtb are not common shared between different classes of mutants. Interestingly, we see no 
evidence of an effect on genomic context in the mutant of the DNA binding domain suggesting 
that the effect of genomic context on CarD activity may be dependent on CarD’s interaction with 
DNA and that this regulatory effect is lost when CarD’s interaction with DNA is mutated.  
Discussion 
In this study, we examined CarD-mediated transcriptional regulation of throughout the 
genome in both Mtb and M. smegmatis. In Mtb, we found that modulating the concentration of 
CarD, affecting the affinity of CarD for RNAP, or mutating the DNA binding motif of CarD all 
have global effects on the transcriptome, together causing significant deregulation of 78% of the 
Mtb transcriptome. We found transcripts that we upregulated in loss of function CarD mutants, 
which suggests that CarDWT can repress or activate transcription in a transcript dependent 
manner. This is the first study to find evidence supporting CarDWT-mediated repression of 
transcription. Other transcription factors that that regulate transcription through stabilization of 
the RNAP-promoter complexes have been shown to repress transcription by hyper-stabilizing 
these complexes, preventing promoter escape or transition to the elongation complex (124) so it 
is reasonable to suggest that CarD may repress transcription from some promoters. In M. 
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smegmatis, a much smaller portion of the genome is deregulated by decreasing CarD’s affinity 
for RNAP or DNA suggesting there may be differences in the role of CarD-mediated regulation 
in the two organisms.  
Our analysis revealed large effects on the transcriptome of the bacterium dependent of 
the concentration of CarD in vivo, with 52% of the transcriptome significantly deregulated when 
two strains of Mtb expressing different concentrations of CarDWT. Additionally, changes in the 
cellular concentration of CarD resulting from an increased affinity of CarD for RNAP may be a 
major driver of transcript deregulation in these strains (Table 2). CarD was initially identified as 
gene upregulated in response to numerous different stress stimuli suggesting that mycobacteria 
may manipulate the concentration of CarD to globally regulate transcription in some 
environments.  
We were able to correlate CarD-mediated regulation of a transcript to its promoter 
sequence by analyzing -10 promoter motifs of transcripts with known TSS in Mtb. The most 
common -10 promoter motif in Mtb is a TANNNT motif and, prior to this study, TANNNT motif 
promoters are the only type of promoter analyzed to determine the effect of CarD on regulation. 
By analyzing the correlations between deregulation in CarD mutants and promoter motifs we 
found that transcripts lacking a recognizable -10 promoter motif were upregulated by decreasing 
CarD’s interactions with RNAP or DNA or by increasing CarD’s cellular concentration over that 
in the CarDWT strain (Fig. 6AB).  
Based on structural studies, it has been suggested that the interaction between W85 in 
CarD (W86 in the Thermus CarD) and a T at the -12 position of the promoter is important for 
transcriptional regulation by CarD (86, 87). While a strain singly expressing CarDW85A is not 
viable in Mtb, we have shown in vitro that mutating the interaction with RNAP or DNA has a 
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similar effect on regulation of transcription as the CarDW85A mutant (108, 109). Through analysis 
of the promoters deregulated greater than 1.5-fold in CarDR47E and/ or CarDK125A we found no 
evidence for an increased rate of encoding a T at the -12 base than promoters of transcripts not 
deregulated at least 1.5-fold (40.67% and 40.86% of promoters have a T at the -12 position in 
deregulated and not deregulated respectively). The structural analysis was based on analysis of a 
promoter activated by CarDWT containing a TANNNT motif in which the upstream T occurred at 
-12. This T in the TANNNT motif varies from -6 to -20 throughout the genome when the first 20 
bp upstream of the promoter are analyzed for promoter motifs and is not more likely to occur at -
12 in promoters containing a TANNNT motif that are deregulated by alterations in CarD than 
those that are not deregulated in our analysis (46.1% and 47.5%, respectively, of transcripts with 
a TANNNT promoter motif that are or are not deregulated greater than 1.5-fold in at least one 
strain have the upstream T of the TANNNT motif at -12). An interaction between W85 and the 
upstream T of the TANNNT motif may be important for CarD-mediated activation of TANNNT 
motif promoters but there is no evidence to support the importance of its position relative to the 
+1 site of the transcript.  
CarD is essential in both M. smegmatis and Mtb and the protein is highly conserved 
through mycobacteria. Both the M. smegmatis and the Mtb CarD function similarly in 
biochemical assays including immunoprecipitation experiments, electrophoretic mobility shift 
assays (EMSAs), and transcription assays. However, throughout the years of studying CarD, we 
have identified several differences between CarD’s function and regulation in the two organisms. 
Firstly, Mtb has more restrictive requirements for CarD than M. smegmatis as Mtb only tolerates 
mutations in CarD that have a minor effect on the interaction with RNAP or that occur within the 
DNA binding motif but retain the interaction with DNA in an EMSA assay while M. smegmatis 
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can survive mutations the dramatically decrease the affinity for RNAP and abolish the 
interaction with DNA, including one strain which likely affects the structure and decreases the 
stability of CarD (101, 108). M. smegmatis can additionally tolerate mutation of the conserved 
tryptophan to an alanine (W85A) in the M. smegmatis CarD protein but not the Mtb CarD 
protein. Mtb cannot tolerate the W85A mutation in either protein background. Furthermore, we 
have identified differences in post transcriptional regulation of CarD between the two organisms. 
In Mtb, the concentration of the protein in the cells is dependent on CarD’s affinity for RNAP 
but this mechanism of controlling the protein concentration is not conserved in M. smegmatis 
(Fig7A, (136)). Based on the RNA-seq experiments detailed in this study, the role of CarD in 
regulating transcription is also much more limited in M. smegmatis than Mtb. Future studies 
examining the role of CarD in regulation of non-ribosomal promoters should be cautious in 
generalizing findings in one organism to make conclusions about other CarD-containing strains.  
One aspect of regulation of CarD’s transcription regulatory activity that may be 
conserved in both Mtb and M. smegmatis is a potential role for genomic context in regulation of 
transcription. In both Mtb and M. smegmatis, there are regions in the genome that have an 
increased chance of deregulated transcripts as compared to the genome as a whole. In M. 
smegmatis there is preliminary data to support a role for the nucleoid associated protein EspR in 
regulation of at least one of these genomic islands of deregulation. This data should be confirmed 
in M. smegmatis and expression of genes in a CarD mutant should be analyzed in a ΔespR 
background in Mtb to determine if the EspR affects regulation of genomic islands of deregulation 
in Mtb.  
This manuscript is the first investigation of the role of CarD, which is localized to 
promoters throughout the genome, on regulation of non-ribosomal promoters and the first to 
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investigate in depth the role of the cellular concentration of CarD on gene expression in vivo. 
Through this analysis we have dramatically advanced our understanding of the determinants and 
extent of CarD mediated transcriptional regulation.  
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Table Legends: 
Table 1: Description of strains used in the Mtb RNA-seq analysis including the allele of CarD 
encoded, the effect of the mutation, and the concentration of CarD in the cell. 
Table 2: Relative contributions of affinity and concentration to gene deregulation in the high 
affinity mutants. All possible expressions of genes in CarD I27F or CarDI27W relative to 
the CarDWT and WT Mtb strains, the number of genes in each category, and the 
regulatory scheme these expression patterns correspond to. Transcripts deregulated in 
the comparison of WT Mtb to CarDWT are only included if also deregulated in the 
relevant high affinity mutant.  
Table 3: Description of strains used in the M. smegmatis RNA-seq analysis including the allele 
of CarD encoded, the effect of the mutation, and the concentration of CarD in the cell. 
128
129
130
131
132  
Figure Legends: 
Figure 1: Transcripts deregulated in strains of Mtb expressing loss of function CarD mutants 
when compared to the CarDWT strain.  
A-B. Pie charts showing regulation of transcripts upon comparison to the ΔcarD attB::tet-
carD strain expressing CarDWT strain in the ΔcarD attB::tet-carD strain expressing 
CarDR47E (A) or CarDK125A (B). The number of transcripts in each category is shown. 
C. Venn diagram comparing genes significantly deregulated in the ΔcarD attB::tet-carD 
strain expressing CarDR47E (pink) or CarDK125A (green) upon comparison to the 
ΔcarD attB::tet-carD strain expressing CarDWT. 
Figure 2: Transcripts deregulated in strains of Mtb expressing mutants of CarD with higher 
affinity for RNAP when compared to the CarDWT strain.  
A-B. Pie charts showing regulation of transcripts upon comparison to the ΔcarD attB::tet-
carD strain expressing CarDWT strain in the ΔcarD attB::tet-carD strain expressing 
CarDI27F (A) or CarDI27W (B). The number of transcripts in each category is shown. 
C. Venn diagram comparing genes significantly deregulated in the ΔcarD attB::tet-carD 
strain expressing CarDI27F (purple) or CarDI27W (blue) upon comparison to the ΔcarD 
attB::tet-carD strain expressing CarDWT. 
Figure 3: Increasing and decreasing CarD’s affinity for RNAP have different effects on the 
transcriptome in Mtb. 
A-B. Venn diagram comparing genes significantly deregulated in the ΔcarD attB::tet-carD 
strain expressing CarDR47E (pink) to genes deregulated in the ΔcarD attB::tet-carD 
strain expressing CarDI27F (A, purple) or CarDI27W (B, purple) upon comparison to the 
ΔcarD attB::tet-carD strain expressing CarDWT. 
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Figure 4: Increasing the concentration of CarDWT has phenotypic consequences in Mtb. 
A. The ratio of carD transcript levels in exponential cultures of the ΔcarD attB::tet-carD 
strain expressing CarDWT or WT Mtb or the to levels in CarDWT when grown in 
Sauton’s media. Transcript levels were determined using qRT-PCR and normalized to 
sigA. 
B. Western blot analysis of two biological replicates of lysates from exponentially 
growing Mtb ΔcarD attB::tet-carD strain expressing CarDWT or WT Mtb in Sauton’s 
media. Membranes were blotted with a monoclonal antibody against RNAP-β (top) or 
a polyclonal antibody against CarD (bottom). 
C. Representative growth curves of the ΔcarD attB::tet-carD strain expressing CarDWT 
(circles) or WT Mtb WT Mtb (squares) in Sauton’s media. 
D. Doubling times of the ΔcarD attB::tet-carD strain expressing CarDWT or WT Mtb in 
Sauton’s media.  
E. Ratio of 16S rRNA levels in exponential cultures of the ΔcarD attB::tet-carD strain 
expressing CarDWT or WT Mtb to levels in CarDWT when grown in Sauton’s media. 
Transcript levels were determined using qRT-PCR and normalized to sigA.  
F. Dot plot of colony forming units (CFU) in the lungs of C57BL/6J mice infected with 
the ΔcarD attB::tet-carD strain expressing CarDWT (circles) or WT Mtb WT Mtb 
(squares). Each time point is the mean ± SEM of data from at least 6 mice per strain. 
Each graph shows the mean ± SEM of data from at least three replicates. Significance was 
determined by t-test. *, p ≤ 0.05; **, p ≤ 0.01.  
Figure 5: Increasing the concentration of CarDWT affects regulation of half of the transcriptome 
in Mtb.  
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A-B. Pie charts showing regulation of transcripts in WT Mtb upon comparison to the 
CarDWT strain. The number of transcripts in each category is shown. 
Figure 6: Transcriptional regulation by CarD is affected by the -10 promoter motif. 
A. The percentage of transcripts with a mapped TSS that have an upstream TANNNT 
(dark blue), GNNANNNT (light blue), or no detectable (red) promoter motif in the 
genome as a whole, in transcripts not deregulated by alterations in CarD, or 
significantly deregulated by alterations in CarD with increasingly stringent fold-
change cut offs from left to right. 
B. The percentage of transcripts with a mapped TSS that have an upstream TANNNT 
(dark blue), GNNANNNT (light blue), or no detectable (red) promoter motif in the 
genome as a whole, transcripts not deregulated 1.5-fold in any tested strain, 
deregulated 1.5-fold in any tested strain, transcripts deregulated at least 1.5-fold by at 
least one tested alteration in CarD, or up or down regulated greater than 1.5 fold in 
WT Mtb, or ΔcarD attB::tet-carD strain expressing CarDI27F, CarDI27W, CarDR47E, or 
CarDK125A. Statistical significance was determined by a Chi-square test. 
D. Graph showing the number of different strains a transcript is significantly deregulated 
in by -10 promoter motifs. Statistical significance was analyzed by ANOVA and 
Tukey’s multiple comparison test.  
*, p ≤ 0.05; **, p ≤ 0.01; ***, or p ≤ 0.001. All comparisons were tested and only 
significantly different comparisons are shown. 
Figure 7: Loss of function mutations in CarD effect a smaller percentage of the genome in M. 
smegmatis than Mtb. 
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A. Western blot analysis of two biological replicates of lysates from exponentially 
growing M. smegmatis ΔcarD attB::tet-carD strain expressing CarDWT or CarDR25E. 
Membranes were blotted with a monoclonal antibody against RNAP-β (top) or a 
polyclonal antibody against CarD (bottom). 
B-C. Pie charts showing regulation of transcripts upon comparison to the M. smegmatis 
ΔcarD attB::tet-carD strain expressing CarDWT strain in the ΔcarD attB::tet-carD 
strain expressing CarDR25E (A) or CarDK90A (B). The number of transcripts in each 
category is shown. 
D. Venn diagram comparing genes significantly deregulated in ΔcarD attB::tet-carD 
strain expressing CarDR25E (pink) or CarDK90A (green) upon comparison to the ΔcarD 
attB::tet-carD strain expressing CarDWT. 
Figure 8: CarD’s regulatory activity may be affected by genomic context and the nucleoid 
associated protein EspR in M. smegmatis. 
A. Reads in M. smegmatis ΔcarD attB::tet-carD strain expressing CarDR25E (red/gold) or 
CarDK90A (blue/aqua) were normalized to read counts in the M. smegmatis ΔcarD 
attB::tet-carD strain expressing CarDWT strain and plotted based on their position in 
the genome (nucleotide positions are numbered). Transcripts with lower read counts 
in the mutant are graphed in gold or aqua and transcripts with higher read counts in 
the mutant are graphed in red or blue. Genomic islands of transcripts downregulated 
in both mutants are designated by an *. Genomic islands of transcripts specifically 
upregulated in CarDK90A are designated by a #. 
B. Ratio of select transcripts between msmeg_3926 and msmeg_3955 in exponential 
cultures of the M. smegmatis ΔcarD attB::tet-carD strain expressing CarDWT, 
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CarDR25E or CarDK90A to levels in CarDWT. Transcript levels were determined using 
qRT-PCR and normalized to sigA.  
C. Ratio of select transcripts between msmeg_3926 and msmeg_3955 in exponential 
cultures of the M. smegmatis ΔcarD attB::tet-carD strain expressing CarDWT or 
CarDR25E in the presence or absence of espR to levels in CarDWT with espR . 
Transcript levels were determined using qRT-PCR and normalized to sigA.  
D. Ratio of select transcripts not encoded between msmeg_3926 and msmeg_3955 in 
exponential cultures of the M. smegmatis ΔcarD attB::tet-carD strain expressing 
CarDWT or CarDR25E in the presence or absence of espR to levels in CarDWT with 
espR . Transcript levels were determined using qRT-PCR and normalized to sigA.  
Figure 9: CarD’s regulatory activity may be affected by genomic context in Mtb. 
A. Reads in Mtb ΔcarD attB::tet-carD strain expressing CarDR47E (periwinkle/red), 
CarDK125A (magenta/ yellow), CarDI27W (blue/green), or CarDI27F (navy/ green) were 
normalized to read counts in the Mtb ΔcarD attB::tet-carD strain expressing CarDWT 
strain and plotted based on their position in the genome (nucleotide positions are 
numbered). Transcripts with lower read counts in the mutant are graphed in 
periwinkle, magenta, blue or navy and transcripts with higher read counts in the 
mutant are graphed in red, yellow, or green. Genomic islands of transcripts 
downregulated in both high affinity mutants are designated by an *. Genomic islands 
of transcripts specifically upregulated in CarDR47E are designated by a #. 
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Major Findings: 
Mycobacterium tuberculosis (Mtb) infects about a third of the world’s population and 
causes more than a million death per year (4). To gain control of this epidemic we must develop 
new therapeutics, which requires a better understanding of unique mycobacterial physiology. It 
has recently become clear that the mycobacterial RNA polymerase (RNAP) differs substantially 
from the well-studied RNAP of Escherichia coli, upon which the majority of studies on 
transcription have been performed. Our group and others have shown that, in comparison to E. 
coli, the mycobacterial RNAP is deficient in its ability to form stable open complex (RPo), an 
intermediate complex formed during transcription initiation (109, 123). Mycobacteria overcome 
this deficiency of their RNAP with essential accessory transcription regulators, including CarD, 
which represent promising targets for future therapeutics. 
CarD was initially discovered as a gene upregulated in response to numerous 
physiologically relevant stresses  (85). It is an essential, highly-conserved gene in mycobacteria 
with homologs in numerous, but not all, bacterial species (85–87). Importantly, there are no 
CarD homologs in eukaryotes. Initial studies on CarD focused on its N-terminal domain, which 
is homologous to the RNAP-interacting domain of the transcription repair coupling factor 
(TRCF, encoded by mfd). Through this domain, CarD interacts with the β1 domain of the β 
subunit of RNAP. CarD’s interactions with RNAP suggested that CarD was likely to be a 
transcriptional regulator (Chapter 1 Fig. 1, (85, 101). To determine which stage of transcription 
may be regulated by CarD, chromatin immunoprecipitation sequencing (ChIP-seq) reactions 
were performed that determined that CarD is co-localized with the RNAP holoenzyme at 
promoters throughout the genome (Chapter 1 Fig. 2, (87)). This result suggests that CarD likely 
regulates transcription initiation. CarD’s crystal structure was therefore modeled onto initiation 
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complexes of RNAP. In the resulting model, CarD’s C-terminal domain, which is largely α-
helical in structure and not homologous to any previously solved protein fold, was poised to 
interact with DNA just upstream of the -10 motif of the promoter (87). Through electrophoretic 
mobility shift assays (EMSAs) we demonstrated that this domain of CarD interacts with DNA 
via a conserved basic patch in a sequence-independent manner (Chapter 1 Fig. 4, (87)).  
CarD’s interactions with RNAP and DNA, as well as the activity of a highly 
conserved tryptophan, are required for optimal growth, antibiotic resistance, and 
pathogenesis. To determine the functional importance of individual activities of CarD to its 
physiological function, we developed and characterized a series of single point mutants in CarD 
that each target an individual activity of CarD. We identified two arginine residues (R25 and 
R47) in CarD that are important for CarD’s interactions with RNAP. Mutation of either residue 
to glutamate decreases CarD’s affinity for RNAP (Chapter 1 Fig. 1, (101)). Within the conserved 
basic patch, we identified two lysine residues (K90 and K125) that are both important for CarD’s 
interaction with DNA. An alanine mutation at K90 (CarDK90A) or a glutamate mutation at K125 
(CarDK125E) abolish CarD’s ability to bind and shift DNA in an EMSA assay (Chapter 2 Fig. 1, 
(108)). An alanine mutant at K125 (CarDK125A) retains the interaction with DNA in an EMSA 
assay, but has functional consequences for the physiology of the bacterium, suggesting this 
mutation may affect CarD’s interaction with DNA in vivo (Chapter 2, (108)). Within the basic 
patch of CarD, we have additionally identified a highly conserved tryptophan residue (W85) that 
is not essential for DNA binding and is predicted to have an alternative activity in regulation of 
transcription. Specifically, structural studies predict this residue functions by wedging into the 
distorted minor groove at the upstream edge of the transcription bubble (86, 87). We constructed 
strains of Mycobacterium smegmatis that singly express CarDWT, a CarD mutant with decreased 
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affinity for RNAP (CarDR25E or CarDR47E), a CarD mutant of the DNA binding domain 
(CarDK90A, CarDK125A, or CarDK125E), or a CarD mutant of the conserved tryptophan residue 
(CarDW85A). In Mtb, only the CarD mutant with mild effects on the interaction with RNAP 
(CarDR47E) and the mutant that retained the interaction with DNA in vitro (CarDK125A) were 
viable, indicating that Mtb has more stringent requirements for CarD than M. smegmatis 
(Chapter 2). In both organisms, these mutation of CarD decreased the growth rate, indicating that 
CarD’s interactions with RNAP and DNA as well as the activity of the conserved tryptophan 
residue are essential for CarD to regulate the transcription of genes required for wild-type (WT)-
like growth (Chapter 1 Fig. 1, Chapter 2 Fig. 2, (101, 108)).  
Because CarD is upregulated in response to numerous stresses (85), we then tested the 
effects of decreased affinities for RNAP or DNA or mutation of the conserved tryptophan on 
antibiotic sensitivity in M. smegmatis. During growth on agar plates, strains of M. smegmatis 
with any of these changes showed increased sensitivity to ciprofloxacin, rifampicin, and 
streptomycin, which target DNA replication, RNA synthesis, and protein synthesis, respectively 
(Chapter 1 Fig. 1, Chapter 2 Fig. 5, (101, 108)). This phenotype of general stress sensitivity 
indicates that mutations in CarD likely inhibit an upstream step required in response to numerous 
diverse stresses. 
In addition to these stress, CarD is also transcriptionally upregulated in response to 
oxidative stress (85). In M. smegmatis, we found that CarD’s interaction with RNAP and the 
activity of the conserved tryptophan were required for resistance to oxidative (H2O2) stress; 
however, in contrast to results seen during antibiotic stress experiments, mutations that decreased 
CarD’s interaction with DNA did not sensitize bacteria to oxidative stress (Chapter 1 Fig. 1, 
Chapter 2 Fig. 3, (101, 108)). Importantly, the conserved tryptophan residue, which is required 
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for resistance to oxidative stress, is physically located within the DNA binding motif of CarD 
(Chapter 1 Fig. 3). The necessity of the tryptophan residue but not the surrounding basic patch 
for resistance to oxidative stress strongly supports the hypothesis that this residue has a 
physiological activity distinct from CarD’s interaction with DNA. Mutation of the tryptophan 
residue is not viable in Mtb and therefore could not be tested; however, the Mtb CarDR47E strain 
is much more sensitive to oxidative stress than the CarDWT strain, again underlining the 
importance of CarD’s interaction with RNAP (Chapter 1 Fig. 1, (101)). The variable requirement 
for individual CarD activities in response to oxidative stress indicates that some transcripts 
regulated by CarD only require a subset of CarD’s activities and suggests that CarD’s activity 
may be promoter-specific. 
During mouse infections, Mtb strains expressing CarDK125A or CarDR47E reach similar 
bacterial burden in the lungs of the mice during acute infection, but are maintained at lower 
bacterial burden during persistent infection, in comparison to the CarDWT strain. In the spleen, 
the bacterial burden of these strains is lower than the CarDWT strain during both acute and 
persistent infection. These data suggest that CarD’s interactions with RNAP and DNA are 
required for resistance to stress or virulence during infection (Chapter 1 Fig. 1, Chapter 2 Fig. 4, 
(101, 108)).  
CarD requires all three of its functional domains to activate transcription from 
ribosomal RNA operons by stabilizing RPo. During initial characterization of CarD, it was 
found that depletion of the CarD protein broadly deregulated transcripts associated with the 
translational machinery, including ribosomal RNA (rRNA) (85). Regulation of rRNA is an 
essential and tightly controlled process in all bacteria as rates of ribosomal protein transcription, 
ribosome biogenesis, and cell growth correlate to the levels of rRNA production (118–120). We 
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therefore focused our initial studies of transcriptional regulation by CarD on regulation of rRNA 
operons. In Mtb there is only one rRNA operon, rrnA, transcription of which is regulated by two 
promoters, P1 and P3 (116, 117). The homologous rrnA operon in M. smegmatis has P1 and P3 
promoters and an additional P2 promoter (116, 117). In lacZ reporter experiments, we found that 
CarDWT activates transcription from rrnA promoters by a mechanism that is dependent on its 
interactions with RNAP and DNA as well as the activity of the conserved tryptophan (Chapter 2 
Fig. 6, (108)).  
To study the mechanism by which CarD activates transcription, we interrogated CarD’s 
effect on transcription in a single round in vitro transcription assay that measures the stability of 
RNAP-promoter complexes. We found that the addition of CarDWT dramatically stabilizes 
RNAP-promoter complexes at rRNA promoters and this stabilizing effect is dramatically 
attenuated by mutations that decrease CarD’s interaction with RNAP or DNA or mutation of the 
conserved tryptophan residue (Chapter 2 Fig. 7, (87, 108). Subsequently, researchers used 
KMnO4 foot printing assays to show that the RPo, specifically, is stabilized by addition of CarD 
(123). 
Our understanding of the mechanism by which CarD stabilizes RPo at rRNA promoters 
was advanced by a kinetic analysis of CarD transcriptional regulation at a rRNA promoter, 
performed by our collaborators in the Galburt lab (109). This study demonstrated that CarD 
interacts with RPo with high affinity and acts to stabilizes the complex by reducing the reverse 
rate of collapse back to RPc. CarD also increases the forward rate of promoter melting through a 
lower affinity interaction with RPc. Importantly, I determined that the cellular concentrations of 
RNAP β, RNAP σ, and CarD in Mtb and are similar to concentrations used in the fluorescence 
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assay, suggesting that CarD both inhibits promoter collapse and enhances opening in vivo 
(Chapter2, Fig. 8B, (109)).  
Increasing CarD’s affinity for RNAP increases growth rate without affecting rRNA 
levels and decreases virulence in Mtb. To further dissect the relationship between CarD’s 
interaction with RNAP, its regulation of rRNA, and the mycobacterial growth rate, we designed 
two CarD mutants with increased affinity for RNAP (CarDI27F and CarDI27W). Both mutations 
have increased affinity for RNAP in immunoprecipitation and biochemical assays, though 
CarDI27W has a higher affinity for RNAP than CarDI27F does (Chapter 3 Fig. 1, (136)). When 
these mutants are expressed in Mtb they grow faster than the CarDWT strain (Chapter 3 Fig. 3, 
carD is expressed at similar levels transcriptionally in the CarDWT, CarDI27F, and CarDI27W 
strains, but protein concentrations increase with CarD’s affinity for RNAP, with CarDWT having 
lower CarD concentrations than CarDI27F, which in turn has less than CarDI27W (Chapter 3 Fig. 3, 
(136)). These data suggest that CarD, a known target of the Clp protease in mycobacteria (133), 
is regulated post-transcriptionally and may be protected from proteolytic degradation when 
associated with RNAP. Because mutations in CarD that decrease growth rate also decrease 16S 
rRNA content, we examined the levels of rRNA in these strains by quantitative real time PCR 
(qRT-PCR) (Chapter 2 Fig. 6, (87, 108). Surprisingly, the CarDWT strain and both strains 
expressing mutants of CarD with higher affinity for RNAP had similar levels of rRNA (Chapter 
3 Fig. 3, (136)). These data indicate that the growth defect in the CarDWT strain was neither 
caused nor ameliorated by alterations in the rRNA content of the bacteria, thus decoupling rRNA 
content and growth rate in the CarD mutants. These studies reveal a new mechanism of 
regulating CarD activity through turnover of free protein and improve our understanding of the 
relationship between rRNA transcription, growth rate, and CarD activity. 
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To test if the restored growth rate of the CarD mutants with higher affinity for RNAP 
corresponded to increased fitness during infection, we infected C57BL/6J mice with WT Mtb, 
CarDWT, CarDI27F or CarDI27W. The CarD mutants with increased affinity for RNAP have 
decreased bacterial burden at 35 days post infection as compared to the CarDWT strain. 
Additionally, the CarDI27W strain, which has the highest affinity for RNAP, also has a lower 
bacterial burden at 21 days post infection, indicating that increasing CarD’s affinity for RNAP is 
detrimental to virulence in Mtb (Chapter 3 Fig. 4, (136)). 
Increasing CarD’s affinity for RNAP increases the lifetime of RPo. To investigate 
whether increasing the affinity of CarD for RNAP affects the stability of transcription-competent 
RNAP-promoter complexes, we performed a multi-round in vitro aborted transcription assay 
(123). Increasing CarD’s affinity for RNAP increased the amount of 3nt product formed as 
compared to the amount formed in the presence of CarDWT (Chapter 3, Fig. 2, (136)), 
demonstrating that increasing the affinity of CarD to the RNAP results in the increased stability 
of an RNAP-promoter complex that is able to produce the aborted transcript in this assay. 
CarD regulates transcription of the majority of the Mtb transcriptome. While CarD’s 
activity has been well studied at rRNA-associated promoters, the activity of CarD at other 
promoters throughout the genome remained elusive. To investigate the role of CarD in regulation 
of non-rRNA promoters, we performed RNA sequencing (RNA-seq) experiments on Mtb strains 
expressing different concentrations of the CarD protein, CarD mutants with altered affinity for 
RNAP, or a CarD mutant with a mutation in the DNA binding domain. Analysis of the 
transcriptomes of these different strains demonstrated that CarD regulates transcription from the 
majority of promoters in the Mtb chromosome, with 80% of transcripts significantly deregulated 
in at least one analyzed strain (Chapter 4 Fig. 1). We found that changes in the concentration of 
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CarD or decreases in CarD’s affinity for RNAP or DNA are responsible for the largest changes 
in the Mtb transcriptome, suggesting that CarD’s activity is particularly sensitive to these 
perturbations (Chapter 4 Fig. 3). Upregulation of many transcripts in response to loss of CarD 
function suggested that under normal conditions, CarD may act in part as a transcriptional 
repressor, possibly by hyper-stabilizing the RNAP-promoter complex (Chapter 4 Fig. 2).  
CarD’s regulatory activity is responsive to promoter sequence. Our analysis of the 
transcriptome in strains with alterations in CarD revealed large differences in the degree of 
deregulation between different transcripts, which suggested that CarD’s activity was regulated in 
a transcript-dependent manner. We found that transcripts that lack a recognizable -10 promoter 
motif are more likely to be highly deregulated, and especially likely to be upregulated, upon 
alterations in CarD (Chapter 4 Fig. 4, (140)). Furthermore, we found that these promoters were 
more likely than promoters with canonical -10 motifs to be deregulated in multiple strains with 
alterations in CarD. (Chapter 4 Fig. 4) This sensitivity to changes in CarD may highlight an 
increased dependence on CarD to drive expression from promoters lacking a recognizable -10 
motif: both -10 promoter motifs and CarD aid in formation of RPo. Importantly, variability in 
CarD-mediated regulation is not completely explained by differences in -10 promoter motifs, 
suggesting there are more, as of yet unidentified, determinants of CarD activity. 
Open Questions 
The work detailed in this thesis has significantly advanced our understanding of the 
physiological role of CarD, the mechanism of transcriptional regulation by CarD, and the cellular 
regulation of the CarD protein. However, this more advanced understanding of mycobacterial 
transcription has raised questions about CarD’s physiological role its promoter specificity. 
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Is CarD a regulator? Throughout this document, I have referred to CarD as a regulator 
of transcriptional activity and stress response.  Arguably, for CarD to be a regulator of these 
things, CarD itself must be regulated in some way such that its activity is responsive to stimuli 
which would enable it to regulate the correct response to these conditions.  At this point, we have 
not extensively investigated regulation of CarD itself.  We know that transcription of carD is 
upregulated in response to numerous stresses but not have thoroughly investigated any 
corresponding changes in the protein concentration. Our RNA-seq analysis has highlighted 
differences in transcript abundance dependent of the concentration of CarD expressed in a cell, 
suggesting that alterations in CarD protein expression could effectively regulate gene expression. 
We have shown that CarD is post-transcriptionally regulated by the Clp protease in Mtb and Clp 
itself is regulated in an oxygenation dependent manner (143), which may indirectly regulate 
CarD activity.  Furthermore, Claudio Gonzalez, our collaborator at the University of Florida, has 
identified a site in CarD’s C-terminal domain which may be a binding site for an unidentified, 
allosteric regulator of CarD activity (unpublished data).  All of these pieces of data are 
supportive of CarD’s activity likely being regulated in response to environmental signals. These 
numerous potential avenues for post-transcriptional regulation in addition to potential 
transcriptional regulation lead me to think that CarD’s activity is likely regulated which is why I 
have called it a regulator throughout this document.  
What determines CarD’s evolutionary conservation and essentiality? CarD is 
conserved in bacteria of numerous bacterial lineages with no clear evolutionary pathway to 
determine its retention (85–87). Additionally, it is not essential in all the bacteria that it is found 
in (130). Together these facts have raised interesting questions regarding CarD’s evolutionary 
conservation. Thus far, bacterial RNAPs have only been characterized from E. coli, Bacillus 
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subtilis, Thermus thermophilus, Thermus aquaticus, and mycobacteria (109, 123, 127–129, 144). 
Of these organisms, E. coli is the only bacterium that doesn’t encode a carD homolog and has 
the only RNAP that can form stable RPo independently (31, 85–87). This may suggest that CarD 
is retained in organisms that form an unstable RPo and has been lost in organisms that encode an 
RNAP that can form a stable RPo independently, although more RNAP would have to be 
characterized to determine if this is supported.  
A related question regards the essential function of CarD. While CarD is essential in 
mycobacteria, it is not essential in B. subtilis, suggesting that an RNAP that forms an unstable 
RPo is not itself enough to make CarD essential (130). If CarD is essential because it is a general 
member of the transcriptional machinery needed for transcription of the majority of the 
transcriptome, then organisms with RNAPs that are unable to form a stable RPo must encode an 
alternate cellular factor that can complement for loss of CarD. Alternatively, CarD’s essential 
function could be regulation of a small subset of the transcriptome that is particularly dependent 
on this regulation. In this case, organisms could alleviate the essentiality of CarD by altering 
their genome in such a way that these relatively few essential transcripts could be adequately 
produced in the absence of CarD. One genetic manipulation that may free a transcript from a 
requirement for CarD could be gene duplication, such that the same amount of transcript could 
be produced from numerous less active promoters, in the absence of CarD, as is produced by one 
strongly activated promoter in the presence of CarD. If CarD is essential for regulation of only 
select transcripts, then rRNA is likely one of these transcripts. Interestingly, B. subtilis, which 
encodes a nonessential CarD, encodes 11 rRNA operons, while there is only one rRNA operon in 
Mtb, which has very stringent requirements for CarD, and two in M. smegmatis, in which CarD 
is essential but more mutations of CarD are tolerated. This supports, but does not prove, a model 
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in which CarD is a general member of the transcriptional machinery but its essentiality is 
determined by the number of rRNA operons encoded in the genome. 
Why does M. smegmatis have more relaxed requirements for CarD as compared to 
Mtb? We consider M. smegmatis to have more relaxed requirements for CarD than Mtb because 
M. smegmatis tolerates mutations in CarD that are not viable in Mtb and CarD protein levels are 
less tightly post-transcriptionally regulated in M. smegmatis than in Mtb (101, 108). While 
CarD’s affinity for RNAP likely determines Clp protease susceptibility in Mtb (136), this does 
not appear to be conserved in M. smegmatis, where mutants with different affinity for RNAP all 
have similar CarD concentrations (unpublished data). CarD is targeted to the Clp protease via a 
C-terminal epitope (133). In M. smegmatis, we can HA-tag the C-terminus of CarD, which 
should protect CarD from proteolytic degradation by Clp (133), but we have been unable to 
generate strains with a C-terminal tagged CarD in Mtb, suggesting they are not viable. 
One explanation for the more relaxed requirements for CarD in M. smegmatis is that M. 
smegmatis encodes two rRNA operons while Mtb only encodes one. If regulation of rRNA is 
CarD’s essential function, the duplication of the rRNA operon may reduce the stringency of M. 
smegmatis’s requirement for CarD. Alternatively, CarD’s essential function may be as a general 
member of the transcription machinery essential for regulation of the majority of the 
transcriptome. In this case, the relaxed requirements for CarD in M. smegmatis may reflect 
inherent differences between the RNAP, promoters, or other effectors of transcription in M. 
smegmatis and Mtb, such that M. smegmatis RNAP is more capable of generating stable open 
complexes in the absence of CarD than the Mtb RNAP. This second hypothesis is supported by 
the RNA-seq data from M. smegmatis in which mutations in CarD caused deregulation of a 
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smaller percentage of the transcriptome that similar mutations caused in Mtb, which suggests that 
CarD’s full activity is required at a smaller percentage of the genome in M. smegmatis than Mtb.  
What are the determinants of CarD’s regulatory activity? The analysis of the Mtb 
transcriptome included in this thesis (Chapter 4) supports a role for CarD as a global regulator of 
transcription but highlighted pronounced differences in the degree of deregulation between 
strains and between transcripts within a strain.  These evidence suggest that CarD’s activity is 
responsive to characteristics of individual transcripts.  Analysis of promoter motifs can partially 
explain this variability but is not the complete story. We additionally saw evidence supporting a 
role for the genomic context of genes and demonstrated that CarD’s activity can be affected by at 
least one nucleoid associated protein. Future research is needed to determine additional factors 
involved in controlling CarD activity and the interplay between these factors. 
How is CarD’s activity affected by other transcriptional regulators? Thus far, 
transcription regulation by CarD has only been studied in non-stressed, exponential cultures of 
mycobacteria in vivo, and with σA-containing holo-RNAP in vitro (108, 109, 123). These studies 
have not addressed whether CarD can regulate transcription of RNAP containing accessory 
sigma factors. This is an important question with regards to CarD’s function, as both CarD and 
accessory sigma factors are known to regulate mycobacteria’s transcriptional response to stress 
(1, 85).  
While my thesis has focused entirely on the effect of CarD on RNAP in isolation, this is 
not an accurate representation of transcriptional regulation in vivo, where many additional 
transcriptional regulators are present. Of particular interest in mycobacteria is the interplay 
between CarD and RbpA. RbpA is another essential transcription initiation regulator in 
mycobacteria that also stabilizes RPo (1, 93, 95, 98, 99). Recently, our collaborators in the 
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Galburt lab at Washington University have shown that CarD and RbpA can act cooperatively to 
stabilize RPo in vitro, which suggests they may both be present at the same initiation complexes 
in vivo (In press). Future studies will address differences between the two transcriptional 
regulators and how their activities affect each other.  
Conclusions 
When I started my graduate studies, CarD was a completely novel transcription regulator 
that was known to associate with RNAP and regulate rRNA through an unknown mechanism 
(85). We now understand the mechanism by which CarD regulates transcription at rRNA 
promoters and comprehend the importance of different individual activities of CarD for this 
regulation (86, 87, 108, 109, 123). Recently, I have begun to elucidate the role of CarD in 
regulation on non-rRNA promoters and have identified factors that influence CarD’s activity at 
these promoters (Chapter 4).  
 Based on our current understanding of CarD, I think that CarD is likely a general member 
of the transcription machinery in Mtb and also master regulator of gene expression that globally 
adjusts gene expression to a given condition. As a general member of the initiation machinery, I 
think CarD has evolved to stabilize open complex formation at the majority of promoters to 
compensate for mycobacterial RNAP’s inability to inherently form stable complexes.  However, 
I suspect that mycobacteria, particularly Mtb, have evolved ways to use this accessory RNAP 
factor to adjust gene expression. We have at least preliminary evidence that CarD’s regulatory 
ability may be effected by transcriptional regulation, post-transcriptional stability, allosteric 
regulators, and the presence of nucleoid associated proteins. By adjusting any of these, and 
potentially other factors, Mtb may be able to globally effect gene regulation by CarD which 
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would allow it to tune its expression profile to a given set of conditions.  In this sense, I think it 
is accurate to call CarD a regulator of the stress response, at least in CarD. 
 In M. smegmatis, I think CarD is definitely a general member of the transcription 
machinery but I am not sure that it is also a master regulator of gene expression.  While CarD is 
also required to stabilize open complexes, I do not thing M. smegmatis has developed as many 
mechanisms to regulate CarD activity.  While we do see condition specific transcriptional 
regulation of CarD and evidence that its activity may be affected by nucleoid associated proteins, 
we don’t see the same post-transcriptional regulation of protein and we saw a smaller percentage 
of the genome deregulated by mutations in CarD. Compared the Mtb, M. smegmatis has an 
expanded array of sigma factors and other transcription factors which may suggest that M. 
smegmatis has evolved more CarD-independent pathways for transcriptional regulation.  
While many open questions remain in regard to CarD, my studies have significantly 
advanced our understanding of the physiology of mycobacteria and represent a new paradigm in 
the field of prokaryotic transcription. 
 
 
 
 
 
 
 
 
 
161  
References 
1.  Flentie K, Garner AL, Stallings CL. 2016. The Mycobacterium tuberculosis transcription machinery: ready to respond to host attacks. J Bacteriol 198:JB.00935–15–. 2.  Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, Roach JC, Kremer K, Petrov DA, Feldman MW, Gagneux S. 2008. High Functional Diversity in Mycobacterium tuberculosis Driven by Genetic Drift and Human Demography. PLoS Biol 6:e311. 3.  Daniel TM. 2006. The history of tuberculosis. Respir Med 100:1862–1870. 4.  WHO. 2015. Global Tuberculosis Report. http://www.who.int/tb/publications/global_report/en/ 1–97. 5.  Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The Growing Burden of Tuberculosis. Arch Intern Med 163:1009–1021. 6.  Sudjaritruk T, Maleesatharn A, Prasitsuebsai W, Fong SM, Le NO, Le TT, Lumbiganon P, Kumarasamy N, Kurniati N, Hansudewechakul R, Yusoff NK, Razali KA, Kariminia A, Sohn AH, Sirisanthana On Behalf Of The Treat Asia Pediatric Hiv Observational Database V. 2013. Prevalence, Characteristics, Management, and Outcome of Pulmonary Tuberculosis in HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database (TApHOD). AIDS Patient Care STDS 27:649–656. 7.  WHO. 2010. Treatment of tuberculosis: guidelines. 4Th Ed 160. 8.  Caminero JA, Sotgiu G, Zumla A, Migliori GB. 2010. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10:621–629. 9.  Stallings CL, Glickman MS. 2010. Is Mycobacterium tuberculosis stressed out? A critical assessment of the genetic evidence. Microbes Infect. 10.  Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. 2009. Acid-susceptible mutants of mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol 191:625–631. 11.  Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S. 2008. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med 14:849–854. 12.  Rengarajan J, Murphy E, Park A, Krone CL, Hett EC, Bloom BR, Glimcher LH, Rubin EJ. 2008. Mycobacterium tuberculosis Rv2224c modulates innate immune responses. Proc Natl Acad Sci  105 :264–269. 13.  Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD. 2004. Role of KatG catalase-peroxidase in mycobacterial pathogenisis: Countering the phagocyte oxidative burst. Mol Microbiol 52:1291–1302. 14.  MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci  94 :5243–5248. 15.  Cooper AM, Segal BH, Frank AA, Holland SM, Orme IM, Orme IANM. 2000. Transient Loss of Resistance to Pulmonary Tuberculosis in p47 phox − / − Mice Transient Loss of Resistance to Pulmonary Tuberculosis in p47 phoxϪ / Ϫ Mice 68. 16.  Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Seok YE, Taylor K, Klein E, Manjunatha U, Gonzales J, Eun GL, Seung KP, Raleigh JA, Sang NC, McMurray 
162  
DN, Flynn JL, Barry CE. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76:2333–2340. 17.  Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, Morris SL, Jacobs WR. 2002. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8:1171–1174. 18.  Bange F-C, Brown AM, William R. Jacobs J. 1996. Leucine auoxtrophy restricts growth of Mycobacterium bovis BCG in macrophages. Infect Immun 64:1794–1799. 19.  Gordhan BG, Smith DA, Alderton H, McAdam RA, Bancroft GJ, Mizrahi V. 2002. Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis. Infect Immun 70:3080–3084. 20.  Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR, Bloom BR. 2000. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 68:2888–2898. 21.  Rengarajan J, Bloom BR, Rubin EJ. 2005. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci United States Am  102 :8327–8332. 22.  Medlab EM, Bernstein S, Sterward DS. 1952. A Bacteriologic Study of Resected Tuberculous Lesions. Am Rev Tuberc Pulm Dis 66:36–43. 23.  Gupta UD, Katoch VM. 2005. Animal models of tuberculosis. Tuberculosis 85:277–293. 24.  Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64:2062–9. 25.  Deb C, Lee C-M, Dubey VS, Daniel J, Abomoelak B, Sirakova TD, Pawar S, Rogers L, Kolattukudy PE. 2009. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 4:e6077. 26.  Sarathy J, Dartois V, Dick T, Gengenbacher M. 2013. Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 57:1648–1653. 27.  Baek S-H, Li AH, Sassetti CM. 2011. Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol 9:e1001065. 28.  Cunningham-Bussel A, Bange FC, Nathan CF. 2013. Nitrite impacts the survival of Mycobacterium tuberculosis in response to isoniazid and hydrogen peroxide. Microbiologyopen 2:901–11. 29.  Franzblau SG, Ann M, Hyun S, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-barturen I, Dick T, Dartois V, Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 92:453–488. 30.  Murakami KS, Darst S A. 2003. Bacterial RNA polymerases: the wholo story. Curr Opin Struct Biol 13:31–39. 31.  Saecker RM, Record MT, Dehaseth PL. 2011. Mechanism of bacterial transcription initiation: RNA polymerase - promoter binding, isomerization to initiation-competent open complexes, and initiation of RNA synthesis. J Mol Biol 412:754–71. 32.  Browning DF, Busby SJ. 2004. The regulation of bacterial transcription initiation. Nat Rev Microbiol 2:57–65. 33.  Rojo F. 2001. Mechanisms of transcriptional repression. Curr Opin Microbiol 4:145–51. 
163  
34.  Lee DJ, Minchin SD, Busby SJW. 2012. Activating transcription in bacteria. Annu Rev Microbiol 66:125–52. 35.  Rodrigue S, Provvedi R, Jacques PÉ, Gaudreau L, Manganelli R. 2006. The σ factors of Mycobacterium tuberculosis. FEMS Microbiol Rev 30:926–941. 36.  Hu Y, Coates ARM. 2001. Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. FEMS Microbiol Lett 202:59–65. 37.  Manganelli R, Provvedi R, Rodrigue S, Beaucher J, Gaudreau L, Smith I. 2004. Sigma factors and global gene regulation in Mycobacterium tuberculosis. J Bacteriol 186:895–902. 38.  Manganelli R, Dubnau E, Tyagi S, Kramer FR, Smith I. 1999. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol Microbiol 31:715–24. 39.  Wosten M. 1998. Eubacterial sigma-factors. FEMS Microbiol Rev 22:127–50. 40.  Newton-Foot M, Gey van Pittius NC. 2013. The complex architecture of mycobacterial promoters. Tuberculosis 93:60–74. 41.  Bashyam MD, Kaushal D, Dasgupta SK, Tyagi  A K. 1996. A study of mycobacterial transcriptional apparatus: identification of novel features in promoter elements. J Bacteriol 178:4847–53. 42.  Agarwal N, Tyagi AK. 2006. Mycobacterial transcriptional signals: requirements for recognition by RNA polymerase and optimal transcriptional activity. Nucleic Acids Res 34:4245–57. 43.  Kremer L, Baulard  A, Estaquier J, Content J, Capron  A, Locht C. 1995. Analysis of the Mycobacterium tuberculosis 85A antigen promoter region. J Bacteriol 177:642–53. 44.  Bashyam MD, Tyagi AK. 1998. Identification and analysis of “extended - 10” promoters from mycobacteria. J Bacteriol 180:2568–2573. 45.  Graham JE, Clark-Curtiss JE. 1999. Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci U S A 96:11554–9. 46.  Cappelli G, Volpe E, Grassi M, Liseo B, Colizzi V, Mariani F. 2006. Profiling of Mycobacterium tuberculosis gene expression during human macrophage infection: Upregulation of the alternative sigma factor G, a group of transcriptional regulators, and proteins with unknown function. Res Microbiol 157:445–455. 47.  Manganelli R, Voskuil MI, Schoolnik GK, Smith I. 2001. The Mycobacterium tuberculosis ECF sigma factor sigmaE: role in global gene expression and survival in macrophages. Mol Microbiol 41:423–437. 48.  Lee J-H, Geiman DE, Bishai WR. 2008. Role of Stress Response Sigma Factor SigG in Mycobacterium tuberculosis. J Bacteriol 190:1128–1133. 49.  Gaudion A, Dawson L, Davis E, Smollett K. 2013. Characterisation of the mycobacterium tuberculosis alternative sigma factor SigG: Its operon and regulon. Tuberculosis 93:482–491. 50.  Raman S, Puyang X, Cheng TY, Young DC, Moody DB, Husson RN. 2006. Mycobacterium tuberculosis SigM positively regulates Esx secreted protein and nonribosomal peptide synthetase genes and down regulates virulence-associated surface lipid synthesis. J Bacteriol 188:8460–8468. 51.  Hu Y, Kendall S, Stoker NG, Coates ARM. 2004. The Mycobacterium tuberculosis sigJ gene controls sensitivity of the bacterium to hydrogen peroxide. FEMS Microbiol Lett 
164  
237:415–423. 52.  Calamita H, Ko C, Tyagi S, Yoshimatsu T, Morrison NE, Bishai WR. 2005. The Mycobacterium tuberculosis SigD sigma factor controls the expression of ribosome-associated gene products in stationary phase and is required for full virulence. Cell Microbiol 7:233–244. 53.  Ando M, Yoshimatsu T, Ko C, Converse PJ, Bishai WR. 2003. Deletion of Mycobacterium tuberculosis Sigma Factor E Results in Delayed Time to Death with Bacterial Persistence in the Lungs of Aerosol-Infected Mice 71:7170–7172. 54.  Kaushal D, Schroeder BG, Tyagi S, Yoshimatsu T, Scott C, Ko C, Carpenter L, Mehrotra J, Manabe YC, Fleischmann RD, Bishai WR. 2002. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A 99:8330–8335. 55.  Dainese E, Rodrigue S, Delogu G, Provvedi R, Laflamme L, Brzezinski R, Fadda G, Smith I, Gaudreau L, Palù G, Manganelli R. 2006. Posttranslational regulation of Mycobacterium tuberculosis extracytoplasmic-function sigma factor sigma L and roles in virulence and in global regulation of gene expression. Infect Immun 74:2457–61. 56.  Chen P, Ruiz RE, Li Q, Silver RF, Bishai WR. 2000. Construction and Characterization of a Mycobacterium tuberculosis Mutant Lacking the Alternate  Sigma Factor Gene, sigF. Infect Immun 68:5575–5580. 57.  Geiman D, Kaushal D, Ko C. 2004. Attenuation of Late -stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infect … 72:1733–1745. 58.  Sun R, Converse PJ, Ko C, Tyagi S, Morrison NE, Bishai WR. 2004. Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol Microbiol 52:25–38. 59.  Avarbock D, Avarbock A, Rubin H. 2000. Differential regulation of opposing RelMtb activities by the aminoacylation state of a tRNA.ribosome.mRNA.RelMtb complex. Biochemistry 39:11640–8. 60.  Dahl JL, Kraus CN, Boshoff HIM, Doan B, Foley K, Avarbock D, Kaplan G, Mizrahi V, Rubin H, Barry CE. 2003. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A 100:10026–31. 61.  Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, Barry CE. 2000. The Stringent Response of Mycobacterium tuberculosis Is Required for Long-Term Survival. J Bacteriol 182:4889–4898. 62.  Klinkenberg LG, Lee J-H, Bishai WR, Karakousis PC. 2010. The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs. J Infect Dis 202:1397–404. 63.  Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, Bishai WR. 2004. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 200:647–57. 64.  Weiss LA, Stallings CL. 2013. Essential roles for Mycobacterium tuberculosis Rel beyond the production of (p)ppGpp. J Bacteriol 195:5629–38. 65.  Ross W, Vrentas CE, Sanchez-Vazquez P, Gaal T, Gourse RL. 2013. The magic spot: a ppGpp binding site on E. coli RNA polymerase responsible for regulation of 
165  
transcription initiation. Mol Cell 50:420–9. 66.  Vrentas CE, Gaal T, Berkmen MB, Rutherford ST, Haugen SP, Vassylyev DG, Ross W, Gourse RL. 2008. Still looking for the magic spot: the crystallographically defined binding site for ppGpp on RNA polymerase is unlikely to be responsible for rRNA transcription regulation. J Mol Biol 377:551–64. 67.  Liu K, Myers AR, Pisithkul T, Claas KR, Satyshur KA, Amador-Noguez D, Keck JL, Wang JD. 2015. Molecular Mechanism and Evolution of Guanylate Kinase Regulation by (p)ppGpp. Mol Cell 57:735–749. 68.  Kriel A, Bittner AN, Kim SH, Liu K, Tehranchi AK, Zou WY, Rendon S, Chen R, Tu BP, Wang JD. 2012. Direct regulation of GTP homeostasis by (p)ppGpp: a critical component of viability and stress resistance. Mol Cell 48:231–41. 69.  Krásný L, Gourse RL. 2004. An alternative strategy for bacterial ribosome synthesis: Bacillus subtilis rRNA transcription regulation. EMBO J 23:4473–83. 70.  Tare P, Mallick B, Nagaraja V. 2013. Co-evolution of specific amino acid in sigma 1.2 region and nucleotide base in the discriminator to act as sensors of small molecule effectors of transcription initiation in mycobacteria. Mol Microbiol 90:569–583. 71.  Parish T. 2014. Two-Component Regulatory Systems of Mycobacteria. Microbiol Spectr 1–14. 72.  Turkarslan S, Peterson EJR, Rustad TR, Minch KJ, Reiss DJ, Morrison R, Ma S, Price ND, Sherman DR, Baliga NS. 2015. A comprehensive map of genome-wide gene regulation in Mycobacterium tuberculosis. Sci Data 2:150010. 73.  Minch KJ, Rustad TR, Peterson EJR, Winkler J, Reiss DJ, Ma S, Hickey M, Brabant W, Morrison B, Turkarslan S, Mawhinney C, Galagan JE, Price ND, Baliga NS, Sherman DR. 2015. The DNA-binding network of Mycobacterium tuberculosis. Nat Commun 6:5829. 74.  Baloni P, Chandra N. 2015. Architectural plan of transcriptional regulation in Mycobacterium tuberculosis. Trends Microbiol 23:123–5. 75.  Arnvig KB, Comas I, Thomson NR, Houghton J, Boshoff HI, Croucher NJ, Rose G, Perkins TT, Parkhill J, Dougan G, Young DB. 2011. Sequence-Based Analysis Uncovers an Abundance of Non-Coding RNA in the Total Transcriptome of Mycobacterium tuberculosis. PLoS Pathog 7:e1002342. 76.  Haning K, Cho SH, Contreras LM. 2014. Small RNAs in mycobacteria: an unfolding story. Front Cell Infect Microbiol 4:1–11. 77.  Pelly S, Bishai WR, Lamichhane G. 2012. A screen for non-coding RNA in Mycobacterium tuberculosis reveals a cAMP-responsive RNA that is expressed during infection. Gene 500:85–92. 78.  DiChiara JM, Contreras-Martinez LM, Livny J, Smith D, McDonough KA, Belfort M. 2010. Multiple small RNAs identified in Mycobacterium bovis BCG are also expressed in Mycobacterium tuberculosis and Mycobacterium smegmatis. Nucleic Acids Res 38:4067–78. 79.  Prisic S, Husson RN. 2014. Mycobacterium tuberculosis Serine/Threonine Protein Kinases. Microbiol Spectr 2. 80.  Sachdeva P, Misra R, Tyagi AK, Singh Y. 2010. The sigma factors of Mycobacterium tuberculosis: Regulation of the regulators. FEBS J 277:605–626. 81.  Gupta M, Sajid A, Sharma K, Ghosh S, Arora G, Singh R, Nagaraja V, Tandon V, Singh Y. 2014. HupB, a nucleoid-associated protein of Mycobacterium tuberculosis, is 
166  
modified by serine/threonine protein kinases in vivo. J Bacteriol 196:2646–57. 82.  Park ST, Kang C-M, Husson RN. 2008. Regulation of the SigH stress response regulon by an essential protein kinase in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 105:13105–10. 83.  Greenstein AE, MacGurn JA, Baer CE, Falick AM, Cox JS, Alber T. 2007. M. tuberculosis Ser/Thr protein kinase D phosphorylates an anti-anti-sigma factor homolog. PLoS Pathog 3:e49. 84.  Chao JD, Papavinasasundaram KG, Zheng X, Chávez-Steenbock A, Wang X, Lee GQ, Av-Gay Y. 2010. Convergence of Ser/Thr and two-component signaling to coordinate expression of the dormancy regulon in Mycobacterium tuberculosis. J Biol Chem 285:29239–46. 85.  Stallings CL, Stephanou NC, Chu L, Hochschild A, Nickels BE, Glickman MS. 2009. CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell 138:146–59. 86.  Bae B, Chen J, Davis E, Leon K, Darst SA, Campbell EA. 2015. CarD uses a minor groove wedge mechanism to stabilize the RNA polymerase open promoter complex. Elife 4:1–19. 87.  Srivastava DB, Leon K, Osmundson J, Garner AL, Weiss LA, Westblade LF, Glickman MS, Landick R, Darst SA, Stallings CL, Campbell EA. 2013. Structure and function of CarD, an essential mycobacterial transcription factor. Proc Natl Acad Sci U S A 110:12619–24. 88.  Betts JC, Lukey PT, Robb LC, McAdam R a., Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717–731. 89.  Paget MS, Molle V, Cohen G, Aharonowitz Y, Buttner MJ. 2001. Defining the disulphide stress response in Streptomyces coelicolor A3(2): identification of the sigmaR regulon. Mol Microbiol 42:1007–20. 90.  Stewart GR, Wernisch L, Stabler R, Mangan J a, Hinds J, Laing KG, Young DB, Butcher PD. 2002. Dissection of the heat-shock response in Mycobacterium tuberculosis using mutants and microarrays. Microbiology 148:3129–38. 91.  Provvedi R, Boldrin F, Falciani F, Palù G, Manganelli R. 2009. Global transcriptional response to vancomycin in Mycobacterium tuberculosis. Microbiology 155:1093–102. 92.  Murphy DJ, Brown JR. 2007. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis 7:84. 93.  Bortoluzzi A, Muskett FW, Waters LC, Addis PW, Rieck B, Munder T, Schleier S, Forti F, Ghisotti D, Carr MD, O’Hare HM. 2013. Mycobacterium tuberculosis RNA polymerase-binding protein A (RbpA) and its interactions with sigma factors. J Biol Chem 288:14438–50. 94.  Hubin EA, Tabib-Salazar A, Humphrey LJ, Flack JE, Olinares PDB, Darst SA, Campbell EA, Paget MS. 2015. Structural, functional, and genetic analyses of the actinobacterial transcription factor RbpA. Proc Natl Acad Sci U S A 112:7171–6. 95.  Tabib-Salazar A, Liu B, Doughty P, Lewis RA, Ghosh S, Parsy M-L, Simpson PJ, O’Dwyer K, Matthews SJ, Paget MS. 2013. The actinobacterial transcription factor RbpA binds to the principal sigma subunit of RNA polymerase. Nucleic Acids Res 41:5679–91. 96.  Dey A, Verma AK, Chatterji D. 2010. Role of an RNA polymerase interacting protein, 
167  
MsRbpA, from Mycobacterium smegmatis in phenotypic tolerance to rifampicin. Microbiology 156:873–83. 97.  Dey A, Verma AK, Chatterji D. 2011. Molecular insights into the mechanism of phenotypic tolerance to rifampicin conferred on mycobacterial RNA polymerase by MsRbpA.Microbiology (Reading, England). 98.  Hu Y, Morichaud Z, Chen S, Leonetti J-P, Brodolin K. 2012. Mycobacterium tuberculosis RbpA protein is a new type of transcriptional activator that stabilizes the σ A-containing RNA polymerase holoenzyme. Nucleic Acids Res 40:6547–57. 99.  Hu Y, Morichaud Z, Perumal AS, Roquet-Baneres F, Brodolin K. 2014. Mycobacterium RbpA cooperates with the stress-response σB subunit of RNA polymerase in promoter DNA unwinding. Nucleic Acids Res 42:10399–408. 100.  Verma AK, Chatterji D. 2014. Dual role of MsRbpA: transcription activation and rescue of transcription from the inhibitory effect of rifampicin. Microbiology 160:2018–29. 101.  Weiss LA, Harrison PG, Nickels BE, Glickman MS, Campbell EA, Darst SA, Stallings CL. 2012. Interaction of CarD with RNA polymerase mediates Mycobacterium tuberculosis viability, rifampin resistance, and pathogenesis. J Bacteriol 194:5621–31. 102.  Gulten G, Sacchettini JC. 2013. Structure of the Mtb CarD/RNAP β-lobes complex reveals the molecular basis of interaction and presents a distinct DNA-binding domain for Mtb CarD. Structure 21:1859–69. 103.  Kaur G, Dutta D, Thakur KG. 2014. Crystal structure of Mycobacterium tuberculosis CarD, an essential RNA polymerase binding protein, reveals a quasidomain-swapped dimeric structural architecture. Proteins 82:879–84. 104.  Gallego-Garcia A, Mirassou Y, Elias-Arnanz M, Padmanabhan S, Jiminez MA. 2012. NMR structure note: N-terminal domain of Thermus thermophilus CdnL. J Biomol NMR 53:355–363. 105.  Šali A, Blundell TL. 1993. Comparative Protein Modelling by Satisfaction of Spatial Restraints. J Mol Biol 234:779–815. 106.  Westblade LF, Campbell E a, Pukhrambam C, Padovan JC, Nickels BE, Lamour V, Darst S a. 2010. Structural basis for the bacterial transcription-repair coupling factor/RNA polymerase interaction. Nucleic Acids Res 38:8357–69. 107.  Campbell EA, Muzzin O, Chlenov M, Sun JL, Olson CA, Weinman O, Trester-Zedlitz ML, Darst SA. 2002. Structure of the bacterial RNA polymerase promoter specificity σ subunit. Mol Cell 9:527–539. 108.  Garner AL, Weiss LA, Manzano AR, Galburt EA, Stallings CL. 2014. CarD integrates three functional modules to promote efficient transcription, antibiotic tolerance, and pathogenesis in mycobacteria. Mol Microbiol 93:682–697. 109.  Rammohan J, Ruiz Manzano A, Garner AL, Stallings CL, Galburt EA. 2015. CarD stabilizes mycobacterial open complexes via a two-tiered kinetic mechanism. Nucleic Acids Res 1–14. 110.  Pashley CA, Parish T. 2003. Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiol Lett 229:211–215. 111.  Gaal T, Ross W, Estrem ST, Nguyen LH, Burgess RR, Gourse RL. 2001. Promoter recognition and discrimination by EsigmaS RNA polymerase. Mol Microbiol 42:939–54. 112.  Ross W, Thompson JF, Newlands JT, Gourse RL. 1990. E. coli Fis protein activates ribosomal RNA transcription in vitro and in vivo. EMBO J 9:3733–42. 113.  Czyz A, Mooney RA, Iaconi A, Landick R. 2014. Mycobacterial RNA Polymerase 
168  
Requires a U-Tract at Intrinsic Terminators and Is Aided by NusG at Suboptimal Terminators. MBio 5:1–10. 114.  Huff J, Czyz A, Landick R, Niederweis M. 2010. Taking phage integration to the next level as a genetic tool for mycobacteria. Gene 468:8–19. 115.  Cooper AM, Segal BH, Frank AA, Holland SM, Orme IM, Orme IANM. 2000. Transient Loss of Resistance to Pulmonary Tuberculosis in p47 phox − / − Mice Transient Loss of Resistance to Pulmonary Tuberculosis. Infect Immun 68:1231–1234. 116.  Gonzalez-y-merchand JA, Colston MJ, Cox RA. 1996. The rRNA operons of Mycobacterium smegmatis and Mycobacterium tuberculosis: comparison of promoter elements and of neighbouring upstream genes. Microbiology 142:667–674. 117.  Gonzalez-y-merchand JA, Garcia MJ, Gonzalez-Rico S, Colston MJ, Cox RA. 1997. Strategies used by pathogenic and nonpathogenic mycobacteria to synthesize rRNA. J Bacteriol 179:6949. 118.  Masayasu N, Gourse R, Baughman G. 1984. Regulation of the Synthesis of Ribosomes and Ribosomal Components. Annu Rev Biochem 53:75–117. 119.  Bremer H, Dennis PP. 1996. Modulation of Chemical Composition and Other Parameters of the Cell by Growth Rate, p. 1553–69. In Escherichia Coli and Salmonella Typhimurium: Cellular and Molecular Biology. ASM Press. 120.  Gourse RL, Gaal T, Bartlett MS, Appleman J A, Ross W. 1996. rRNA transcription and growth rate-dependent regulation of ribosome synthesis in Escherichia coli. Annu Rev Microbiol 50:645–77. 121.  Chao MC, Rubin EJ. 2010. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol 64:293–311. 122.  Gengenbacher M, Kaufmann SHE. 2012. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 36:514–32. 123.  Davis E, Chen J, Leon K, Darst SA, Campbell EA. 2015. Mycobacterial RNA polymerase forms unstable open promoter complexes that are stabilized by CarD. Nucleic Acids Res 43:433–445. 124.  Monsalve M, Calles B, Mencía M, Salas M, Rojo F. 1997. Transcription activation or repression by phage psi 29 protein p4 depends on the strength of the RNA polymerase-promoter interactions. Mol Cell 1:99–107. 125.  García-Moreno D, Abellón-Ruiz J, García-Heras F, Murillo FJ, Padmanabhan S, Elías-Arnanz M. 2010. CdnL, a member of the large CarD-like family of bacterial proteins, is vital for Myxococcus xanthus and differs functionally from the global transcriptional regulator CarD. Nucleic Acids Res 38:4586–98. 126.  Yang XF, Goldberg MS, He M, Xu H, Blevins JS, Norgard M V. 2008. Differential expression of a putative CarD-like transcriptional regulator, LtpA, in Borrelia burgdorferi. Infect Immun 76:4439–44. 127.  Whipple FW, Sonenshein  A L. 1992. Mechanism of initiation of transcription by Bacillus subtilis RNA polymerase at several promoters. J Mol Biol 223:399–414. 128.  Xue Y, Hogan BP, Erie D A. 2000. Purification and initial characterization of RNA polymerase from Thermus thermophilus strain HB8. Biochemistry 39:14356–14362. 129.  Miropolskaya N, Ignatov  A., Bass I, Zhilina E, Pupov D, Kulbachinskiy  a. 2012. Distinct Functions of Regions 1.1 and 1.2 of RNA Polymerase   Subunits from Escherichia coli and Thermus aquaticus in Transcription Initiation. J Biol Chem 287:23779–23789. 
169  
130.  Kobayashia K, Ashikaga S, Aymerich S, Bessieres P, Boland F, Brignell SC, Bron S, Bunai K, Christiansen LC, Danchin A, Débarbouillé M, Dervyn E, Deuerling E, Devine K, Dreesen O, Errington J, Fillinger S, Foster SJ, Fujita Y, Galizzi A, Gardan R, Eschevins C, Fukushima T, Haga K, Harwood CR, Ehrlichb SD, Albertinid A, Amatid G, Andersene KK, Arnaudf M, Asai K, Ashikagah S, Aymerichi S, Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P, Boland F, Brignell SC, Bron S, Bunai K, Chapuis J, Christiansen LC, Danchin A, Débarbouille M, Dervyn E, Deuerling E, Devine K, Devine SK, Dreesen O, Errington J, Fillinger S, Foster SJ, Fujita Y, Galizzi A, Gardan R, Eschevins C, Fukushima T, Haga K, Harwood CR, Hecker M, Hosoya D, Hullo MF, Kakeshita H, Karamata D, Kasahara Y, Kawamura F, Koga K, Koski P, Kuwana R, Imamura D, Ishimaru M, Ishikawa S, Ishio I, Le Coq D, Masson A, Mauël C, Meima R, Mellado RP, Moir A, Moriya S, Nagakawa E, Nanamiya H, Nakai S, Nygaard P, Ogura M, Ohanan T, O’Reilly M, O’Rourke M, Pragai Z, Pooley HM, Rapoport G, Rawlins JP, Rivas L a, Rivolta C, Sadaie A, Sadaie Y, Sarvas M, Sato T, Saxild HH, Scanlan E, Schumann W, Seegers JFML, Sekiguchi J, Sekowska A, Séror SJ, Simon M, Stragier P, Studer R, Takamatsu H, Tanaka T, Takeuchi M, Thomaides HB, Vagner V, van Dijl JM, Watabe K, Wipat A, Yamamoto H, Yamamoto M, Yamamoto Y, Yamane K, Yata K, Yoshida K, Yoshikawa H, Zuber U, Ogasawara N. 2003. Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A 100:4678–83. 131.  Nickels BE. 2009. Genetic assays to define and characterize protein-protein interactions involved in gene regulation. Methods 47:53–62. 132.  Gulten G, Sacchettini JC. 2013. Structure of the Mtb CarD/RNAP β-Lobes Complex Reveals the Molecular Basis of Interaction and Presents a Distinct DNA-Binding Domain for Mtb CarD. Structure 21:1859–69. 133.  Raju RM, Unnikrishnan M, Rubin DHF, Krishnamoorthy V, Kandror O, Akopian TN, Goldberg AL, Rubin EJ. 2012. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog 8. 134.  Schaechter M, Maaloe O, Kjeldgaard NO. 1958. Dependency on Medium and Temperature of Cell Size and Chemical Composition during Balanced Growth of Salmonella typhimurium. J Gen Microbiol 19:592–606. 135.  Binder BJ, Liu YC. 1998. Growth rate regulation of rRNA content of a marine Synechococcus (cyanobacterium) strain. Appl Environ Microbiol 64:3346–3351. 136.  Garner AL, Rammohan J, Huynh JP, Onder LM, Chen J, Bae B, Jensen D, Weiss LA, Manzano AR, Darst SA, Campbell EA, Nickels BE, Galburt EA, Stallings CL. 2016. Effects of Increasing the Affinity of CarD for RNA Polymerase on Mycobacterium tuberculosis Growth, rRNA Transcription, and Virulence (In submission). 137.  Oliveros JC. 2007. Venny. An Interactive Tool for comparing lists with Venn Diagrams. 138.  Anders S, Pyl PT, Huber W. 2015. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 31:166–169. 139.  Anders S, Huber W, S A, W H. 2010. Differential expression analysis for sequence count data. Genome Biol 11:R106. 140.  Cortes T, Schubert OT, Rose G, Arnvig KB, Comas I, Aebersold R, Young DB. 2013. Genome-wide Mapping of Transcriptional Start Sites Defines an Extensive Leaderless 
170  
Transcriptome in Mycobacterium tuberculosis. Cell Rep 5:1121–1131. 141.  Blasco B, Chen JM, Hartkoorn R, Sala C, Uplekar S, Rougemont J, Pojer F, Cole ST. 2012. Virulence regulator EspR of mycobacterium tuberculosis is a nucleoid-associated protein. PLoS Pathog 8. 142.  Dillon SC, Dorman CJ. 2010. Bacterial nucleoid-associated proteins, nucleoid structure and gene expression. Nat Rev Microbiol 8:185–95. 143.  Sherrid AM, Rustad TR, Cangelosi GA, Sherman DR. 2010. Characterization of a Clp Protease Gene Regulator and the Reaeration Response in Mycobacterium tuberculosis. PLoS One 5. 144.  China  A., Tare P, Nagaraja V. 2010. Comparison of promoter-specific events during transcription initiation in mycobacteria. Microbiology 156:1942–1952. 
 
